canin
leishmaniasi
import
infecti
diseas
worldwid
although
commonli
use
antibodi
test
often
fals
neg
direct
detect
pathogen
polymeras
chain
reaction
pcr
necessari
howev
pcr
perform
special
laboratori
avail
less
develop
countri
aim
studi
evalu
sensit
specif
rapid
inhous
pcr
diagnosi
canin
leishmania
infantum
infect
prospect
sampl
dog
edta
blood
sampl
conjunctiv
swab
lymph
node
aspir
bone
marrow
aspir
analys
presenc
leishmania
dna
use
pcrun
system
biogal
gale
lab
ac
ltd
kibbutz
gale
israel
result
compar
real
time
pcr
gold
standard
identif
leishmania
kinetoplast
dna
minicircl
dna
extract
conduct
use
dneasi
blood
tissu
kit
qiagen
gmbh
sensit
specif
confid
rang
ci
determin
specif
sampl
examin
overal
sensit
pcrun
ci
bone
marrow
aspir
lymph
node
aspir
ci
conjunctiv
swab
ci
blood
test
easi
perform
provid
unambigu
result
conclus
test
recommend
use
practic
posit
result
prove
infect
neg
result
howev
exclud
infect
therefor
requir
diagnost
disclosur
studi
financ
biogal
gale
lab
ac
ltd
kibbutz
gale
israel
mcluckiea
spencer
tasker
n
dhand
spencer
ja
beatti
faculti
veterinari
scienc
mari
bashir
institut
infecti
diseas
sydney
australia
univers
bristol
bristol
uk
feli
catu
gammaherpesviru
first
gammaherpesviru
ghv
identifi
domest
cat
preval
studi
identifi
viru
domest
cat
usa
australia
singapor
recent
central
europ
data
avail
uk
cat
consequ
felin
health
yet
elucid
speci
ghv
infect
typic
clinic
silent
unless
immun
dysfunct
natur
host
case
caus
rang
lymphoprolif
neoplast
diseas
aim
studi
determin
preval
risk
factor
infect
pet
cat
uk
residu
dna
whole
blood
submit
molecular
diagnost
unit
langford
veterinari
servic
univers
bristol
quantit
polymeras
chain
reaction
qpcr
test
haemoplasma
avail
studi
dna
sampl
test
posit
least
one
haemoplasma
speci
haemoplasma
neg
sampl
ship
australia
qpcr
target
glycoprotein
b
gene
perform
oper
blind
sampl
data
age
sex
neuter
statu
breed
haemoplasma
pcr
result
univari
multivari
logist
regress
analys
conduct
investig
associ
variabl
detect
pvalu
consid
signific
infect
detect
confid
interv
ci
blood
sampl
uk
cat
entir
male
cat
like
posit
neuter
male
cat
odd
ratio
ci
twentyon
posit
cat
coinfect
least
one
haemoplasma
speci
neg
cat
harbour
haemoplasma
dna
sampl
posit
dna
three
haemoplasma
speci
time
greater
odd
test
posit
haemoplasma
neg
cat
multivari
analys
adjust
age
sex
neuter
statu
cat
studi
demonstr
domest
cat
uk
infect
confirm
viru
global
endem
identif
neuter
statu
risk
factor
detect
provid
novel
evid
support
transmiss
viru
territori
encount
disclosur
disclosur
report
st
also
receiv
financi
support
infecti
diseas
research
past
elizabeth
blackwel
institut
univers
bristol
ecvim
clinic
studi
fund
univers
bristol
campaign
alumni
fund
rcv
trust
fund
blue
sky
wellcom
trust
st
member
world
forum
companion
anim
vector
born
diseas
support
bayer
anim
health
st
member
european
advisori
board
cat
diseas
support
merial
st
work
molecular
diagnost
unit
langford
veterinari
servic
univers
bristol
carri
haemoplasma
pcr
describ
studi
st
paid
provid
continu
profession
develop
notforprofit
organis
occasion
commerci
compani
around
world
statement
disclosur
australian
collabor
jb
receiv
financi
support
dugdal
guy
peel
bequest
faculti
veterinari
scienc
univers
sydney
studi
jb
receiv
financi
support
australian
companion
anim
health
foundat
felin
health
research
foundat
research
relat
gammaherpesviru
pathogenesi
support
australian
postgradu
award
australian
govern
depart
educ
train
jb
receiv
financi
support
morri
anim
foundat
oncogen
viru
discoveri
jb
research
support
speaker
honoraria
continu
educ
provid
australian
veterinari
associ
australian
small
anim
veterinari
associ
wsava
nd
provid
consult
servic
boehring
ingelheim
merial
ss
disclosur
report
multipl
pathogen
report
potenti
caus
agent
canin
infecti
respiratori
diseas
complex
cirdc
dog
purpos
studi
survey
occurr
wellknown
newli
emerg
pathogen
dog
respiratori
diseas
around
vienna
austria
includ
studi
dog
privatelyown
kennelkept
present
acut
chronic
sign
respiratori
diseas
swab
nasal
mucosa
tonsil
anim
well
bronchoalveolar
lavag
fluid
balf
dog
evalu
via
bacteri
cultur
pcr
viral
agent
canin
parainfluenza
viru
cpiv
canin
respiratori
coronaviru
crcov
canin
adenoviru
type
canin
distemp
viru
cdv
canin
influenza
viru
civ
addit
pair
serum
sampl
obtain
acut
diseas
dog
serolog
test
crcov
antibodi
via
immunoflouresc
antibodi
test
ifat
fecal
sampl
dog
examin
crenosoma
vulpi
angiostrongylu
vasorum
baermann
techniqu
swab
fecal
sampl
clinic
healthi
dog
serv
control
group
obtain
evalu
describ
n
dog
pathogen
could
isol
nasal
andor
tonsillar
swab
n
show
mix
infect
crcov
detect
n
cpiv
n
n
dog
balf
one
dog
test
posit
cdv
evid
civ
strain
found
obtain
sampl
n
dog
bordetella
bronchiseptica
detect
three
nasal
tonsillar
balf
sampl
concurr
five
bacteri
isol
show
particular
resist
antibiot
mycoplasma
cyno
recov
balf
n
swab
n
dog
respect
signific
crcov
antibodi
titer
increas
detect
n
pair
serum
sampl
collect
n
concurr
eight
dog
reveal
crcov
specif
nucleic
acid
obtain
swab
fecal
examin
detect
c
vulpi
infect
n
sampl
crcov
seem
emerg
respiratori
pathogen
austrian
dog
cirdc
contrast
studi
incid
b
bronchiseptica
infect
studi
low
though
cyno
consid
cofactor
respiratori
diseas
dog
occurr
rare
studi
disclosur
disclosur
report
leptospirosi
import
worldwid
zoonosi
human
leptospirosi
remain
rare
switzerland
incid
canin
leptospirosi
unusu
high
compar
european
countri
sever
form
associ
pulmonari
haemorrhag
common
aim
prospect
studi
determin
exposur
appar
healthi
dog
pathogen
leptospira
spp
switzerland
examin
whether
dog
contribut
spread
pathogen
leptospira
spp
via
urinari
shed
ethic
approv
obtain
studi
protocol
sampl
stratifi
cover
whole
switzerland
n
sampl
collect
april
decemb
inclus
criteria
clinic
sign
leptospirosi
antileptospir
vaccin
within
last
week
antibiot
treatment
within
last
month
sera
test
microscop
agglutin
test
mat
antibodi
serovar
grippotyphosa
australi
pomona
tarassovi
canicola
icterohaemorrhagia
hardjo
bratislava
autumnali
altodouro
copenhageni
pyrogen
ballum
urin
test
pathogen
leptospira
spp
use
real
time
pcr
pcr
sera
ci
show
reciproc
mat
titr
ci
least
one
serovar
seroposit
mat
common
serovar
australi
ci
bratislava
ci
copenhageni
ci
canicola
ci
grippotyphosa
ci
pomona
ci
autumnali
ci
icterohaemorrhagia
ci
seroposit
invers
correl
time
sinc
last
antileptospir
vaccin
p
unvaccin
dog
n
overal
preval
mat
titr
ci
serovar
sera
react
australi
ci
bratislava
ci
copenhageni
ci
grippotyphosa
ci
canicola
ci
pomona
ci
autumnali
ci
urin
pcr
perform
dog
one
posit
pcr
result
ci
result
suggest
antileptospir
vaccin
lead
mat
seroposit
beyond
week
post
vaccin
result
unvaccin
dog
show
dog
switzerland
commonli
expos
pathogen
leptospira
spp
without
develop
sign
diseas
howev
base
find
urinari
shed
pathogen
leptospir
healthi
dog
appear
uncommon
disclosur
disclosur
report
clinic
present
vasorum
infect
dog
variabl
unexplain
excess
bleed
primari
complaint
infect
dog
observ
mouth
n
extern
bleed
n
larg
subcutan
hematoma
n
hemoptysi
n
brain
hemorrhag
n
hemoabdomen
post
ovariectomi
n
epistaxi
around
eye
tracheal
tube
dog
caus
bleed
initi
suspect
minor
trauma
surgic
mistak
variou
surgic
approach
undertaken
problem
solv
four
dog
receiv
nsaid
bleed
prompt
referr
thrombocytopenia
lowest
ul
found
dog
coagul
time
obtain
pt
prolong
ptt
act
tt
fibrinogen
clau
method
detect
limit
buccal
mucos
bleed
time
normal
one
except
least
one
test
abnorm
mildli
prolong
median
time
elaps
first
recogn
clinic
sign
attribut
vasorum
diagnosi
week
day
month
dog
vasorum
prime
suspect
present
respiratori
sign
occur
day
month
first
bleed
occur
concurr
bleed
hemoptysi
absent
dog
dog
cough
present
bleed
prompt
referr
month
hemoptysi
month
bleed
lip
noncough
dog
mild
nonspecif
radiograph
abnorm
eleven
dog
recov
quickli
unev
initi
appropri
therapi
four
dog
die
day
admiss
dog
day
caus
death
respiratori
failur
cerebr
hemorrhag
dog
dog
pretreat
nsaid
present
sever
hemoptysi
die
brain
hemorrhag
die
peritars
hematoma
mark
anemia
bleed
may
recogn
abnorm
vasorum
infect
caus
bleed
like
vari
individu
dog
may
combin
thrombocytopenia
iatrogen
abnorm
platelet
function
util
coagul
factor
hyperfibrinolysi
without
high
index
suspicion
diagnosi
may
delay
point
fatal
outcom
disclosur
disclosur
report
first
author
disclosur
report
particip
studi
sponsor
boehring
ingelheim
never
topic
abstract
nowaday
leptospirosi
dog
often
caus
infect
serovar
serogroup
australi
au
grippotyphosa
gri
pomona
pom
addit
serovar
serogroup
icterohaemorrhagia
ict
canicola
therefor
bival
vaccin
contain
serovar
serogroup
ict
longer
provid
adequ
protect
aim
studi
determin
develop
antibodi
titer
vaccin
nonvaccin
serovar
healthi
dog
vaccin
tetraval
leptospirosi
vaccin
nobivac
one
year
healthi
dog
includ
prospect
monocentr
crosssect
studi
inclus
criteria
initi
mat
titer
leptospira
serovar
dog
vaccin
twice
week
week
nobivac
total
serum
sampl
per
dog
taken
year
mat
perform
dog
test
initi
mat
neg
titer
common
serovar
copenhageni
cop
ict
analysi
complet
mat
cours
possibl
dog
titer
serovar
cop
bratislava
bra
gri
median
lower
titer
detect
serovar
median
au
median
ict
median
signific
decreas
titer
test
serovar
observ
titer
one
year
initi
vaccin
mat
titer
highest
mat
titer
found
week
initi
vaccin
serovar
cop
bra
gri
ict
potenti
higher
antibodi
titer
second
vaccin
next
blood
draw
like
occur
one
year
first
vaccin
still
mat
posit
least
one
serovar
howev
antibodi
titer
induc
leptospir
vaccin
height
persist
allow
conclus
immun
disclosur
studi
sponser
msd
msd
produc
vaccin
nobivac
coauthor
sutton
hl
klaasen
employe
msd
anemia
frequent
dog
result
mani
clinic
condit
must
determin
allow
appropri
treatment
improv
prognosi
among
report
caus
vectorborn
pathogen
vbp
emerg
europ
retrospect
studi
describ
frequenc
infecti
anemia
case
respect
screen
vbp
systemat
occurr
might
underestim
publish
prospect
studi
use
comprehens
pcr
assess
evalu
implic
vbp
anem
dog
prospect
assess
occurr
clinic
biolog
impact
vbp
anem
dog
year
french
veterinari
teach
hospit
caus
anemia
also
report
anem
clientown
dog
includ
hematocrit
ht
hemoglobin
hb
gdl
exclud
given
doxycyclin
imidocarb
propion
within
one
month
appoint
perform
pcr
ehrlichia
cani
anaplasma
platysphagocytophilum
babesiatheileria
spp
hepatozoon
sp
mycoplasma
haemocani
mh
candidatu
mhaematoparvum
leishmania
spp
serolog
test
snap
snap
leish
signal
histori
treatment
clinic
laboratori
diagnosticimag
find
record
three
boardcertifi
specialist
determin
etiolog
anemia
clinic
pathologist
oncologist
internist
vbpassoci
anemia
vbpaa
case
posit
pcr
result
year
dog
anem
ci
exclud
previou
doxycyclin
imidocarb
proprion
administr
bernes
mountain
dog
overrepres
compar
canin
hospit
popul
period
p
vbpaa
repres
case
ci
wherea
ci
ci
dog
posit
snap
snap
leish
respect
vbpaa
case
includ
dog
posit
pcr
mh
babesiosi
babesiosi
posit
mh
thrombocyt
anaplasmosi
monocyt
ehrlichiosi
leishmaniasi
vbpaa
repres
first
caus
hemolysi
mutivari
regress
model
clinic
find
nt
differ
vbpaa
nonvbpaa
case
vbpaa
case
show
less
sever
regen
anemia
import
leucocyt
count
nonvbpaa
case
p
frequenc
vbpaa
appear
higher
previous
report
vbpaa
case
appear
less
sever
nonvbpaa
case
mh
frequent
vbp
encount
especi
oncolog
case
frequenc
similar
report
healthi
french
dog
although
find
limit
geograph
locat
activ
hospit
referr
studi
suggest
consid
vbp
face
anem
dog
disclosur
disclosur
report
acut
haemorrhag
diarrhoea
syndrom
ahd
wellknown
diseas
exact
pathogenesi
still
unclear
recent
canin
circoviru
dogcv
detect
might
potenti
play
primari
role
repres
cofactor
develop
ahd
thu
aim
studi
determin
preval
dogcv
healthi
dog
dog
ahd
dog
canin
parvoviru
cpv
infect
evalu
pathogen
role
dogcv
patient
group
total
dog
dog
ahd
healthi
dog
cpvposit
dog
includ
faecal
sampl
test
two
realtim
taqman
pcr
assay
target
dogcv
replicas
capsid
gene
comparison
dogcvposit
dogcvneg
dog
standard
evalu
clinic
paramet
faecal
consist
perform
daili
hospit
signific
differ
three
group
preval
dogcv
healthi
dog
dog
ahd
dog
cpvinfect
howev
within
cpvinfect
group
dogcvposit
dog
significantli
higher
mortal
rate
compar
dogcvneg
dog
time
recoveri
significantli
affect
conclus
dogcv
detect
faec
healthi
dog
seem
primari
caus
ahd
howev
presenc
dogcv
might
influenc
sever
mortal
rate
dog
sever
intestin
barrier
destruct
occur
cpv
infect
disclosur
disclosur
report
felin
leukaemia
viru
felv
ubiquit
prognosi
cat
persist
infect
felv
poor
develop
immunosuppress
anaemia
lymphoma
due
develop
natur
resist
felv
infect
age
current
recommend
vaccin
cat
sustain
risk
exposur
everi
year
vaccin
efficaci
data
avail
support
practic
studi
object
demonstr
efficaci
leucofeligen
felvrcp
virbac
carro
franc
three
year
first
annual
vaccin
booster
twentyeight
specif
pathogen
free
cat
week
age
femal
male
particip
studi
cat
vaccin
leucofeligen
felvrcp
lg
purifi
felvenvelop
antigen
adjuv
subcutan
inject
week
apart
primari
vaccin
booster
inject
one
year
later
cat
receiv
vaccin
contain
felv
valenc
serv
control
group
three
year
first
annual
booster
vaccin
group
cat
inocul
pathogen
felv
strain
dose
pfucat
intraperiton
rout
cat
regularli
observ
appear
gener
health
alter
bodi
temperatur
bodi
weight
followup
blood
sampl
taken
inocul
week
week
inocul
antibodi
andor
antigen
detect
elisa
antibodi
titr
time
inocul
demonstr
prolong
humor
immun
respons
felv
valenc
leucofeligen
felvrcp
presenc
antigen
indic
felv
infect
persist
infect
defin
detect
antigen
three
consecut
occas
five
nonconsecut
occas
week
week
inocul
cat
vaccin
leucofeligen
felvrcp
cat
control
group
present
antibodi
protein
year
first
annual
booster
cat
neg
antigen
experiment
felv
infect
challeng
persist
infect
observ
leucofeligen
felvrcp
vaccin
cat
cat
control
group
leucofeligen
felvrcp
prevent
develop
persist
infect
vaccin
cat
three
year
last
vaccin
inject
risk
develop
persist
infect
seven
time
higher
control
group
leucofeligen
felvrcp
protect
cat
felv
persist
infect
three
year
disclosur
author
employe
virbac
canin
leishmaniasi
major
global
parasit
zoonot
diseas
caus
protozoa
leishmania
spp
potenti
fatal
dog
clinic
present
highli
variabl
broad
spectrum
sign
degre
sever
treatment
usual
repres
challeng
due
elev
preval
kidney
diseas
canin
popul
leishmaniasi
import
consid
effect
treatment
drug
renal
side
effect
recent
data
shown
marbofloxacin
leishmanicid
effect
without
caus
chang
renal
paramet
nonazotem
affect
dog
purpos
studi
evalu
efficaci
effect
renal
function
marbofloxacin
dog
leishmaniasi
concurr
chronic
renal
diseas
ckd
twenti
eight
dog
leishmaniasi
ckd
anim
stage
stage
base
iri
recommend
coexist
diseas
enrol
studi
dog
treat
oral
marbofloxacin
dose
mgkgday
day
physic
exam
blood
pressur
cbc
serum
chemistri
profil
urinalysi
includ
urin
creatin
protein
ratio
urinari
cystatin
c
record
baselin
day
treatment
marbofloxacin
day
determin
drug
effect
renal
function
lymph
node
aspir
also
taken
day
quantifi
parasit
load
realtim
pcr
valu
express
meanaes
p
consid
signific
dog
studi
treatment
marbofloxacin
well
toler
obviou
side
effect
clinic
sign
relat
diseas
notabl
improv
dog
impair
renal
function
evidenc
improv
ckd
biomark
signific
decreas
urinari
protein
loss
ae
ae
p
signific
decreas
systol
blood
pressur
ae
ae
mmhg
p
moreov
dog
show
signific
reduct
parasit
load
parasit
load
remain
stabl
relat
aforement
find
dog
show
signific
increas
plasma
albumin
concentr
ae
ae
gl
p
signific
decreas
globulin
concentr
ae
ae
gl
p
signific
chang
found
paramet
studi
conclus
base
result
marbofloxacin
chosen
effect
safe
altern
treatment
dog
leishmania
concurr
ckd
disclosur
disclosur
report
studi
describ
abstract
receiv
financi
support
grant
research
compani
vetoquinol
sa
puppi
critic
period
quantiti
matern
deriv
antibodi
mda
suffici
ensur
passiv
protect
infecti
diseas
could
interfer
develop
activ
immunis
vaccin
studi
aim
evalu
impact
presenc
mda
develop
activ
protect
parvovirosi
canigen
dhppil
vaccin
virbac
franc
sixti
convent
beagl
puppi
week
age
day
male
femal
particip
studi
base
mda
titr
bodi
weight
puppi
alloc
either
vaccin
group
group
two
vaccin
inject
day
day
group
three
vaccin
inject
finish
primari
vaccin
cours
day
unvaccin
group
group
puppi
group
group
receiv
canigen
dhppil
vaccin
formul
minimum
titr
canin
parvoviru
type
strain
blood
sampl
taken
sever
occas
serolog
followup
day
canin
parvoviru
type
antibodi
titr
measur
seroneutralis
test
sn
sn
antibodi
titr
vaccin
consid
posit
correl
clinic
protect
week
age
puppi
puppi
mda
respect
titr
rang
first
vaccin
inject
seroconvers
respect
observ
puppi
without
mda
contrast
seroconvers
rate
respect
puppi
mda
day
independ
presenc
mda
vaccin
puppi
develop
antibodi
cpv
variant
day
second
inject
primari
vaccin
therefor
addit
benefit
sn
antibodi
titr
observ
third
inject
primari
vaccin
field
condit
second
inject
primari
vaccin
canigen
dhppil
perform
week
age
protect
puppi
parvovirosi
due
variant
third
inject
primari
vaccin
week
age
may
remain
need
especi
breed
poor
genet
respons
cpv
vaccin
case
puppi
high
level
mda
titr
persist
beyond
week
age
disclosur
author
employe
virbac
citrobact
spp
higher
resist
frequenc
found
amoxicillinclavulan
acid
thirdgener
cephalosporin
although
lower
resist
aztreonam
ciprofloxacin
amikacin
chloramphenicol
sulphamethoxazolethrimetoprim
also
signific
isol
suscept
meropenem
fifti
percent
isol
multidrugresist
twentyon
mdr
isol
confirm
esblproduc
name
n
n
n
blashv
n
blatem
n
eight
isol
pampc
blacmyproduc
five
isol
also
harbour
blatem
blactxm
esbl
pampcproduc
isol
recov
n
cat
affect
diarrhoea
upper
respiratori
tract
diseas
abscess
otiti
stomat
cystiti
shelter
cat
household
n
receiv
antimicrobi
treatment
time
sampl
collect
esblpampcproduc
e
coli
n
belong
phylogenet
group
collect
n
diarrheic
cat
n
live
shelter
n
household
n
shelter
cat
upper
respiratori
tract
diseas
n
household
cat
cystiti
n
shelter
cat
cystiti
studi
show
dissemin
mdr
enterobacteriacea
varieti
common
defin
clinic
condit
among
felin
popul
southern
itali
type
immun
respons
leishmania
infantum
infect
play
key
role
diseas
progress
prognosi
canin
leishmaniosi
canl
patient
could
therefor
benefit
therapi
aim
modul
immun
system
dietari
nucleotid
activ
hexos
correl
compound
ahcc
although
combin
nmethylglucamin
antimoni
mga
allopurinol
firstlin
therapi
recommend
canl
longterm
allopurinol
administr
may
increas
urinari
xanthin
concentr
lead
urolithiasi
hyperxanthinuria
also
stimul
leishmania
promastigot
growth
vitro
moreov
allopurinol
resist
recent
describ
l
infantum
associ
clinic
relaps
aim
studi
evalu
efficaci
safeti
treatment
consist
mga
combin
dietari
nucleotid
ahcc
dog
clinic
leishmaniosi
sixtynin
dog
natur
occur
clinic
canl
includ
multicentr
openlabel
positivelycontrol
clinic
trial
random
two
group
allopurinol
control
group
mgkg
allopurinol
po
bid
six
month
supplement
group
mgkg
ahcc
mgkg
dietari
nucleotid
impromun
bioiberica
sa
barcelona
spain
po
sid
six
month
dog
receiv
mgkg
mga
glucantim
merial
laboratorio
sa
barcelona
spain
sc
everi
hour
first
day
day
treatment
dog
clinic
evalu
varieti
analyt
measur
blood
urin
bone
marrow
sampl
initi
signific
differ
group
studi
paramet
final
data
analys
allopurinol
n
supplement
n
reveal
significantli
lower
clinic
score
supplement
end
studi
p
total
patient
allopurinol
group
develop
xanthinuria
none
supplement
p
signific
differ
found
group
distribut
studi
patient
accord
iri
stage
chronic
kidney
diseas
treatment
result
significantli
reduc
parasit
load
measur
realtim
quantit
pcr
rtqpcr
increas
ratio
tendenc
normal
protein
electrophoret
pattern
acut
phase
respons
conclus
pilot
studi
combin
mga
supplement
contain
dietari
nucleotid
ahcc
six
month
dog
clinic
leishmaniosi
compar
standard
canl
treatment
mga
plu
allopurinol
result
better
clinic
efficaci
decreas
xanthinuria
gener
improv
clinicopatholog
disord
treatment
disclosur
disclosur
report
sergi
segarra
employ
bioiberica
sa
barcelona
biochem
paramet
includ
alanin
aminotransferas
alt
alkalin
phosphatas
ap
often
use
make
presumpt
diagnosi
liver
diseas
dog
especi
idiopath
copperassoci
form
chronic
hepat
long
subclin
phase
dog
show
clinic
sign
liver
diseas
howev
would
phase
therapeut
intervent
may
effect
dog
breed
hereditari
predisposit
develop
hepat
biochem
screen
subclin
dog
may
valuabl
tool
identifi
affect
dog
earli
stage
therefor
aim
studi
determin
sensit
specif
alt
ap
detect
hepatocellular
injuri
clinic
healthi
labrador
retriev
hereto
patient
file
clientown
clinic
healthi
labrador
retriev
review
labrador
underw
liver
biopsi
screen
copper
toxicosi
part
research
program
copper
associ
hepat
faculti
veterinari
medicin
utrecht
univers
age
sex
liver
histopatholog
result
alt
ap
record
determin
sensit
specif
dog
roc
analys
use
total
dog
show
histolog
abnorm
control
dog
show
hepatocellular
injuri
includ
case
primari
hepat
case
reactiv
hepatopathi
dog
median
alt
ul
rang
median
ap
ul
rang
use
threshold
ul
alt
ul
ap
upper
refer
valu
laboratori
sensit
detect
hepatocellular
injuri
clinic
healthi
dog
alt
ap
specif
alt
ap
respect
new
threshold
alt
ap
determin
use
point
closest
topleft
part
plot
perfect
sensit
specif
new
threshold
ul
alt
ul
ap
use
valu
sensit
increas
alt
ap
specif
decreas
alt
ap
overal
alt
ap
low
sensit
detect
hepatocellular
injuri
labrador
subclin
liver
diseas
decreas
threshold
cutoff
improv
sensit
result
substanti
decreas
specif
therefor
new
biomark
need
earli
detect
subclin
affect
dog
order
avoid
progress
late
stage
hepat
liver
cirrhosi
disclosur
disclosur
report
concentr
thought
common
dog
excess
hepat
cu
result
hepatocyt
damag
oxid
stress
result
cell
death
subsequ
necroinflammatori
chang
accumul
abnorm
hepat
cu
inflammatori
liver
diseas
dog
link
genet
metabol
derang
copper
metabol
environment
factor
excess
dietari
copper
intak
andor
result
cholestat
disord
chelat
therapi
low
cu
diet
often
success
manag
case
abnorm
hepat
cu
goal
studi
determin
incid
abnorm
hepat
cu
liver
biopsi
submit
diagnost
laboratori
correl
hepat
cu
concentr
histolopatholog
diagnosi
hypothes
hepat
cu
would
higher
dog
necroinflammatori
liver
chang
compar
noninflammatori
chang
second
aim
determin
concentr
hepat
cu
relat
extent
hepat
inflamm
examin
record
case
liver
histopatholog
hepat
cu
quantit
year
fresh
liver
tissu
analyz
cu
via
flame
atom
absorpt
spectroscopi
express
lgg
dri
weight
liver
dwl
normal
subset
sampl
receiv
year
cu
concentr
correl
histopatholog
sampl
group
inflammatori
predomin
character
lymphoplasmacyt
suppur
classifi
mild
moder
sever
inflammatori
chang
noninflammatori
sampl
character
hepatocellular
swell
hyperplasia
lipidosi
third
group
character
either
nonspecif
reactiv
hepatopathi
fibrosi
hepat
neoplasia
statist
analysi
includ
twosampl
ttest
oneway
anova
signific
set
p
sampl
cu
quantit
histopatholog
case
hepat
cu
lgg
dwl
mean
cu
concentr
rang
lgg
dwl
inflammatori
liver
diseas
associ
significantli
higher
mean
cu
noninflammatori
diseas
p
mean
cu
inflammatori
group
classifi
mild
moder
sever
significantli
higher
compar
noninflammatori
group
p
find
indic
highest
hepat
cu
concentr
associ
inflammatori
liver
chang
sever
inflammatori
chang
tend
reflect
increas
hepat
cu
cu
associ
liver
diseas
common
histopatholog
demonstr
necroinflammatori
chang
hepat
cu
quantit
disclosur
hepatobiliari
diseas
commonli
encount
dog
divid
four
main
categori
parenchym
biliari
vascular
neoplast
disord
mani
case
clinic
sign
hepatobiliari
diseas
nonspecif
current
biochem
indic
establish
presenc
hepatobiliari
diseas
specifi
underli
diseas
thorough
extens
diagnost
workup
need
recent
microrna
mir
identifi
promis
new
serum
biomark
hepatobiliari
diseas
human
dog
aim
present
studi
investig
whether
serum
level
establish
group
microrna
use
differenti
variou
hepatobiliari
diseas
dog
realtim
polymeras
chain
reaction
use
quantif
microrna
serum
dog
establish
diagnosi
hepatobiliari
diseas
compar
healthi
dog
hepatobiliari
diseas
includ
parenchym
acutechron
hepat
biliari
mucocelescholang
extra
hepat
bile
duct
obstruct
vascular
congenit
portosystem
shunt
neoplast
adenomascarcinomasmalign
lymphoma
subgroup
linear
regress
use
investig
effect
diagnost
subgroup
serum
level
natur
logarithm
differ
microrna
healthi
dog
refer
categori
pvalu
adjust
multipl
comparison
use
benjaminhochberg
correct
microrna
panel
consist
possibl
distinguish
parenchym
biliari
neoplast
hepatobiliari
diseas
within
group
differenti
mention
subgroup
could
made
differenti
microrna
express
found
adenoma
congenit
portosystem
shunt
group
subgroup
increas
level
one
microrna
associ
hepatobiliari
diseas
gener
uniqu
upregul
chronic
hepat
hepatocellular
carcinoma
respect
studi
show
serum
microrna
profil
promis
new
tool
valuabl
diagnos
differenti
sever
common
hepatobiliari
diseas
dog
disclosur
disclosur
report
studi
financi
support
ecvim
clinic
studi
fund
author
declar
conflict
interest
hepat
lipidosi
common
featur
canin
congenit
portosystem
shunt
cpss
howev
origin
signific
lipidosi
fulli
understood
genet
basi
intrahepat
portosystem
shunt
ihpss
extrahepat
portosystem
shunt
ehpss
differ
phenotyp
result
portal
blood
circumv
liver
ident
aim
studi
confirm
hepat
lipidosi
ihpss
ehpss
gain
insight
pathogenesi
behind
hepat
lipid
accumul
cpss
studi
lipid
accumul
cpss
oil
red
stain
perform
hepat
tissu
dog
shunt
ehpss
n
ihpss
n
compar
control
tissu
n
lipid
intens
quantifi
use
imagej
microarray
analysi
perform
liver
tissu
dog
ihpss
n
ehpss
n
compar
control
n
mrna
express
differ
affect
gene
confirm
use
realtim
pcr
ihpss
n
ehpss
n
control
n
statist
differ
calcul
mannwhitney
u
test
group
increas
lipid
content
detect
compar
control
ehpss
p
ihpss
p
use
oil
red
stain
remark
geneexpress
profil
indic
shunt
type
numer
gene
involv
lipid
metabol
appear
list
regul
gene
compar
healthi
tissu
eleven
gene
interest
select
qpcr
base
lipidrel
function
signific
differ
p
mrna
express
confirm
seven
gene
upregul
gene
ihpss
ehpss
crp
plin
wherea
downregul
gene
overal
increas
lipid
concentr
confirm
ihpss
well
ehpss
use
oil
red
addit
lipid
relat
gene
found
aberrantli
express
ihpss
ehpss
dog
indic
hepat
lipidosi
cpss
could
secondari
effect
portosystem
shunt
studi
provid
basi
futur
investig
pathogenesi
behind
lipid
accumul
disclosur
disclosur
report
disclosur
report
liver
diseas
cat
poorli
understood
research
etiolog
pathogenesi
possibl
therapi
hamper
due
lack
suitabl
vitro
cell
cultur
model
cat
adult
stem
cell
cultur
also
known
organoid
ideal
suit
diseas
model
purpos
recent
liver
progenitor
cell
mous
rat
dog
human
liver
success
cultur
vitro
method
permit
threedimension
stabl
longterm
expans
adult
liver
stem
cell
studi
aim
develop
robust
cultur
system
genet
stabl
felin
liver
organoid
mimic
vivo
liver
progenitor
cell
differenti
toward
function
hepatocyt
establish
felin
organoid
cultur
biliari
duct
fragment
isol
five
adult
normal
liver
fresh
liver
frozen
liver
fine
needl
aspir
maintain
cultur
suspens
matrigel
droplet
cultur
medium
character
organoid
cultur
consist
gene
express
profil
quantit
revers
transcriptas
pcr
immunocytochemistri
prolifer
assay
edu
incorpor
induct
hepatocyt
matur
wnt
agonist
withdrawn
notch
signal
inhibit
diseas
model
hepat
lipidosi
liver
organoid
cat
mice
dog
human
incub
either
vehicl
free
fatti
acid
ffa
stain
lipophil
dye
fluoresc
quantifi
use
flow
cytometri
felin
organoid
b
oxid
excess
ffa
studi
use
carnitin
inhibitor
etomoxir
supplement
lcarnitin
organoid
could
cultur
success
felin
liver
sampl
felin
liver
organoid
grew
spheric
structur
highli
prolif
cultur
six
month
passag
organoid
express
adult
stem
cell
marker
hepat
progenitorbiliari
marker
earli
hepatocyt
marker
alb
low
express
matur
hepatocyt
marker
ttr
fah
matur
marker
increas
organoid
cultur
without
wnt
agonist
combin
notch
inhibitor
indic
potenti
differenti
toward
hepatocytelik
phenotyp
felin
liver
organoid
show
lipid
accumul
expos
excess
ffa
accumul
lipid
human
liver
organoid
lipid
accumul
enhanc
b
oxid
block
etomoxir
attenu
medium
supplement
lcarnitin
conclus
felin
liver
organoid
cultur
longterm
liver
sampl
differenti
hepatocytelik
phenotyp
present
first
primari
liver
cell
cultur
system
cat
offer
great
potenti
diseas
model
felin
hepat
lipidosi
disclosur
studi
gener
support
winn
felin
foundat
grant
number
felin
hepat
lipidosi
hl
common
potenti
lifethreaten
diseas
result
prolong
anorexia
increas
catabol
aim
retrospect
studi
identifi
clinic
laboratori
paramet
associ
mortal
data
collect
medic
record
cat
diagnos
hl
base
liver
cytolog
histopatholog
hebrew
univers
veterinari
teach
hospit
year
studi
includ
cat
femal
male
cat
live
indoor
fed
dri
commerci
diet
cat
mixedbre
cat
median
age
year
rang
common
presumpt
primari
condit
includ
gastrointestin
diseas
pancreat
cholangiohepat
cat
stress
event
hl
idiopath
cat
follow
significantli
p
associ
mortal
older
age
dull
weak
hyper
saliv
hypoproteinemia
hypoalbuminemia
increas
serum
creatin
kinas
activ
hypocholesterolemia
hepat
failur
base
presenc
abnorm
liver
function
analyt
present
primari
condit
unassoci
mortal
occurr
hypoalbuminemia
hyperammonemia
hyperbilirubinemia
electrolyt
disord
effus
hypotens
hospit
significantli
p
associ
mortal
decreas
serum
bhydroxybutyr
acid
hospit
significantli
p
associ
surviv
largest
studi
felin
hl
perform
past
year
sever
identifi
prognost
marker
may
therapeut
target
includ
hypoalbuminemia
possibl
predispos
effus
hypotens
hyperammonemia
improv
serum
bhydroxybutyr
acid
concentr
marker
correct
catabol
state
disclosur
disclosur
report
presenc
systol
murmur
appar
halthi
cat
previous
describ
aim
retrospectv
studi
determin
whether
aortosept
angl
aosa
assess
echocardiographi
correl
presenc
systol
murmur
cardiolog
normal
cat
medic
record
januari
march
review
inclus
criteria
includ
normal
echocardiograph
exam
regardless
presenc
cardiac
murmur
cat
also
normotens
systol
blood
pressur
mmhg
euthyroid
cat
echocardiograph
evid
dynam
right
ventricular
outflow
obstruct
includ
cat
normal
diastol
thick
left
ventricl
mild
hypertrophi
subaort
portion
interventricular
septum
also
includ
aosa
measur
right
parastern
five
chamber
view
previous
describ
echocardiograph
paramet
mean
three
consecut
measur
use
statist
fortyon
cat
differ
breed
includ
femal
male
age
ae
mean
ae
sd
cardiac
murmur
without
cardiac
murmur
aosa
cat
cardiac
murmur
significantli
narrow
p
aosa
cat
without
cardiac
murmur
presenc
septal
hypertrophi
associ
presenc
systol
murmur
p
cat
septal
hypertrophi
older
p
howev
correl
aosa
age
p
conclus
narrow
aosa
associ
presenc
systol
murmur
cat
might
consid
potenti
caus
eject
murmur
appar
healthi
cat
longitudin
studi
need
assess
narrow
aosa
might
play
role
remodel
interventricular
septum
level
left
outflow
tract
disclosur
disclosur
report
high
degre
accuraci
requir
use
echocardiographi
diagnos
hypertroph
cardiomyopathi
hcm
cat
variat
measur
mm
may
affect
classif
individu
normal
abnorm
studi
adult
cat
analys
interobserv
variabl
two
echocardiograph
specialist
veterinari
cardiolog
train
twentyfour
femal
european
shorthair
cat
colonyh
compliant
eu
regul
examin
month
age
observ
cardiac
ultrasound
imag
taken
consciou
cat
measur
aortic
diamet
ao
left
atrial
diamet
la
diastol
interventricular
septum
ivsd
diastol
interventricular
septum
outflow
ivsdlvot
diastol
systol
left
ventricular
intern
dimens
lvidd
diastol
left
ventricular
free
wall
lvpwd
left
ventricular
free
wall
outflow
lvpwdlvot
cardiac
ultrasound
measur
repeat
observ
store
imag
measur
analys
effect
age
observ
mean
valu
time
point
ageobserv
interact
addit
base
ivsd
lvpw
thick
cat
categor
normal
mm
mm
cat
kg
bw
abnorm
gundler
et
al
linear
mix
model
generalis
appropri
perform
use
sa
cat
defin
random
term
normal
residu
distribut
model
involv
quantit
output
check
level
signific
posthoc
analys
adjust
arisk
inflat
signific
effect
age
ao
p
ivsd
p
ivsdlvot
p
livdd
p
lvid
p
signific
ageobserv
interact
found
paramet
signific
differ
observ
found
ivsd
p
ivsdlvot
p
lvidd
lvid
p
lvpwlvot
p
lvpw
p
measur
higher
ivsd
ivsdlvot
higher
measur
differ
estim
mean
valu
rang
lvpw
ivsd
differ
mean
valu
mm
paramet
except
lvidd
mm
cat
weigh
kg
bw
classif
cat
abnorm
mm
significantli
differ
observ
ivsd
p
lvpw
interobserv
variabl
signific
paramet
although
independ
cat
age
interobserv
differ
exceed
mm
lvidd
caution
warrant
determin
find
left
ventricular
hypertrophi
base
ivsd
thick
due
signific
interobserv
differ
measur
disclosur
disclosur
report
feugier
van
hoek
employe
royal
canin
sa
aimargu
franc
wellknown
congenit
thorac
cardiovascular
anomali
dog
patent
ductu
arteriosu
persist
right
aortic
arch
cardiovascular
anomali
clinic
signific
preval
report
veterinari
medicin
contrari
development
anomali
thorac
vessel
may
caus
clinic
sign
usual
detect
identifi
incident
find
preval
unknown
howev
might
import
interfer
thorac
surgeri
intervent
procedur
interpret
thorac
imag
possibl
aim
studi
therefor
determin
preval
anatom
variat
great
thorac
vessel
ct
thorac
studi
dog
carri
langford
veterinari
servic
univers
bristol
review
poor
qualiti
ct
young
dog
clinic
evid
congenit
cardiac
diseas
regurgit
exclud
total
studi
met
inclus
criteria
panel
three
board
cardiologist
one
board
diagnost
imag
review
abnorm
overal
dog
show
anatom
anomali
common
anomali
aberr
retroesophag
right
subclavian
arteri
n
one
dog
show
dilat
azygo
vein
associ
coarctat
caudal
vena
cava
none
dog
persist
left
cranial
vena
cava
anatom
variat
observ
includ
three
type
branch
common
carotid
arteri
arteri
aris
point
type
present
dog
n
arteri
aris
separ
type
ii
identifi
dog
n
common
trunk
bicarotid
trunk
type
iii
dog
n
case
n
azygo
vein
drain
cranial
vena
cava
n
right
atrium
n
drainag
site
equivoc
incident
anatom
anomali
thorac
great
vessel
appear
rare
dog
n
dog
undergo
thorac
ct
show
anomali
aberr
retroesophag
right
subclavian
arteri
common
abnorm
persist
left
cranial
vena
cava
appear
uncommon
detect
dog
present
popul
three
differ
branch
pattern
common
carotid
arteri
identifi
type
carotid
aris
point
brachyocephal
trunk
frequent
disclosur
disclosur
report
author
conflict
interest
disclosur
declar
regard
studi
differ
sed
agent
commonli
use
veterinari
medicin
due
hemodynam
effect
may
alter
echocardiograph
measur
cat
screen
heart
diseas
hypertroph
cardiomyopathi
hcm
object
studi
evalu
effect
sedat
combin
dexmedetomidin
buprenorphin
echocardiograph
variabl
blood
pressur
heart
rate
hr
healthi
cat
healthi
clientown
cat
prospect
includ
studi
cat
sedat
dexmedetomidin
buprenorphin
dose
adjust
bodi
weight
standard
echocardiograph
doppler
examin
blood
pressur
hr
measur
perform
prior
sedat
repeat
ten
minut
sedat
result
compar
use
nonparametr
method
left
ventricular
intern
diamet
enddiastol
lvidd
systol
lvid
right
ventricular
intern
diamet
enddiastol
rvidd
left
atrium
la
pulmon
deceler
time
systol
sbp
diastol
dbp
mean
arteri
map
blood
pressur
increas
sedat
p
aortic
v
max
ao
pulmon
arteri
vmax
pulm
maximum
veloc
fraction
shorten
fs
accelerationdeceler
time
atdt
hr
decreas
sedat
p
interventricular
septum
enddiastol
ivsd
systol
ivss
left
ventricular
posterior
wall
enddiastol
lvpwd
systol
lvpw
aortic
diamet
ao
left
atrialaort
diamet
laao
pulmon
acceler
time
differ
preand
postsed
sed
dosag
signific
effect
echocardiograph
variabl
blood
pressur
hr
conclus
blood
pressur
increas
hr
decreas
sedat
echocardiograph
variabl
import
hcmscreen
ie
wall
thick
laao
affect
combin
dexmedetomidin
buprenorphin
disclosur
disclosur
report
medetomidin
expect
depress
cardiac
perform
dog
increas
vagal
tone
via
baroreceptor
stimul
consequ
bradycardia
drop
cardiac
output
inotropi
asymptomat
dog
suffer
mixomat
mitral
valv
diseas
mmvd
previou
studi
show
reduct
mitral
regurgit
appear
colorflow
doppler
echocardiographi
counterpart
possibl
loss
contractil
hypothesi
present
studi
combin
propofol
use
endotrach
intub
warrant
provid
vasodil
inhibit
baroreflex
vagalrel
undesir
event
would
prevent
reduc
dog
weigh
less
kg
need
sedat
endotrach
intub
short
noninvas
procedur
show
systol
apic
heart
murmur
recruit
mmvd
confirm
laao
sed
protocol
consist
iv
inject
lgkg
medetomidin
group
follow
singl
iv
bolu
mgkg
propofol
mp
group
sedat
revers
im
inject
atipamezol
dog
screen
enrol
randomli
assign
equal
mp
group
clinic
paramet
echocardiograph
variabl
thorac
radiograph
oscillometr
blood
pressur
measur
collect
blind
fashion
baselin
minut
medetomidin
administr
three
hour
atipamezol
inject
regurgit
jet
area
arjlaa
significantli
decreas
group
shorten
fraction
bodi
weightindex
lvid
decreas
increas
respect
group
p
systol
blood
pressur
show
valu
upper
physiolog
limit
group
signif
decreas
mp
group
signific
chang
record
laao
time
point
group
valu
remain
bodi
weightindex
lvidd
echocardiograph
variabl
show
particular
trend
thorac
radiograph
evoc
heart
enlarg
without
pulmonari
venou
congest
pulmonari
oedema
respiratori
rate
chang
heart
rate
show
similar
signif
decreas
group
degre
sedat
optim
clinic
procedur
case
sedat
lgkg
medetomidin
combin
propofol
dose
mgkg
use
endotrach
intub
safe
dog
suffer
mmvd
stage
laao
affect
inotropi
less
medetomidin
use
alon
disclosur
disclosur
report
prospect
observ
studi
aim
quantifi
interobserv
ieo
agreement
cardiologist
noncardiologist
underw
train
cours
echocardiographi
ultrasonograph
ivcd
focus
echocardiograph
paramet
healthi
beagl
dog
two
veterinari
internist
one
resid
one
specialist
novic
echocardiographi
underw
echocardiographi
train
cours
one
month
later
healthi
beagl
dog
examin
time
two
internist
one
cardiologist
ivcd
assess
via
subxiphoid
window
ivcsx
dorsolater
window
ivcdl
caudal
last
rib
blandaltman
analysi
use
assess
ieo
agreement
two
seri
clinic
measur
coeffici
variat
cv
calcul
quantifi
ieo
variabl
widest
limit
agreement
loa
la
minor
lvidd
lvid
laao
fs
mm
mm
mm
cv
respect
ivcdsx
loa
ivcd
min
ivcd
max
ae
cm
ae
cm
cv
respect
ivcdld
loa
ae
cm
cv
base
interobserv
reproduc
minim
train
ec
seem
suffici
measur
standard
cardiac
paramet
evalu
ivcld
consid
good
base
narrow
ioa
howev
ivcdsx
consid
unaccept
may
due
variat
measur
ivcd
ivcsx
effect
respiratori
cycl
minim
maxim
measur
standard
ivcsx
techniqu
investig
impact
respiratori
phase
ivcd
dog
need
train
cours
echocardiographi
seem
suffici
train
non
cardiologist
veterinarian
measur
ivcdld
basic
echocardiograph
paramet
healthi
beagl
dog
studi
need
determin
whether
ieo
accept
breed
differ
bodi
conform
valu
measur
estim
volum
statu
clinic
set
remain
determin
ivcdsx
measur
requir
standard
allow
quantit
analysi
disclosur
disclosur
report
dyspnea
caus
primari
respiratori
diseas
congest
heart
failur
common
emerg
dog
earli
accur
diagnosi
essenti
optim
therapi
howev
physic
examin
pe
alon
may
insuffici
differenti
caus
dyspnea
patient
instabl
frequent
necessit
delay
radiographi
echocardiographi
human
patient
emerg
clinicianperform
focus
cardiac
ultrasound
fcu
help
differenti
caus
dyspnea
quickli
safe
hypothes
fcu
perform
emerg
critic
care
ecc
clinician
would
improv
diagnost
accuraci
dyspneic
dog
compar
medic
histori
pe
alon
ecc
faculti
resid
underw
structur
fcu
train
program
goal
includ
recogn
basic
cardiac
structur
function
quantit
measur
left
atrial
aortic
root
diamet
laao
right
parastern
view
dog
present
dyspnea
univers
pennsylvania
veterinari
hospit
prospect
recruit
exclus
criteria
includ
intraven
fluid
therapi
within
hour
present
known
trauma
sever
system
diseas
preclud
particip
medic
histori
pe
fcu
obtain
present
ecc
clinician
blind
radiograph
echocardiograph
data
record
diagnosi
respiratori
r
cardiac
c
fcu
thorac
radiographi
perform
within
hour
echocardiographi
perform
cardiologist
cardiolog
resid
within
hour
ecc
clinician
diagnost
accuraci
calcul
goldstandard
diagnosi
agreement
boardcertifi
cardiologist
criticalist
access
diagnost
test
result
comparison
group
made
use
mannwhitney
test
agreement
laao
fcu
echocardiographi
investig
use
univari
linear
regress
signific
set
p
thirtyeight
dog
recruit
dog
goldstandard
diagnosi
could
determin
remain
dog
use
analysi
group
r
group
c
laao
echocardiographi
p
fcu
p
vertebr
heart
size
p
significantli
higher
group
c
vs
group
r
laao
fcu
echocardiographi
significantli
associ
b
p
r
prior
fcu
dog
ci
correctli
diagnos
ecc
clinician
two
cardiac
respiratori
case
misassign
follow
fcu
examin
dog
correctli
diagnos
one
cardiac
respiratori
case
misassign
dog
correct
diagnosi
reassign
incorrectli
follow
fcu
conclus
perform
fcu
ecc
clinician
follow
train
improv
diagnost
accuraci
compar
medic
histori
pe
alon
dyspneic
dog
disclosur
disclosur
report
multipl
studi
shown
import
arrhythmia
secondari
cardiac
well
extracardiac
diseas
splenic
mass
trauma
dog
arrhythmia
commonli
implic
plausibl
caus
sudden
death
although
sudden
death
commonli
recogn
cat
littl
known
import
arrhythmia
associ
primari
secondari
myocardi
injuri
therefor
aim
studi
determin
frequenc
complex
arrhythmia
cat
symptomat
hypertroph
dilat
restrict
cardiomyopathi
transient
congest
heart
failur
refer
myocard
thorac
trauma
holter
examin
analyz
number
ventricular
vpc
supraventricular
prematur
beat
apc
arrhythmia
complex
ventricular
tachycardia
vtach
ront
supraventricular
tachycardia
svt
addit
arrhythmia
nine
cat
thorac
trauma
cat
hypertroph
cardiomyopathi
hcm
myocard
restrict
cardiomyopathi
rcm
dilat
cardiomyopathi
dcm
enrol
median
heart
rate
higher
cat
hcm
vtach
found
hcm
longest
beat
myocard
longest
beat
rcm
longest
beat
dcm
longest
beat
cat
intermitt
complet
avblock
found
rcm
cat
atrial
fibril
afib
found
hcm
intermitt
sustain
rcm
intermitt
cat
svt
found
hcm
longest
beat
myocard
longest
beat
dcm
longest
beat
frequenc
arrhythmia
significantli
higher
cat
cardiomyopathi
compar
cat
myocard
thorac
trauma
serum
troponin
concentr
higher
cat
myocard
quantiti
complex
arrhythmia
markedli
higher
studi
similar
previou
studi
interestingli
chronic
myocardi
remodel
less
measur
myocardi
cell
death
arrhythmogen
acut
myocardi
damag
compar
dog
trauma
even
chest
suspect
myocard
appear
caus
clinic
import
arrhythmia
contrast
arrhythmia
may
quit
sever
cat
primari
heart
diseas
conceiv
may
caus
sudden
death
disclosur
disclosur
report
poincar
e
scatterplot
creat
plot
rr
interv
subsequ
rr
interv
remain
larg
unexploit
mean
heart
rate
variabl
hrv
analysi
dog
primari
aim
studi
describ
poincar
e
plot
pattern
normal
dog
establish
refer
rang
quantit
descriptor
repres
shortterm
hrv
repres
longterm
hrv
repres
sympathovag
balanc
compar
descriptor
convent
measur
hrv
secondari
aim
explor
effect
activ
level
poincar
e
plot
twentyfour
hour
ambulatori
ecg
record
obtain
healthi
dog
analys
use
novacor
holtersoft
ultima
version
time
frequencydomain
measur
hrv
poincar
e
plot
descriptor
gener
refer
rang
calcul
use
refer
valu
advisor
addit
poincar
e
plot
develop
hour
nighttim
data
sleep
hour
daytim
data
activ
hour
poincar
e
plot
demonstr
pattern
differ
comet
shape
describ
normal
human
refer
rang
ms
ms
show
statist
signific
correl
mean
heart
rate
sdnn
sdnnidx
rmssd
posit
correl
also
found
sdann
hf
msec
lf
msec
p
r
comparison
poincar
e
plot
deriv
day
nighttim
data
confirm
arm
shape
deriv
mostli
period
rest
period
activ
popul
stalk
shape
valu
deriv
daytim
data
mean
ms
ms
significantli
lower
valu
deriv
nighttim
data
mean
ms
ms
indic
overal
reduct
hrv
day
support
statist
signific
decreas
sdnn
mean
night
ms
day
ms
mean
night
day
sdnnidx
mean
night
ms
day
ms
rmssd
mean
night
ms
day
ms
conclus
hour
poincar
e
plot
show
distinct
pattern
healthi
dog
standard
descriptor
correl
convent
measur
hrv
clinic
use
limit
wide
refer
rang
amount
activityrest
within
record
mark
effect
poincar
e
plot
pattern
associ
quantit
descriptor
disclosur
disclosur
report
symmetr
dimethylarginin
sdma
promis
new
marker
felin
renal
function
potenti
detect
kidney
diseas
earli
stage
dimethylarginin
interfer
nitric
oxid
format
inhibit
nitric
oxid
synthas
lead
increas
level
sdma
human
cardiovascular
diseas
includ
hypertroph
cardiomyopathi
hcm
aim
studi
assess
serum
sdma
cat
hcm
compar
healthi
cat
cat
kidney
diseas
serum
sdma
concentr
measur
felin
serum
sampl
idexx
sdma
trademark
store
previou
research
cat
one
year
age
classifi
hcm
sign
azotem
kidney
diseas
kidney
diseas
sign
cardiac
diseas
clinic
healthi
base
follow
paramet
physic
examin
echocardiographi
ecg
blood
pressur
measur
hematolog
biochemistri
thyroxin
cat
year
age
healthi
cat
cat
kidney
diseas
urinanalysi
twoway
anova
age
diseas
group
factor
tukeyhsd
post
hoc
analysi
perform
logtransform
sdma
present
median
rang
cat
hcm
lgdl
healthi
cat
lgdl
significantli
lower
sdma
concentr
p
compar
cat
kidney
diseas
lgdl
signific
differ
cat
hcm
healthi
cat
p
result
indic
hcm
caus
increas
concentr
sdma
cat
sdma
may
therefor
valid
marker
gfr
patient
disclosur
idexx
laboratori
provid
financi
support
serum
sdma
analysi
describ
submit
abstract
hypertroph
cardiomyopathi
hcm
common
cat
variabl
prognosi
rang
clinic
sign
cardiac
death
congest
heart
failur
chf
may
manifest
pleural
effus
pleff
andor
pulmonari
edema
ped
reduc
left
ventricular
lv
systol
function
associ
increas
risk
chf
cat
hcm
human
mmode
deriv
measur
longitudin
displac
mitral
tricuspid
annular
plane
maps
taps
respect
consid
import
determin
systol
function
reduc
human
patient
hcm
aim
studi
evalu
maps
taps
healthi
control
cat
cat
hcm
hypothes
cat
hcm
lower
maps
taps
valu
control
cat
pleff
ae
ped
lower
maps
taps
valu
cat
ped
alon
lower
maps
taps
valu
associ
reduc
surviv
electron
patient
record
veterinari
teach
hospit
retrospect
review
cat
evalu
echocardiographi
cat
inadequ
echocardiograph
imag
diseas
result
lvh
exclud
cat
includ
hcm
group
lv
wall
thick
mm
healthi
cat
undergo
echocardiographi
lv
wall
thick
mm
includ
control
anatom
mmode
left
apic
fourchamb
view
use
record
maps
free
wall
mapsefw
septum
mapseiv
taps
studi
includ
cat
hcm
asymptomat
chf
control
cat
compar
control
hcm
cat
lower
mapseiv
mm
vs
mm
p
mapsefw
mm
iqr
vs
mm
p
taps
mm
iqr
vs
mm
p
within
hcm
group
cat
chf
lower
mapseiv
mm
vs
mm
p
mapsefw
mm
vs
mm
p
taps
mm
vs
mm
p
compar
asymptomat
cat
mapsefw
lower
cat
pleff
ae
ped
mm
ped
alon
mm
p
logrank
analysi
show
shorter
surviv
cat
lower
mapseiv
p
mapsefw
p
taps
p
conclus
longitudin
lv
systol
function
assess
maps
taps
lower
cat
hcm
lowest
patient
overt
chf
lower
maps
taps
also
associ
shorter
surviv
time
suggest
systol
longitudin
dysfunct
present
cat
hcm
prognost
signific
disclosur
disclosur
report
differ
speci
increas
circul
serotonin
concentr
link
develop
valvular
lesion
similar
seen
myxomat
mitral
valv
diseas
mmvd
canin
refer
valu
circul
lack
previou
studi
suggest
breed
differ
healthi
dog
higher
concentr
cavali
king
charl
spaniel
ckc
breed
highli
affect
mmvd
studi
aim
investig
interbre
variat
serum
healthi
dog
healthi
privatelyown
dog
age
year
breed
examin
european
center
absenc
cardiovascular
clinic
relev
organrel
system
diseas
ensur
thorough
clinic
investig
includ
echocardiographi
serum
frozen
store
later
analyz
batch
valid
elisa
median
concentr
interquartil
rang
ngml
overal
differ
found
breed
well
center
examin
femal
dog
higher
concentr
p
age
associ
concentr
bonferronicorrect
pairwis
comparison
breed
signific
comparison
within
center
overal
breed
differ
found
center
p
pairwis
bonferronicorrect
analysi
within
center
show
breed
differ
comparison
includ
center
breed
sex
multilinear
regress
analysi
final
model
adjust
breed
center
remain
signific
p
newfoundland
belgian
shepherd
ckc
highest
concentr
valu
approxim
time
higher
dachshund
finnish
lapphund
german
shepherd
lowest
concentr
conclus
interbre
variat
serum
concentr
found
healthi
dog
year
age
differ
like
influenc
genet
factor
taken
account
design
clinic
trial
disclosur
disclosur
report
precordi
lead
system
consist
group
unipolar
lead
place
thorac
surfac
record
electr
activ
heart
horizont
plane
human
medicin
sequenc
ventricular
depolar
result
characterist
qr
complex
pattern
precordi
lead
rs
r
ratio
right
precordi
lead
qr
left
precordi
lead
purpos
prospect
studi
evalu
qr
complex
morpholog
precordi
lead
use
previous
describ
precordi
lead
system
dog
differ
morphotyp
sixti
healthi
dog
enrol
underw
physic
examin
thorac
radiograph
electrocardiogram
use
system
previous
describ
standard
echocardiographi
dog
alloc
three
group
accord
thorac
index
dorsoventr
thorax
diamet
x
thorax
diamet
brachycephal
dolicocephal
mesocephal
shapirowilcoxon
wtest
use
test
normal
mean
valu
ae
standard
deviat
well
median
rang
calcul
nonparametr
analysi
varianc
perform
data
evalu
differ
qr
complex
appear
among
three
thorax
shape
kruska
walli
test
evalu
repeat
three
measur
intraclass
correl
coeffici
execut
data
analysi
perform
commerci
avail
statist
softwar
sa
q
wave
absent
group
present
dolicocephal
group
group
r
wave
amplitud
precordi
lead
statist
differ
three
group
p
brachycephal
group
show
lowest
r
wave
amplitud
dolicocephal
group
present
highest
r
wave
amplitud
wave
p
p
statist
differ
three
group
show
highest
amplitud
dolicocephal
group
lowest
amplitud
mesocephal
group
r
ratio
precordi
lead
except
statist
differ
three
group
lead
brachycephal
dog
present
ratio
r
dolicocephal
mesocephal
dog
r
p
base
data
previous
propos
precordi
lead
system
provid
correct
evalu
ventricular
depolar
right
ventricl
lead
brachiocephal
dog
due
differ
orient
cardiac
dipol
thorax
studi
need
evalu
altern
posit
lead
latter
two
group
dog
disclosur
disclosur
report
human
earli
identif
diseas
possibl
detect
repolaris
abnorm
precordi
chest
lead
particularli
twave
invers
possibl
jpoint
abnorm
hypothes
ecg
abnorm
would
abl
identifi
arvc
popul
boxer
dog
ecg
prospect
record
adult
boxer
dog
present
cardiolog
servic
five
veterinari
referr
centr
one
gener
practic
uk
dog
aortic
stenosi
exclud
arvc
n
diagnos
base
upon
presenc
h
holter
control
dog
n
evid
ventricular
arrhythmia
signific
heart
murmur
clinic
sign
histori
cardiovascular
diseas
wave
classifi
posit
neg
precordi
chest
lead
j
wave
record
present
absent
identif
jpoint
slur
notch
describ
human
signific
differ
age
weight
sex
group
jpoint
abnorm
identifi
dog
greatest
lead
variabl
differ
precordi
lead
signific
differ
frequenc
jpoint
abnorm
identifi
dog
arvc
vs
control
p
frequenc
twave
invers
vari
accord
chest
lead
lead
rare
arvc
control
lead
common
arvc
control
arvc
dog
significantli
greater
preval
twave
invers
lead
vs
control
p
lead
vs
control
p
roc
analysi
perform
twave
invers
lead
sensit
specif
detect
arvc
auc
p
popul
dog
preval
arvc
posit
predict
valu
neg
predict
valu
conclus
twave
invers
lead
preval
boxer
dog
arvc
control
dog
pilot
studi
disclosur
disclosur
report
bridg
membran
anchor
protein
organ
cardiac
dyad
facilit
calciuminduc
calcium
releas
sarcoplasm
reticulum
excitationcontract
coupl
human
patient
plasma
concentr
reduc
patient
arrhythmogen
right
ventricular
cardiomyopathi
arvc
neg
correl
sever
ventricular
tachycardia
boxer
dog
predispos
arvc
hypothes
plasma
would
lower
affect
dog
neg
correl
ventricular
arrhythmia
boxer
dog
year
age
without
arvc
group
arvc
boxer
control
bc
respect
dog
stage
preclin
myxomat
mitral
valv
diseas
mmvd
healthi
control
dog
hc
recruit
dog
underw
physic
examin
echocardiographi
blood
sampl
measur
plasma
group
arvc
bc
mmvd
underw
measur
plasma
ntermin
probtyp
natriuret
peptid
ntprobnp
cardiac
troponin
ctni
boxer
underw
hour
ecg
monitor
genotyp
striatin
mutat
comparison
group
made
use
kruskalw
mannwhitney
test
univari
regress
model
construct
investig
relationship
plasma
concentr
clinic
variabl
binari
logist
regress
model
construct
investig
clinic
predictor
arvc
posit
statu
signific
set
p
twentythre
dog
without
evid
congest
heart
failur
recruit
bc
arvc
mmvd
hc
plasma
concentr
significantli
differ
bc
ngml
rang
arvc
ngml
mmvd
ngml
hc
ngml
group
p
ntprobnp
p
ctni
concentr
significantli
differ
group
arvc
dog
significantli
greater
number
ventricular
prematur
complex
per
hour
vpcshr
p
bc
howev
correl
vpcshr
b
p
longest
run
ventricular
tachycardia
p
maximum
rate
ventricular
tachycardia
p
striatin
mutat
p
left
ventricular
enddiastol
dimens
p
fraction
shorten
p
binari
logist
regress
analysi
detect
signific
clinic
predictor
arvc
vs
bc
statu
conclus
plasma
concentr
decreas
canin
arvc
patient
concurr
heart
failur
larger
cohort
longitudin
studi
may
determin
mark
transit
function
heart
fail
heart
disclosur
disclosur
report
multicent
studi
tmtchf
case
enrol
anteced
event
lvwt
decreas
ci
month
mm
mm
p
laao
also
decreas
p
ctni
elev
present
normalis
myocardi
thicken
resolv
ctni
ngml
vs
ngml
p
therapi
discontinu
tmtchf
cat
ci
month
present
cat
remain
asymptomat
tmtchf
affect
younger
cat
anteced
event
common
howev
clinic
echocardiograph
characterist
present
differenti
two
group
tmt
caus
chf
cat
better
prognosi
hcmchf
disclosur
disclosur
report
prospect
enrol
firsttim
dyspnoeic
cat
present
firstopinion
practic
collect
signal
histor
clinic
data
present
use
standard
form
firstopinion
clinician
investig
case
supervis
clinician
dd
cl
jh
review
final
diagnosi
categoris
case
cardiac
respiratori
neoplast
traumat
miscellan
base
upon
object
accept
clinic
radiograph
echocardiograph
postmortem
criteria
record
lack
critic
data
exclud
relationship
historicalclin
variabl
dyspnoea
aetiolog
examin
receiv
oper
characterist
roc
standard
diagnost
test
perform
analys
use
find
optim
cutoff
select
histor
clinic
variabl
could
differenti
cardiac
noncardiac
dyspnoea
total
cat
enrol
definit
diagnosi
reach
case
fiftyeight
cardiac
respiratori
neoplasia
traumat
fifteen
cat
cardiac
dyspnoea
recent
histori
cough
fifteen
cat
heart
murmur
cardiac
group
two
neoplasia
thirteen
cat
gallop
sound
cardiac
group
eleven
arrhythmia
cardiac
one
traumat
individu
variabl
help
identifi
congest
heart
failur
chf
aetiolog
dyspnea
includ
presenc
gallop
sound
rectal
temperatur
heart
rate
bpm
respiratori
rate
find
low
sensit
high
specif
predict
posttest
probabl
histori
cough
fail
exclud
chf
aetiolog
find
provid
firstopinion
clinician
simpl
mean
stratifi
dyspnoeic
felin
patient
dyspnoeic
cat
hypothermia
tachycardia
gallop
sound
profound
tachypnea
like
chf
underli
dyspnea
addit
diagnost
requir
cat
without
find
help
differenti
aetiolog
cat
histori
cough
automat
assum
noncardiac
disclosur
disclosur
report
one
author
salari
paid
vin
author
reciev
speaker
honoraria
pharmaceut
compani
deliv
lectur
gener
practition
none
relat
research
direct
indirect
financi
support
provid
research
felin
cardiomyopathi
current
classifi
accord
human
system
despit
poor
character
felin
phenotyp
includ
effect
age
difficulti
ascrib
categori
mani
cat
unknown
etiolog
case
lack
diagnost
consensu
aim
appli
cluster
analysi
techniqu
determin
whether
gross
histopatholog
find
cat
without
myocardi
diseas
could
use
construct
altern
cardiomyopathi
classif
heart
cat
submit
necropsi
march
decemb
examin
prospect
singl
train
observ
use
standard
set
criteria
macroscop
microscop
evalu
assign
diagnosi
base
convent
classif
cluster
analysi
perform
use
twostep
cluster
method
heart
analys
sequenti
felin
necropsi
cluster
analysi
carri
subset
cat
complet
data
cat
median
age
year
male
pedigre
believ
die
result
heart
diseas
cluster
analysi
result
two
cluster
cat
cluster
extens
replac
p
interstiti
p
perivascular
p
subendocardi
fibrosi
p
like
intramur
arteriosclerosi
p
left
atrial
enlarg
p
inflammatori
cell
infiltr
p
cat
cluster
addit
cat
cluster
greater
score
myofib
disarray
p
greater
myocyt
hypertrophi
p
thicker
right
ventricular
wall
p
heart
weight
significantli
greater
cat
cluster
p
cat
cluster
like
die
cardiac
diseas
p
classif
base
convent
patholog
cat
cluster
hypertroph
cardiomyopathi
hcm
n
endstag
hcm
n
endomyocardi
form
restrict
cardiomyopathi
ercm
n
unclassifi
cardiomyopathi
ucm
n
cat
cluster
classifi
normal
n
hcm
n
ercm
n
dilat
cardiomyopathi
n
arrhythmogen
right
ventricular
cardiomyopathi
n
inflammatori
epicarditismyocarditisendocard
n
ucm
n
cluster
analysi
fail
identifi
distinct
phenotyp
would
correspond
current
describ
form
felin
cardiomyopathi
instead
cluster
appear
reflect
diseas
sever
suggest
either
current
describ
felin
cardiomyopathi
spectrum
singl
diseas
gross
patholog
combin
semiquantit
histopatholog
use
light
microscopi
insuffici
allow
discrimin
disclosur
disclosur
report
boehring
ingelheim
phd
support
fund
ceva
speaker
fee
aratana
grant
fund
cardiologist
grade
murmur
intens
ordin
scale
modifi
system
propos
levin
previou
studi
smallbre
dog
mitral
valv
diseas
demonstr
clinic
use
inform
obtain
classifi
murmur
scale
scale
provid
addit
probabilist
inform
probabl
congest
heart
failur
pulmonari
hypertens
whether
classifi
murmur
dog
pulmon
stenosi
ps
subaort
stenosi
sa
scale
provid
use
clinic
inform
simpl
classif
scheme
suffic
unknown
therefor
examin
abil
murmur
intens
predict
sever
ps
sa
dog
dog
ps
dog
sa
identifi
medic
record
dog
year
old
includ
dog
sa
year
old
exclud
dog
complex
cardiac
defect
undergon
intervent
procedur
receiv
cardiac
medic
exclud
murmur
grade
scale
note
attend
cardiologist
dopplerderiv
pressur
gradient
pg
across
stenot
valv
record
murmur
reclassifi
use
descript
scale
soft
moder
loud
palpabl
dog
soft
murmur
grade
ii
pg
mmhg
regardless
diseas
dog
moder
grade
iii
murmur
pressur
gradient
mmhg
pg
mmhg
howev
dog
loud
murmur
dog
palpabl
murmur
pressur
gradient
mmhg
sever
stenosi
increas
increas
murmur
intens
howev
murmur
rate
soft
grade
ii
inform
casebycas
basi
soft
murmur
specif
sensit
identifi
pg
mmhg
dog
ps
sa
soft
grade
ii
murmur
mild
diseas
dog
palpabl
murmur
mostli
sever
diseas
requir
addit
diagnost
therefor
simpl
scale
soft
soft
palpabl
suffic
physic
evalu
dog
ps
sa
addit
inform
obtain
complex
classif
disclosur
disclosur
report
differenti
innoc
cardiac
murmur
patholog
one
challeng
first
opinion
veterinari
practic
aim
studi
investig
whether
phonocardiogram
plasma
ntprobnp
level
help
differenti
hypothes
plasma
ntprobnp
level
puppi
innoc
cardiac
murmur
differ
without
murmur
wherea
ntprobnp
level
puppi
sever
congenit
cardiac
anomali
increas
also
phonocardiograph
characterist
innoc
cardiac
murmur
expect
differ
patholog
murmur
septemb
septemb
asymptomat
cairn
terrier
puppi
auscult
breeder
particip
voluntari
screen
program
congenit
portosystem
shunt
blood
collect
individu
measur
blood
ammonia
level
surplu
plasma
sampl
ntprobnp
measur
median
age
puppi
rang
day
puppi
innoc
murmur
period
asymptomat
young
dog
refer
cardiolog
servic
evalu
murmur
median
age
day
rang
day
dog
murmur
underw
echocardiogram
day
perform
cardiologist
auscult
dog
refer
dog
wide
rang
congenit
anomali
found
besid
phonocardiogram
record
electron
stethoscop
point
maxim
intens
murmur
phonocardiogram
view
analyz
comput
screen
quantit
descript
phonocardiogram
murmurtosystol
durat
ratio
calcul
median
ntprobnp
level
puppi
without
murmur
differ
puppi
innoc
murmur
rang
versu
rang
pmoll
p
median
ntprobnp
concentr
group
congenit
cardiac
anomali
rang
pmoll
anomali
caus
leftsid
overload
result
higher
level
rightsid
stenot
disord
dog
sever
cardiac
disord
higher
ntprobnp
level
innoc
cardiac
murmur
median
murmurtosystol
ratio
rang
significantli
shorter
median
murmurtosystol
ratio
congenit
cardiac
anomali
rang
p
dog
sever
congenit
cardiac
anomali
especi
pulmon
stenosi
may
low
ntprobnp
valu
ntprobnp
measur
suitabl
routin
screen
test
detect
congenit
cardiac
anomali
howev
ntprobnp
level
exceed
pmoll
murmur
longer
systol
phonocardiogram
like
caus
congenit
cardiac
anomali
disclosur
disclosur
report
dog
differ
breed
includ
mildmoder
mmvd
minim
mmvd
dog
underw
clinic
examin
standard
echocardiograph
examin
contrast
echocardiographi
util
secondgener
contrast
medium
assess
mp
ptt
clinic
echocardiograph
variabl
regress
mp
ptt
evalu
linear
quadrat
fit
variabl
show
p
enter
multipl
linear
regress
model
perform
stepwis
backward
manner
use
p
threshold
ptt
variabl
enter
multipl
regress
model
increas
fraction
shorten
fs
p
eject
fraction
ef
p
bw
normal
left
ventricular
lv
volum
systol
lvvsn
p
lv
diamet
diastol
lviddn
p
associ
increas
ptt
increas
bw
normal
lv
free
wall
systol
lvfwn
associ
decreas
ptt
p
adjust
r
mp
variabl
enter
multipl
regress
model
increas
fs
p
lvvsn
p
ewav
decelerationtim
p
associ
longer
mptime
conclus
increas
lv
systol
function
volum
correspond
advanc
stage
mmvd
extent
may
predict
increas
ptt
decreas
mp
left
atrial
la
size
import
decisionmak
prognost
dog
myxomat
mitral
valv
diseas
mmvd
previous
group
shown
allometr
scale
base
singl
dimens
echocardiograph
measur
la
show
good
correl
realtim
echocardiograph
measur
la
volum
wherea
index
method
howev
biplan
method
might
accur
reflect
la
volum
especi
enlarg
heart
aim
studi
compar
la
volum
obtain
echocardiographi
obtain
simpson
modifi
method
disc
smod
arealength
method
use
acquisit
ninetysix
privat
own
dog
breed
diagnos
mmvd
examin
use
echocardiographi
accord
acvim
classif
dog
classifi
congest
heart
failur
chf
class
class
dog
without
chf
dog
class
dog
class
age
rang
year
median
year
bodi
weight
rang
kg
median
kg
fiftyeight
male
femal
includ
heart
rate
rang
beatsmin
median
bmin
la
volum
obtain
offlin
analysi
refer
point
manual
place
endocardi
border
trace
use
autom
detect
process
creat
cast
la
caviti
acquisit
exact
time
la
volum
calcul
use
smod
arealength
method
orthogon
view
blandaltman
plot
use
compar
measur
la
volum
calcul
la
volum
obtain
two
differ
biplanar
method
measur
calcul
volum
correct
bodi
weight
none
calcul
la
volum
base
either
two
biplan
method
show
good
agreement
la
volum
obtain
acquist
comparison
la
volum
smod
underestim
la
volum
differ
method
increas
increas
la
volum
arealength
method
overestim
la
volum
differ
method
increas
increas
la
volum
conclus
comparison
smod
might
underestim
arealength
method
might
overestim
la
volum
dog
mmvd
disclosur
disclosur
report
threedimension
echocardiograph
dataset
analyz
offlin
dedic
softwar
packag
morpholog
variabl
measur
variabl
known
associ
bodi
size
index
use
previous
report
scale
factor
differ
ckc
breed
analyz
use
unpair
student
ttest
mannwhitney
utest
appropri
data
distribut
compar
healthi
dog
ckc
significantli
smaller
bw
p
normal
anterolateralposteromedi
annulu
diamet
p
annulu
height
p
tent
height
p
tent
area
p
normal
tent
volum
p
posterior
leaflet
length
p
normal
posterior
leaflet
area
p
greater
annulu
spheric
index
p
conclus
mv
healthi
ckc
circular
less
tent
compar
breed
disclosur
disclosur
report
dr
j
om
receiv
financi
support
boehring
ingelheim
oasmia
pharmaceut
ceva
sant
animal
relat
studi
dr
borgarelli
receiv
financi
support
ceva
relat
studi
develop
progress
myxomat
mitral
valv
diseas
mmvd
dog
difficult
predict
identif
young
age
dog
high
risk
develop
congest
heart
failur
futur
desir
aim
studi
investig
predict
valu
select
clinic
echocardiograph
characterist
associ
mmvd
obtain
young
age
predict
longterm
cardiac
allcaus
mortal
cavali
king
charl
spaniel
ckc
studi
includ
privatelyown
ckc
examin
age
year
januari
june
longterm
outcom
assess
telephon
interview
owner
valu
variabl
predict
mortal
cardiac
allcaus
investig
cox
proport
hazard
kaplanmei
analys
presenc
mild
sever
mitral
regurgit
mr
hazard
ratio
hr
confid
interv
ci
p
intermitt
mr
p
echocardiographi
significantli
associ
increas
hazard
cardiac
death
interact
mr
sex
signific
allcaus
mortal
p
show
male
mild
sever
mr
higher
allcaus
mortal
compar
male
mr
p
wherea
differ
found
femal
mr
group
risk
cardiac
p
allcaus
p
mortal
increas
increas
left
ventricular
endsystol
intern
dimens
normal
bodi
weight
lvid
n
conclus
mild
sever
mr
intermitt
mr
decreas
lvid
n
dog
year
age
associ
cardiac
death
later
life
ckc
disclosur
disclosur
report
myxomat
mitral
valv
diseas
mmvd
common
heart
diseas
dog
high
preval
among
cavali
king
charl
spaniel
ckc
valvular
chang
may
caus
mitral
regurgit
mr
time
dog
progress
congest
heart
failur
increas
circul
concentr
serotonin
suggest
involv
pathogenesi
mmvd
ckc
acid
serotonin
metabolit
excret
urin
urin
commonli
use
human
medicin
biomark
serotoninsecret
tumor
aim
present
studi
investig
urinari
associ
mmvd
sever
ckc
hypothes
urin
concentr
increas
ckc
mmvd
urin
concentr
would
correl
serotonin
concentr
serum
plasma
serum
plasma
urin
sampl
collect
dog
year
age
divid
four
group
control
dog
beagl
evid
heart
diseas
con
n
ckc
minim
mr
due
mmvd
nmr
n
ckc
mild
mr
due
mmvd
mmr
n
ckc
moder
sever
mr
due
mmvd
smr
n
urinari
analyz
highperform
liquid
chromatographi
hplc
creatinin
correct
variat
urin
dilut
jaff
method
serotonin
concentr
serum
platelet
poor
plasma
determin
valid
enzymelink
immunosorb
assay
result
preliminari
analys
subset
dog
three
four
group
con
nmr
smr
mean
age
year
rang
present
median
interquartil
rang
analys
remain
sampl
ongo
signific
differ
urinari
creatinin
ratio
lmolmmol
found
con
dog
n
nmr
dog
n
smr
dog
n
overal
p
femal
dog
n
show
significantli
higher
male
dog
n
versu
p
preliminari
data
reveal
associ
crea
age
p
r
serum
serotonin
concentr
p
r
plasma
serotonin
concentr
p
r
conclus
preliminari
data
indic
urinari
concentr
depend
sex
age
dog
analys
necessari
draw
final
conclus
regard
possibl
associ
urinari
concentr
mmvd
sever
dog
disclosur
disclosur
report
disclosur
regard
studi
pulmonari
veintopulmonari
arteri
ratio
pvpa
shown
decreas
west
highland
white
terrier
affect
pulmonari
fibrosi
comparison
ageand
breedmatch
control
suggest
potenti
use
noninvas
diagnosi
pulmonari
hypertens
ph
aim
present
work
determin
valu
pvpa
predict
tricuspid
regurgit
pressur
gradient
trpg
compar
echocardiograph
indic
dog
precapillari
ph
differ
origin
echocardiograph
imag
obtain
dog
tricuspid
regurgit
jet
retrospect
review
pv
pa
acceler
time
eject
time
ratio
pulmonari
flow
et
main
pulmonari
arteri
aorta
ratio
mpaao
right
pulmonari
arteri
distens
index
rpadi
evalu
dog
group
control
n
trpg
mmhg
mildli
n
trpg
mmhg
moder
n
trpg
mmhg
sever
n
trpg
mmhg
affect
ph
ten
dog
clinic
heathi
remain
dog
suffer
angiostrongylosi
n
brachycephal
syndrom
n
bronchomalacia
n
heartworm
diseas
n
chronic
pulmonari
thromboembol
n
ph
unknown
origin
n
eosinophil
bronnchopneumopathi
n
pulmonari
fibrosi
n
diffus
pulmonari
carcinoma
result
spearman
correl
analys
reveal
strongest
correl
r
p
trpg
follow
pvpamm
r
p
mpaao
r
p
rpadi
r
p
et
r
p
possess
accur
cutoff
auc
se
sp
predict
trpg
mmhg
follow
pvpamm
auc
se
sp
rpadi
auc
se
sp
et
auc
se
sp
mpaao
auc
se
sp
conclus
pvpa
measur
mm
accur
predictor
trpg
may
particularli
use
tr
absent
difficult
measur
dog
affect
precapillari
ph
disclosur
disclosur
report
far
base
subject
assess
aim
evalu
reliabl
right
atrial
area
index
raai
character
right
atrial
size
ph
sever
dog
studi
prospect
multicent
observ
includ
client
own
dog
dog
ph
healthi
dog
control
group
ph
classifi
accord
tricuspid
regurgit
pressur
gradient
trpg
mild
trpg
mmhg
n
dog
moder
trpg
mmhg
n
dog
sever
trpg
mmhg
n
dog
nine
dog
ph
rightsid
congest
heart
failur
chf
echocardiograph
view
right
atrium
obtain
left
apic
view
optim
right
heart
right
atrial
area
measur
planimetri
end
ventricular
systol
raai
calcul
right
atrial
area
divid
bodi
surfac
area
right
atrial
area
show
strong
posit
linear
correl
bodi
surfac
area
healthi
dog
r
p
raai
significantli
higher
p
dog
moder
ph
ae
cm
sever
ph
ae
cm
mild
ph
ae
cm
control
group
ae
cm
differ
raai
found
dog
two
latter
group
dog
moder
sever
ph
weak
posit
correl
found
raai
trpg
r
p
trpg
differ
dog
rightsid
chf
ae
mmhg
without
rightsid
chf
ae
mmhg
convers
raai
significantli
higher
p
dog
rightsid
chf
ae
cm
comparison
without
rightsid
chf
ae
cm
accur
cutoff
valu
predict
rightsid
chf
cm
sensit
specif
intraand
interobserv
measur
variabl
clinic
accept
averag
coeffici
variat
studi
show
raai
increas
dog
moderatetosever
ph
particularli
high
dog
rightsid
chf
raai
expect
provid
benefici
inform
assess
ph
sever
dog
possibl
ph
lead
remark
hemodynam
consequ
tricuspid
regurgit
absent
difficult
measur
studi
need
verifi
raai
prognost
factor
dog
ph
disclosur
disclosur
report
eighteen
dog
diagnos
dcm
preclin
clinic
dcm
seven
femal
male
age
time
initi
admiss
year
rang
weight
kg
heparinis
plasma
taurin
level
measur
dog
low
mean
lmoll
rang
normal
refer
low
taurin
supplement
start
addit
convent
cardiac
medic
dog
lost
followup
remain
dog
still
aliv
time
studi
dead
dog
preclin
dcm
one
still
aliv
two
dead
remain
preclin
time
death
mean
surviv
time
mst
overal
popul
dog
clinic
dcm
day
ci
mst
subgroup
ec
low
taurin
level
start
taurin
supplement
day
mst
three
dog
normal
taurin
level
day
p
like
american
cocker
spaniel
also
ec
diagnos
dcm
phenotyp
commonli
affect
taurin
defici
consid
mst
prognosi
ec
dcm
may
better
breed
affect
dcm
addit
mst
taurin
defici
ec
may
better
ec
normal
taurin
level
larger
sampl
prospect
studi
need
disclosur
disclosur
report
establish
link
autonom
nervou
system
an
dysfunct
human
cardiovascular
diseas
alter
heart
rate
variabl
hrv
associ
human
diseas
sever
outcom
howev
canin
hrv
studi
larg
fail
show
similar
relationship
electron
measur
cardiac
vagal
tone
cardiac
index
parasympathet
activ
cipa
prognost
valu
dog
howev
measur
impract
clinic
set
deceler
capac
dc
novel
measur
vagal
tone
quantifi
decelerationrel
heart
rate
modul
ecg
record
power
predictor
human
cardiac
mortal
prognost
valu
dc
measur
canin
heart
diseas
unknown
sought
assess
dc
popul
normal
doberman
pinscher
affect
dilat
cardiomyopathi
dcm
clinic
record
holter
data
collect
retrospect
clientown
doberman
pinscher
compris
healthi
anim
normal
preclin
dcm
dcm
dcm
congest
heart
failur
dcmchf
accept
echocardiograph
measur
criteria
use
diagnosi
dcm
normal
group
healthi
dog
present
dcm
screen
dcm
group
includ
dog
identifi
previous
larg
multicentr
prospect
clinic
trial
protect
trial
well
clinic
case
present
screen
inclus
criteria
quantit
holter
analysi
perform
data
export
measur
dc
compar
logtransform
dc
clinic
group
use
ageadjust
linear
regress
differ
logdc
dcm
dcmchf
group
present
averag
margin
effect
rel
normal
group
whose
valu
standardis
zero
examin
associ
reduc
dc
primari
endpoint
pendp
chf
sudden
cardiac
death
dcm
group
two
subgroup
defin
median
logdc
time
pendp
compar
use
kaplanmei
method
age
adjust
cox
proport
hazard
model
compar
normal
group
logdc
reduc
dcmchf
group
p
direct
effect
observ
dcm
group
p
within
dcm
group
median
time
pendp
shorter
dog
logdc
median
day
rel
risk
ci
dc
measur
canin
ecg
support
gradual
reduct
vagal
tone
earli
cours
dcm
wider
prospect
studi
evalu
techniqu
may
lead
addit
prognost
inform
individu
dog
disclosur
disclosur
report
two
author
jh
mp
offer
commerci
veterinari
holter
monitor
rental
analysi
part
exist
cardiolog
referr
servic
proport
preclin
dcm
case
previous
recruit
widescal
prospect
studi
fund
boehring
ingelheim
permiss
grant
data
includ
present
studi
fund
provid
author
jh
cl
mp
receiv
hororaria
pharmaceut
compani
provid
cpd
veterinarian
fund
directli
given
studi
support
studi
use
pathfind
digit
softwar
provid
spacelab
uk
fund
provis
arrhythmiainduc
cardiomyopathi
aicm
defin
systol
andor
diastol
ventricular
dysfunct
result
prolong
elev
heart
rhythm
revers
upon
control
heart
rate
familiar
dilat
cardiomyopathi
dcm
primari
cardiac
diseas
genet
predisposit
caus
mainli
left
ventricular
systol
failur
best
author
knowledg
data
regard
echocardiograph
differ
two
disord
dog
aim
studi
therefor
retrospect
evalu
echocardiograph
paramet
dog
aicm
secondari
sustain
accessori
pathwaysmedi
tachycardia
apmt
dog
familiar
dcm
accord
breed
presenc
apmt
two
group
dog
made
group
report
monodimension
bdimension
echocardiograph
measur
index
bodi
surfac
area
taken
one
author
mp
group
includ
dog
differ
breed
mean
age
ae
sd
ae
year
mean
bodi
weight
ae
kg
f
aicm
induc
apmt
diagnos
endocardi
map
prior
ablat
accessori
pathway
group
b
doberman
pinscher
mean
age
ae
year
mean
bodi
weight
ae
kg
f
familiar
dcm
group
echocardiograph
paramet
obtain
sinu
rhythm
apmt
compar
assess
effect
acut
chang
heart
rate
echocardiograph
measur
obtain
group
sinu
rhythm
compar
determin
possibl
screen
factor
differenti
two
entiti
normal
distribut
valu
assess
shapirowilk
wtest
normal
distribut
data
test
use
student
ttest
nonnorm
distribut
data
use
wilcoxon
sum
rank
test
group
shorten
fraction
fs
eject
fraction
ef
significantli
higher
sinu
rhythm
tachycardia
p
respect
shorten
fraction
ef
significantli
higher
group
group
b
p
respect
enddiastol
volum
index
endsystol
volum
index
epointsept
separ
significantli
lower
group
b
p
respect
echocardiograph
differ
aicm
dog
dcm
dog
found
may
reflect
differ
pathophysiolog
mechan
differ
rate
evolut
myocardi
diseas
studi
need
determin
cutoff
valu
allow
differenti
aicm
familiar
dcm
disclosur
disclosur
report
heart
undergo
continu
lifelong
remodel
process
human
cardiac
remodel
adult
life
cours
year
age
character
echocardiograph
distinct
pattern
decreas
lv
enddiastol
endsystol
dimensionsvolum
lv
systol
function
increas
advanc
age
gebhard
c
et
al
echocardiographi
alter
pronounc
women
men
longitudin
data
character
cardiac
remodel
dog
limit
object
studi
character
echocardiograph
indic
cardiac
remodel
adult
life
cours
irish
wolfhound
iw
iw
examin
physic
examin
echocardiographi
electrocardiographi
av
inclus
criteria
studi
dog
indic
cardiac
diseas
old
age
death
examin
perform
yr
yr
yr
year
age
male
bw
kg
femal
bw
kg
elig
first
comparison
mean
valu
age
group
student
ttest
use
pvalu
consid
statist
signific
adult
life
cours
male
statist
signific
increas
lvid
lvidd
right
atrial
left
atrial
dimens
statist
signific
decreas
fs
youngest
oldest
age
examin
meansaesd
lvid
ae
vs
ae
mm
lvidd
ae
vs
ae
mm
ra
ae
vs
ae
mm
la
ae
vs
ae
mm
fs
ae
ae
pvalu
comparison
femal
youngest
oldest
age
examin
increas
mean
lvid
ae
ae
mm
p
lvidd
ae
ae
p
ra
ae
mm
ae
mm
p
la
ae
ae
mm
p
attenu
decreas
fs
ae
ae
p
conclus
iw
echocardiograph
indic
cardiac
remodel
adult
life
cours
demonstr
lv
dimens
increas
fraction
shorten
fs
decreas
advanc
age
femal
gender
attenu
remodel
process
disclosur
disclosur
report
chronic
kidney
diseas
ckd
commonli
diagnos
cat
uk
previou
studi
estim
preval
cat
popul
uk
littl
known
ckd
diagnos
treat
primarycar
set
uk
aim
present
studi
estim
preval
incid
ckd
uk
describ
diagnost
procedur
treatment
employ
cat
present
veterinari
clinic
januari
decemb
includ
studi
use
vetcompass
databas
potenti
case
identifi
search
electron
patient
record
key
term
associ
ckd
diagnosi
random
sampl
potenti
case
review
detail
identifi
cat
diagnos
ckd
data
extract
databas
demograph
diagnosi
treatment
comorbid
preval
incid
estim
adjust
sampl
approach
cat
present
potenti
case
identifi
potenti
case
review
detail
new
preexist
case
confirm
estim
preval
ci
estim
incid
new
case
ci
studi
period
median
age
diagnosi
year
iqr
yr
cat
present
owner
report
clinic
sign
major
cat
sign
diagnosi
weight
loss
polydipsia
commonli
report
combin
biochemistri
urinalysi
common
method
diagnosi
one
fifth
cat
upc
perform
one
third
vet
record
iri
stage
half
stage
cat
iri
ckd
stage
diagnosi
one
third
cat
least
one
blood
pressur
measur
cat
diagnos
hypertens
commerci
renal
diet
benazepril
common
treatment
prescrib
one
cat
present
primarycar
practic
uk
diagnos
ckd
upc
blood
pressur
perform
minor
cat
despit
recognis
import
proteinuria
hypertens
influenc
prognosi
treatment
cat
diagnos
ckd
improv
knowledg
veterinarian
diagnos
ckd
primarycar
practic
allow
target
continu
educ
practition
studi
also
highlight
need
better
owner
educ
regard
ckd
disclosur
chronic
kidney
diseas
ckd
common
age
cat
histolog
characteris
chronic
tubulointerstiti
inflamm
fibrosi
cytokin
transform
growth
factor
beta
associ
sever
renal
fibrosi
cat
cellular
mechan
underli
fibrot
process
remain
incomplet
understood
aim
studi
characteris
crandellre
felin
kidney
crfk
cell
line
use
vitro
model
felin
kidney
cell
morpholog
crfk
characteris
light
microscopi
express
intermedi
filament
protein
cytokeratin
vimentin
desmin
assess
immunofluoresc
crfk
cell
compar
immunohistochem
distribut
formalin
fix
felin
kidney
tissu
obtain
postmortem
owner
inform
consent
confluent
monolay
crfk
expos
either
ngml
recombin
hr
lyse
express
collagen
type
connect
tissu
growth
factor
ctgf
mrna
quantifi
rtqpcr
experi
carri
triplic
gene
express
data
normalis
housekeep
gene
analys
anova
posthoc
dunnett
test
express
mean
fold
chang
comparison
control
crfk
form
monolay
spindleshap
cell
strongli
express
vimentin
cytokeratin
desmin
vimentin
express
fix
felin
kidney
tissu
localis
glomerulu
scatter
cell
within
interstitium
wherea
cytokeratin
confin
tubular
epithelium
desmin
express
detect
treatment
crfk
cell
induc
morpholog
chang
cell
becom
elong
irregular
highest
concentr
exposur
ngml
increas
express
fold
p
ctgf
fold
p
comparison
control
exposur
ngml
increas
express
p
ctgf
p
p
comparison
control
result
studi
demonstr
crfk
resembl
cell
renal
interstiti
glomerular
origin
cell
morpholog
suggest
fibroblast
phenotyp
characteris
warrant
also
demonstr
upregul
gene
express
collagen
ctgf
well
autoinduc
express
crfk
cell
support
role
cytokin
felin
renal
fibrosi
signal
pathway
may
therefor
repres
target
treatment
aim
prevent
progress
renal
diseas
cat
disclosur
disclosur
report
first
author
abstract
current
undertak
phd
fund
elanco
anim
health
establish
whether
develop
ckd
mayb
causal
link
intervent
approach
employ
rat
model
renal
warm
ischaemia
rwi
examin
effect
tg
inhibit
tgi
renal
fibrosi
hypoxia
suggest
import
trigger
perpetu
factor
develop
ckd
cat
rat
follow
rwi
tubulointerstiti
fibrosi
develop
absenc
signific
glomerular
involv
male
spragu
dawley
rat
g
subject
renalhilarclamp
minut
follow
right
nephrectomi
without
intraren
tgi
day
rwi
n
n
shamoper
rat
subject
right
nephrectomi
alon
nx
n
subcutan
minipump
load
either
nacl
mmoll
tgi
zedira
germani
deliv
lgkgh
intraren
extracellular
matrix
protein
tubulointerstitium
intraglomerular
mesangi
area
igma
determin
masson
trichrom
stain
mt
collagen
iiiiv
immunofluoresc
quantifi
multiphas
imag
analysi
extracellular
tg
enzym
activ
etgact
extracellular
protein
total
kidney
transglutaminas
determin
situ
presenc
protein
confirm
western
blot
result
compar
use
onewayanova
follow
bonferonni
multipl
comparison
test
day
rwi
group
show
signific
increas
serum
creatinin
fold
mt
collagen
iii
iv
etgact
fold
compar
nx
group
follow
rwi
tgi
significantli
reduc
increas
serum
creatinin
mt
collagen
iii
iv
etgact
signific
linear
correl
obtain
tubulointerstiti
fibrosi
mt
collagen
iiiiiv
howev
follow
rwi
increas
glomerular
collagen
etgact
observ
rwi
rat
mimic
major
histopatholog
function
featur
felin
ckd
tgi
reduc
develop
tubulointerstiti
fibrosi
follow
rwi
improv
decreas
renal
function
provid
evid
causal
link
two
howev
neither
tg
pathway
collagen
deposit
activ
glomeruli
allow
protect
glomerular
mechan
toward
rwi
postul
sanchezlara
elliott
j
syme
h
brown
c
haylor
j
felin
chronic
kidney
diseas
associ
upregul
transglutaminas
collagen
crosslink
enzym
veterinari
patholog
disclosur
disclosur
report
calcif
retrospect
observ
cohort
studi
examin
associ
plasma
concentr
hypertens
cat
ckd
clinicopatholog
inform
cat
diagnosi
azotaem
ckd
sourc
record
two
first
opinion
practic
clinic
data
present
median
th
th
percentil
comparison
made
hypertens
ht
normotens
nt
cat
diagnosi
ckd
use
independ
sampl
ttest
mannwhitney
u
test
cat
treat
medic
known
influenc
systol
blood
pressur
sbp
exclud
normotens
group
subsequ
use
identifi
predictor
incid
hypertens
use
cox
regress
analysi
hazard
ratio
hr
confid
interv
ci
report
cat
followup
day
diagnosi
ckd
develop
hypertens
within
period
exclud
analysi
sbp
pack
cell
volum
pcv
consid
continu
variabl
whilst
tercil
bodi
weight
median
enter
categor
variabl
studi
includ
cat
ckd
iri
stage
n
iri
stage
n
ht
nt
baselin
ht
cat
significantli
higher
concentr
mmoll
p
creatinin
p
phosphat
p
concentr
differ
group
nineti
nt
cat
avail
cox
regress
analysi
develop
hypertens
final
multivari
model
n
increas
sbp
p
decreas
pcv
p
bodi
weight
kg
p
signific
risk
factor
hypertens
felin
ckd
addit
p
signific
independ
risk
factor
develop
hypertens
multivari
model
pgml
p
pgml
p
compar
pgml
conclus
ckd
cat
hypertens
higher
concentr
normotens
counterpart
moreov
azotaem
cat
normotens
concentr
appear
associ
risk
incid
hypertens
model
adjust
baselin
systol
blood
pressur
pcv
bodi
weight
mechan
influenc
blood
pressur
cat
remain
elucid
disclosur
work
present
part
phd
studentship
support
grant
royal
canin
ltd
henk
van
den
broek
first
present
author
phd
student
project
royal
veterinari
colleg
felin
morbilliviru
fmopv
origin
discov
hong
kong
suggest
associ
tubulointerstiti
nephriti
sinc
detect
urin
cat
japan
usa
germani
aim
studi
identifi
paramyxovirus
includ
morbilliviru
urin
sampl
geriatr
cat
without
azotaem
ckd
establish
relationship
fmopv
azotaem
ckd
exist
addit
urinari
marker
tubular
damag
dysfunct
evalu
nonazotaem
cat
without
fmopv
paramyxovirus
blood
urin
sampl
obtain
cat
three
uk
first
opinion
practic
part
geriatr
screen
programm
cat
assign
either
azotaem
ckd
group
defin
serum
creatinin
concentr
lmoll
concurr
urin
specif
graviti
nonazotaem
group
viral
rna
extract
urin
rtpcr
perform
sampl
panparamyxovirida
primer
dna
extract
posit
sampl
genom
sequenc
viru
identif
urin
protein
creatinin
ratio
upc
urin
albumin
creatinin
ratio
uac
urin
cystatin
c
creatinin
ucc
ratio
calcul
use
previous
valid
immunoturbidimetr
assay
comparison
group
made
use
fisher
exact
test
mann
whitney
u
test
statist
signific
defin
p
three
paramyxovirus
identifi
close
relat
felin
paramyxoviru
access
number
homolog
five
distinct
morbillivirus
identifi
close
relat
fmopv
access
number
homolog
respect
fmopv
detect
significantli
differ
azotaem
ckd
nonazotaem
group
vs
respect
p
paramyxoviru
detect
significantli
differ
azotaem
ckd
nonazotaem
group
vs
respect
p
nonazotaem
cat
signific
associ
detect
paramyxoviru
upc
p
ucc
p
uac
p
similarli
detect
fmopv
associ
upc
p
ucc
p
uac
p
fmopv
paramyxovirus
detect
urin
geriatr
cat
uk
without
azotaem
ckd
howev
incid
viru
detect
significantli
differ
azotaem
nonazotaem
cat
associ
detect
virus
increas
excret
urinari
marker
tubular
damag
dysfunct
identifi
studi
evalu
paramyxoviru
infect
associ
subsequ
develop
azotaem
ckd
morbid
nevertheless
warrant
disclosur
disclosur
report
urinari
tract
infect
uti
common
caus
antibiot
prescript
dog
clinic
sign
unspecif
infect
appropri
diagnost
workup
prerequisit
correct
diagnosi
aim
studi
assess
impact
diagnost
workup
decis
treat
dtt
antibiot
dog
suspect
uti
small
anim
practic
studi
design
prospect
cohort
studi
small
anim
practic
denmark
dog
clinic
sign
uti
enrol
diagnost
workup
diagnosi
prescrib
treatment
regist
urin
sampl
submit
refer
laboratori
gold
standard
bacteri
cultur
bc
antibiot
prescript
consid
correct
dtt
case
signific
bacteriuria
refer
bc
fiftysix
clinic
enrol
dog
diagnost
pathway
dipstickmicroscopybc
n
b
dipstickbc
n
c
dipstickmicroscopi
n
dipstick
n
overal
diagnos
uti
veterinarian
though
signific
bacteriuria
refer
bc
correct
dtt
made
total
overprescript
underprescript
dog
diagnost
pathway
led
correct
dtt
b
c
case
pathway
without
bc
led
correct
dtt
respect
signific
differ
correct
dtt
could
found
diagnost
pathway
result
reveal
high
proport
antibiot
overprescript
dog
suspect
uti
regardless
diagnost
pathway
pursu
disclosur
disclosur
report
studi
support
uccar
research
centr
wwwuccarekudk
vetfond
fondet
sygdomsbekaempels
ho
vore
familiedyr
aim
studi
investig
impact
diagnost
workup
appropri
choic
treatment
cot
assess
whether
bacteri
cultur
bc
improv
cot
canin
uti
small
anim
sa
practic
studi
design
prospect
cohort
studi
small
anim
sa
practic
denmark
dog
clinic
sign
uti
enrol
diagnost
workup
diagnosi
prescrib
treatment
regist
urin
sampl
submit
refer
laboratori
gold
standard
bc
appropri
cot
defin
prescrib
antibiot
invitro
suscept
combin
choos
firstlin
agent
secondlin
agent
fiftysix
clinic
enrol
dog
base
refer
bc
dog
uti
appropri
cot
institut
case
inappropri
secondlin
agent
prescrib
firstlin
agent
invitro
resist
prescrib
diagnost
workup
includ
bc
case
appropri
cot
institut
case
regardless
bc
includ
diagnost
workup
signific
differ
could
demonstr
group
conclus
high
proport
overprescript
secondlin
agent
perform
bc
significantli
improv
antibiot
choic
dog
uti
bc
respons
time
may
limit
factor
practic
set
disclosur
disclosur
report
studi
support
uccar
research
centr
wwwuccarekudk
vetfond
fondet
sygdomsbekaempels
ho
vore
familiedyr
measur
urinari
alkalin
phosphatas
ualp
urinari
cglutamyl
transpeptidas
uggt
activ
readili
avail
inexpens
studi
uggt
ualp
limit
small
number
dog
aki
singl
etiolog
experimentallyinduc
aki
aim
investig
clinic
util
diagnos
natur
occur
aki
larg
heterogen
group
dog
studi
includ
clientown
dog
aki
dog
chronic
kidney
diseas
ckd
urinari
tract
infect
uti
healthi
control
ualp
uggt
activ
normal
urinari
creatinin
concentr
ualpucrea
uggtucrea
respect
ualp
ucrea
uggtucrea
significantli
correl
r
p
differ
significantli
p
among
studi
group
aki
group
either
uti
ckd
group
p
control
group
area
receiv
oper
characterist
curv
ualpucrea
uggtucrea
predictor
aki
respect
optim
cutoff
point
ualpucrea
uggtucrea
show
poor
sensitivityspecif
respect
higher
cutoff
point
specif
associ
decreas
sensit
respect
conclus
uggtucrea
ualpucrea
demonstr
poor
discriminatori
power
diagnos
aki
dog
contrari
previou
report
naturallyoccur
experimentallyinduc
aki
therefor
recommend
screen
test
aki
ualpucrea
superior
marker
aki
uggtucrea
sinc
measur
readili
avail
inexpens
may
serv
ancillari
biomark
earli
detect
aki
appropri
cutoff
point
high
specif
use
disclosur
disclosur
report
cystinuria
classic
inborn
error
metabol
character
select
proxim
renal
tubular
defect
affect
cystin
ornithin
lysin
arginin
cola
reabsorpt
lead
cystin
crystal
urolithiasi
cystinuria
caus
defect
one
two
gene
encod
rbat
b
subunit
b
basic
amino
acid
transport
system
document
first
mutat
caus
cystinuria
cat
crystallograp
amino
acid
test
use
assess
cystinuria
exon
flank
region
gene
sequenc
genom
dna
compar
feli
refer
genom
sequenc
dna
sequenc
affect
cat
reveal
uniqu
homozyg
missens
mutat
one
exon
nonpurposebr
shorthair
cat
other
gene
one
exon
nonpurposebr
mediumhair
cat
one
exon
main
coon
sphinx
cat
one
exon
nonpurposebr
longhair
cat
genotyp
assay
identifi
anoth
cystinur
domest
mediumhair
cat
homozyg
mutat
origin
identifi
purebr
cat
missens
mutat
result
deleteri
amino
acid
substitut
highli
conserv
residu
b
protein
remain
sequenc
domest
shorthair
cat
heterozyg
singl
nucleotid
polymorph
snp
splice
donor
site
homozyg
snp
branchpoint
respect
studi
identifi
first
mutat
caus
felin
cystinuria
reveal
human
dog
diseas
genet
heterogen
cat
common
find
dog
predispos
condit
pathogen
potenti
associ
bacteria
clearli
understood
suggest
dog
requir
least
monitor
retrospect
casecrossov
studi
sought
describ
sbu
dog
follow
longitudin
dog
cultur
concurr
urinalysi
cystocentesisderiv
urin
perform
one
occas
identifi
record
uvet
anim
hospit
werribe
urin
sampl
dog
treat
antibiot
exclud
base
urin
cultur
result
record
clinic
sign
dog
classifi
clinic
urinari
tract
infect
sbu
growth
bacteria
age
breed
sex
neuter
statu
concurr
condit
microorgan
cultur
urinalysi
paramet
record
dog
urinalysi
sbu
episod
nogrowth
episod
compar
use
condit
logist
regress
aim
assess
valu
individu
urinalysi
paramet
predict
sbu
dog
total
dog
includ
total
pair
urinalysi
cultur
result
median
pair
result
rang
review
dog
mani
dog
predispos
condit
common
chang
urin
composit
caus
endocrin
diseas
drug
n
renal
diseas
n
dog
underli
condit
record
dog
variou
breed
predominantli
femal
spay
n
senior
median
age
year
rang
commonli
cultur
organ
sbu
escherichia
coli
n
enterococcu
spp
n
five
dog
sbu
multidrug
resist
bacteria
whilst
urinalysi
paramet
often
abnorm
individu
dog
pyuria
identifi
microscop
sediment
examin
reliabl
differenti
sbu
nogrowth
episod
ci
suggest
urinalysi
paramet
pyuria
commonli
reflect
concurr
diseas
process
rather
sbu
furthermor
confirm
urin
sediment
analysi
crucial
monitor
dog
affect
condit
predispos
sbu
uti
particularli
urin
cultur
plan
disclosur
disclosur
report
cat
ureterolithiasi
emerg
medic
condit
could
predispos
upper
urinari
tract
infect
although
cultur
urin
sampl
directli
renal
pelvi
gold
standard
confirm
pyelonephr
cultur
urin
obtain
cystocentesi
commonli
perform
case
ureter
obstruct
cultur
urin
collect
cystocentesi
could
neg
interrupt
urin
flow
affect
uret
object
studi
determin
incid
pyelonephr
felin
ureter
obstruct
investig
clinic
sign
laboratori
find
could
help
diagnos
pyelonephr
compar
result
urin
cultur
obtain
pyelocentesi
cystocentesi
individu
cat
pyelocentesi
perform
surgic
manag
ureter
obstruct
retrospect
includ
pyelonephr
diagnos
posit
urin
cultur
obtain
sampl
collect
pyelocentesi
signal
clinicopatholog
data
abdomin
ultrasonographi
find
compar
cat
pyelonephr
group
p
cat
neg
urin
cultur
obtain
pyelocentesi
group
p
fortyf
cat
includ
cultur
urin
collect
pyelocentesi
posit
cat
isol
e
coli
n
raoultella
terrigina
n
enterobact
cloaca
n
enterococcu
faecali
n
cat
p
group
significantli
older
pgroup
averag
monocyt
count
significantli
higher
p
group
signific
differ
observ
concern
clinic
data
laboratori
find
result
abdomin
ultrasonographi
two
group
three
cat
p
group
cat
pgroup
receiv
antibiot
therapi
prior
urin
cultur
thirtythre
cat
p
group
pgroup
urinari
cultur
also
perform
sampl
collect
cystocentesi
case
p
group
urin
obtain
cystocentesi
steril
case
cultur
result
similar
sampl
collect
pyelocentesi
cystocentesi
two
cat
pgroup
posit
urin
cultur
obtain
cystocentesi
studi
incid
pyelonephr
cat
ureter
obstruct
felin
ureterolithiasi
one
common
caus
acut
azotaemia
cat
placement
ureter
stent
subcutan
ureter
bypass
sub
devic
recent
develop
order
overcom
limit
tradit
medic
surgic
therapi
object
studi
compar
clinic
outcom
complic
rate
cat
ureter
calculi
manag
ureter
stent
sub
retrospect
compar
studi
perform
medic
record
cat
diagnos
felin
ureter
obstruct
undergo
placement
stent
sub
devic
review
inform
signal
clinic
sign
biochem
data
surgic
procedur
length
hospit
complic
minim
followup
obtain
total
cat
diagnos
ureterolithiasi
enrol
stent
place
twentyseven
cat
stent
group
cat
receiv
sub
devic
sub
group
regard
preoper
azotemia
differ
observ
group
signific
differ
periop
mortal
rate
group
ureter
stent
versu
sub
p
signific
decreas
serum
creatinin
urea
concentr
observ
group
first
h
surgic
intervent
p
consid
immedi
postop
complic
number
addit
surgic
procedur
significantli
higher
stent
group
p
includ
stent
occlus
uroabdomen
refractori
sign
cystiti
sub
group
devic
occlus
lower
urinari
tract
obstruct
justifi
addit
surgic
procedur
two
cat
stent
placement
associ
increas
lower
urinari
tract
sign
includ
hematuria
stent
group
versu
sub
group
p
pollakiuriastranguria
stent
group
versu
sub
group
p
compar
sub
group
cat
aliv
end
studi
impair
surviv
time
assess
stent
group
shorter
median
surviv
time
month
p
spite
fact
stent
placement
led
rapid
improv
azotaemia
procedur
associ
higher
mortal
postop
complic
recurr
lower
urinari
sign
possibl
explan
find
reli
physic
irrit
induc
distal
stent
curl
urinari
bladder
sub
placement
induc
rapid
decreas
azotaemia
fewer
complic
shorter
oper
time
less
recurr
lower
urinari
tract
sign
sub
devic
safe
altern
stent
placement
resolut
felin
ureterolithiasi
improv
outcom
reduc
lower
urinari
tract
sign
disclosur
disclosur
report
part
work
accept
present
ecv
congress
surgic
public
rebound
hyperglycemia
defin
fast
hyperglycemia
attribut
counterregulatori
hormon
respons
nocturn
hypoglycemia
somogyi
effect
recent
studi
human
rais
doubt
exist
phenomenon
postul
extrem
rare
veterinari
medicin
rebound
hyperglycemia
often
defin
independ
time
occurr
data
cat
scarc
clinic
signific
larg
unknown
aim
evalu
glucos
concentr
increas
normal
due
counterregul
healthi
cat
insulininduc
hypoglycemia
defin
frequenc
rebound
hyperglycemia
diabet
cat
investig
differ
cat
without
rebound
hyperglycemia
six
healthi
cat
treat
insulin
pzi
degludec
iukg
glucos
concentr
measur
twice
inject
everi
hour
hour
percentag
cat
posthypoglycem
glucos
concentr
baselin
base
calcul
rang
differ
marshal
et
al
comput
medic
record
diabet
cat
insulin
therapi
blood
glucos
curv
evalu
cat
reveal
biochem
hypoglycemia
includ
data
cat
without
rebound
hyperglycemia
compar
time
hypoglycemia
detect
hypoglycemia
rebound
hyperglycemia
defin
glucos
mmoll
follow
increas
mmoll
within
hour
healthi
cat
insulin
prepar
dose
led
hypoglycemia
induc
rebound
hyperglycemia
howev
curv
posthypoglycemia
glucos
concentr
exceed
baselin
highest
glucos
concentr
mmoll
pzi
among
diabet
cat
hypoglycemia
rebound
hyperglycemia
group
rebound
hyperglycemia
group
group
differ
age
bodi
weight
sex
group
daili
insulin
dose
higher
median
iukg
rang
vs
iukg
p
good
metabol
control
less
frequent
vs
p
serum
fructosamin
concentr
higher
lmoll
vs
lmoll
p
glucos
nadir
timetonadir
insulin
type
glargin
porcin
zinc
differ
conclus
healthi
cat
insulininduc
hypoglycemia
caus
rebound
hyperglycemia
although
posthypoglycemia
glucos
exce
baselin
cat
diabet
cat
rebound
hyperglycemia
occur
case
hypoglycemia
associ
higher
insulin
dose
wors
metabol
control
higher
fructosamin
reason
rebound
hyperglycemia
seen
certain
cat
current
unclear
disclosur
ye
disclosur
report
claudia
reusch
consult
boehring
ingelheim
consult
novarti
anim
health
past
receiv
financi
support
endocrin
research
variou
compani
nestl
purina
hill
provet
antlia
sa
glycemicon
clinic
studi
fund
ecvimca
societi
compar
endocrinolog
treatment
canin
diabet
mellitu
dm
alway
requir
exogen
insulin
therapi
two
type
commonli
use
insulin
lent
insulin
neutral
protamin
hegerdon
nph
insulin
aim
prospect
random
clinic
trial
compar
effect
lent
nph
insulin
dog
dm
clientown
dog
newli
diagnos
dm
enrol
dog
relev
concurr
diseas
prior
administr
diabetogen
drug
exclud
dog
random
two
group
lent
insulin
caninsulin
nph
insulin
humulin
group
dog
treat
insulin
sc
bid
fed
bid
commerci
diet
low
simpl
carbohydr
high
fiber
followup
evalu
done
week
reevalu
physic
exam
blood
glucos
curv
bgc
serum
fructosamin
concentr
perform
glycem
control
classifi
good
basi
absenc
pupd
bodi
weight
stabil
normal
attitudeact
valu
bgc
within
mgdl
eight
dog
treat
lent
nph
insulin
time
diagnosi
group
homogen
consid
age
bodi
weight
gender
serum
glucos
concentr
serum
fructosamin
concentr
last
reevalu
mean
aesd
glucos
concentr
bgc
median
rang
serum
fructosamin
concentr
evalu
lent
group
mgdl
lgdl
nph
group
mgdl
lgdl
respect
differ
signific
group
median
rang
lent
insulin
dose
per
inject
ukg
significantli
lower
p
compar
ukg
median
dose
nph
significantli
differ
ukg
ukg
median
fructosamin
concentr
significantli
lower
p
compar
nph
group
lent
group
p
good
glycem
control
found
dog
treat
lent
nph
insulin
respect
howev
differ
signific
p
hypoglycem
event
nadir
mgdl
identifi
patient
bgc
lent
group
nph
group
differ
signific
accord
preliminari
result
use
insulin
prepar
effect
treatment
dog
dm
howev
success
rate
nph
insulin
seem
greater
lent
insulin
disclosur
past
ff
receiv
financi
support
continu
educ
cours
organ
msd
produc
caninsulin
diet
studi
provid
free
royal
canin
gg
owner
laboratori
laboratorio
la
vallonea
perform
laboratori
analysi
without
cost
owner
obes
risk
factor
canin
human
pancreat
obes
older
cat
increas
risk
develop
diabet
pancreat
common
comorbid
diabet
cat
obes
cat
howev
previous
associ
pancreat
aim
studi
investig
differ
serum
level
pancreat
lipas
immunoreact
fpli
trypsinlik
immunoreact
ftli
cobalamin
clinic
healthi
lean
overweight
compar
diabet
cat
year
age
diabet
cat
recruit
patient
popul
univers
hospit
companion
anim
clinic
healthi
cat
primarili
recruit
advertis
fiftytwo
indoorconfin
cat
includ
diabet
overweight
lean
underw
physic
examin
hemogram
biochemistri
quantit
fpli
ftli
cobalamin
measur
perform
anova
use
analyz
diabet
bodi
condit
age
associ
logtransform
level
fpli
ftli
cobalamin
pearson
chi
test
use
compar
proport
diabet
overweight
lean
cat
fpli
ftli
indic
pancreat
fpli
lgl
ftli
ngml
result
given
median
rang
compar
clinic
healthi
lean
cat
diabet
cat
higher
level
fpli
versu
lgl
p
proport
diabet
cat
level
fpli
ftli
indic
pancreat
also
larger
p
compar
lean
cat
overweight
cat
lower
cobalamin
p
tend
higher
level
fpli
versu
lgl
p
larger
proport
obes
cat
fpli
indic
pancreat
p
differ
found
compar
fpli
level
diabet
obes
cat
p
compar
cat
year
age
clinic
healthi
cat
year
age
higher
level
fpli
p
lower
cobalamin
p
larger
proport
cat
p
ftli
ngml
indic
pancreat
diabet
overweight
cat
higher
level
fpli
compar
lean
cat
whether
correl
increas
preval
subclin
pancreat
remain
determin
cat
year
age
increas
level
fpli
lower
cobalamin
associ
may
exist
ftli
well
disclosur
disclosur
report
felin
hypersomatotrop
hs
result
acromegali
typic
caus
growthhormon
gh
secret
pituitari
adenoma
thought
common
caus
felin
diabet
mellitu
medic
pituitari
inhibit
challeng
human
cat
condit
could
relat
variabl
express
somatostatin
sstr
dopamin
dr
receptor
express
five
differ
sstr
subtyp
five
differ
subtyp
dr
predomin
dr
subtyp
human
pituitari
pasireotid
somatostatin
analogu
high
bind
affin
effect
control
gh
secret
felin
acromegal
somatostatin
analogu
high
bind
affin
octreotid
lanreotid
aim
studi
document
receptor
express
felin
somatotrophinoma
compar
healthi
felin
pituitari
utilis
novel
customis
multiplex
rtqpcr
assay
investig
express
profil
somatostatin
dopamin
receptor
ghsecret
pituitari
adenoma
pituitari
adenoma
rna
extract
ghsecret
adenoma
eight
control
cat
follow
multiplex
rtqpcr
analys
multipl
gene
includ
somatostatin
receptor
dopamin
receptor
growth
hormon
receptor
growth
hormon
secretagogu
receptor
housekeep
normalis
gene
express
acromegal
cat
vs
control
cat
undetect
express
upregul
acromegal
vs
control
p
p
p
magnitud
upregul
vari
somatostatin
receptor
felin
ghsecret
adenoma
express
sstr
similar
human
ghsecret
adenoma
higher
express
howev
higher
express
vs
human
may
explain
greater
biochem
respons
pasireotid
octreotid
decreas
express
larger
tumour
may
mechan
allow
uncheck
adenoma
growth
receptor
express
profil
felin
ghsecret
adenoma
help
search
improv
medic
manag
option
felin
hypersomatotrop
disclosur
data
present
poster
abstract
boston
usa
relationship
canin
diabet
mellitu
dm
hyperlipidaemia
pancreat
long
recognis
howev
question
caus
consequ
relationship
remain
unclear
studi
aim
identifi
correl
serum
lipid
concentr
biomark
pancreat
glutar
acid
methylresorufin
ester
dggr
lipas
inflamm
creactiv
protein
crp
diabet
dog
could
support
causal
relationship
hyperlipidaemia
pancreat
dm
twenti
four
diabet
dog
dm
control
dog
con
includ
retrospect
studi
control
dog
evid
inflammatori
pancreat
diseas
seven
dog
histolog
confirm
chronic
pancreat
cp
without
dm
also
includ
due
chang
refer
interv
ri
studi
lipas
measur
repres
proport
upper
limit
ri
dm
con
respect
differ
dm
con
group
statist
signific
lipas
crp
signific
differ
identifi
dm
cp
group
cp
con
group
crp
significantli
differ
p
median
rang
triglycerid
ri
mmoll
dm
con
cp
group
respect
median
rang
cholesterol
ri
mmoll
dm
group
con
group
cholesterol
concentr
avail
cp
dog
triglycerid
cholesterol
significantli
higher
dog
dm
p
compar
con
dog
weak
posit
correl
lipas
crp
r
p
dm
group
found
cp
group
con
group
howev
neither
crp
lipas
show
signific
correl
cholesterol
triglycerid
dm
group
con
group
weak
posit
correl
lipas
tg
r
p
result
studi
add
evid
dm
inflammatori
diseas
commonli
associ
acut
pancreat
inflamm
studi
also
illustr
poor
sensit
dggr
lipas
potenti
clinic
util
crp
recognit
cp
studi
although
lipid
profil
dog
dm
abnorm
lipid
concentr
correl
inflammatori
pancreat
biomark
patient
disclosur
although
treatment
felin
hyperthyroid
well
character
longterm
prognosi
ideal
therapi
cat
thyroid
cyst
unclear
therefor
examin
clinic
find
treatment
respons
seri
cat
thyroid
cyst
medic
record
cat
confirm
thyroid
cyst
technetium
scan
ultrasound
necropsi
review
signal
clinic
featur
imag
procedur
diagnost
test
treatment
protocol
outcom
record
thirtyseven
cat
identifi
cat
hyperthyroid
median
time
initi
diagnosi
hyperthyroid
cyst
diagnosi
month
clinic
sign
includ
palpabl
neck
mass
weight
loss
dysphagia
poor
appetit
dyspnea
median
aspir
cyst
fluid
volum
cat
ml
advanc
imag
cat
necropsi
cat
confirm
small
cm
mediumlarg
cm
huge
cm
thyroid
cyst
cat
respect
cat
huge
thyroid
cyst
like
display
dysphagia
dyspnea
prior
methimazol
radioiodin
treatment
record
hyperthyroid
cat
respect
hyperthyroid
cat
cyst
underw
subsequ
treatment
receiv
mbq
receiv
mbq
hyperthyroid
resolv
cat
followup
data
thyroid
cyst
resolv
cat
receiv
mbq
cat
receiv
mbq
three
cat
underw
thyroid
cystectomi
remov
residu
thyroid
cyst
without
complic
four
cat
underw
initi
thyroid
cystectomi
without
therapi
euthan
postop
refractori
hypocalcemia
histopatholog
find
cat
undergo
thyroidectomi
reveal
thyroid
carcinoma
adenomat
hyperplasia
thyroid
cyst
may
encount
hyperthyroid
rare
euthyroid
cat
clinic
sign
relat
compress
effect
cyst
includ
dysphagia
dyspnea
advanc
imag
help
character
cyst
small
cyst
might
requir
specif
intervent
huge
cyst
difficult
cure
high
abl
dose
appear
resolv
cyst
effect
smaller
dose
thyroid
cystectomi
primari
treatment
appear
contraind
due
high
risk
hypoparathyroid
use
surgic
thyroid
cystectomi
follow
therapi
consid
cat
warrant
intervent
hyperthyroid
resolv
larg
cyst
persist
disclosur
disclosur
report
newli
diagnos
hyperthyroid
cat
two
londonbas
first
opinion
practic
recruit
studi
ica
measur
istat
plasma
calcitonin
concentr
measur
previous
valid
immunoradiometr
assay
measur
time
diagnosi
time
establish
euthyroid
limit
blank
lob
assay
pgml
mannwhitney
u
test
use
compar
plasma
calcitonin
concentr
hypocalcaem
ica
mmoll
normocalcaem
hyperthyroid
cat
wilcoxon
sign
rank
test
use
evalu
chang
plasma
calcitonin
concentr
follow
treatment
spearman
rank
correl
use
evalu
correl
baselin
plasma
calcitonin
concentr
ica
plasma
total
thyroxin
concentr
statist
signific
defin
p
thirti
seven
hyperthyroid
cat
recruit
studi
five
cat
classifi
hypocalcaem
thirti
two
cat
classifi
normocalcaem
baselin
plasma
calcitonin
concentr
detect
four
cat
one
hypocalcaem
cat
pgml
three
normocalcaem
cat
pgml
lob
remain
cat
plasma
calcitonin
concentr
significantli
differ
hypocalcaem
normocalcaem
cat
p
follow
treatment
plasma
calcitonin
concentr
chang
significantli
remain
lob
cat
n
p
correl
baselin
plasma
calcitonin
concentr
ica
r
p
r
p
plasma
calcitonin
concentr
undetect
hyperthyroid
cat
associ
ica
suggest
hypercalcitonin
mechan
develop
hypocalcaemia
patient
caus
hypocalcaemia
hyperthyroid
cat
remain
enigmat
disclosur
disclosur
report
onset
perman
hypothyroid
delay
mani
month
even
year
treatment
whether
cat
develop
similar
pattern
iinduc
hypothyroid
unknown
hypothyroid
gener
consid
uncommon
transient
clinic
irrelev
therefor
investig
preval
iinduc
hypothyroid
cat
determin
onset
durat
transient
persist
clinic
relev
hyperthyroid
cat
success
treat
lowdos
median
dose
mbq
underw
assess
serum
tsh
concentr
month
posttreat
cat
develop
high
tsh
concentr
classifi
either
overt
subclin
hypothyroid
base
find
low
normal
valu
respect
month
cat
hypothyroid
overtli
hypothyroid
subsequ
remain
cat
becam
hypothyroid
month
result
total
cat
subclin
hypothyroid
cat
manifest
obviou
clinic
sign
associ
hypothyroid
howev
preval
new
worsen
azotemia
significantli
higher
hypothyroid
cat
euthyroid
cat
levothyroxin
supplement
cat
significantli
decreas
serum
tsh
creatinin
concentr
cat
untreat
hypothyroid
subsequ
normal
high
tsh
low
concentr
within
month
median
month
cat
transient
hypothyroid
took
month
normal
high
tsh
concentr
persist
remain
cat
period
month
median
month
result
show
itreat
cat
develop
subclin
hypothyroid
even
low
dose
howev
small
proport
develop
overt
hypothyroid
cat
develop
hypothyroid
time
even
month
posttreat
approxim
recov
normal
thyroid
function
within
month
hypothyroid
persist
month
cat
new
progress
azotemia
appear
import
clinic
featur
associ
felin
hypothyroid
whether
hypothyroid
cat
especi
subclin
without
azotemia
treat
lt
unclear
especi
serum
concentr
remain
well
within
refer
interv
disclosur
disclosur
report
monitor
cortisol
concentr
establish
method
assess
trilostan
treatment
howev
repeat
measur
never
examin
dog
hyperadrenocortic
receiv
trilostan
recruit
multicentr
open
label
prospect
studi
cortisol
concentr
measur
differ
time
pretrilostan
hour
posttrilostan
hour
postacth
stimul
measur
repeat
interv
week
repeat
dose
trilostan
adjust
discret
attend
veterinarian
dog
receiv
dose
trilostan
minimum
week
consecut
test
coeffici
variat
cv
calcul
result
mannwhitney
u
test
use
examin
signific
differ
individu
group
cortisol
valu
group
cv
univari
multipl
stepwis
linear
regress
analys
use
assess
associ
rang
factor
cortisol
cv
result
centr
use
chemiluminesc
assay
median
cv
rang
cortisol
measur
submit
esveeqa
scheme
total
dog
recruit
monitor
test
perform
popul
dog
pair
result
total
daili
dose
trilostan
howev
pair
one
centr
postacth
cortisol
signific
differ
absolut
cortisol
concentr
measur
pretrilostan
median
nmoll
postacth
stimul
median
nmoll
howev
posttrilostan
cortisol
median
nmoll
significantli
lower
signific
associ
pretrilostan
cortisol
one
centr
pretrilostan
cortisol
femal
entir
dog
also
postacth
cortisol
number
revisit
signific
differ
cv
posttrilostan
median
postacth
stimul
cortisol
median
howev
cv
pretrilostan
cortisol
median
significantli
lower
signific
associ
postacth
cortisol
cv
dose
postacth
cortisol
cv
hac
type
also
posttrilostan
cortisol
cv
centr
conclud
pretrilostan
cortisol
significantli
repeat
either
posttrilostan
postacth
stimul
cortisol
dog
kept
dose
week
studi
underway
assess
reliabl
measur
predictor
clinic
respons
disclosur
disclosur
report
studi
sponsor
dechra
product
ltd
mani
patient
studi
receiv
free
medic
reduc
laboratori
fee
author
receiv
financi
support
endocrin
research
dechra
past
addit
author
receiv
financi
support
endocrin
clinic
research
project
anipoc
ltd
nestl
purina
hill
provet
antlia
sa
glycemicon
clinic
studi
fund
ecvimca
bsava
petsav
univers
glasgow
veterinari
fund
societi
compar
endocrinolog
author
paid
provid
continu
profession
develop
wide
rang
commerci
compani
notforprofit
organis
around
world
one
author
current
consult
boehring
ingelheim
consult
novarti
anim
health
past
canin
hypercortisol
usual
treat
medic
either
mitotan
trilostan
effect
suppress
cortisol
secret
good
treatment
option
case
pituitarydepend
hypercortisol
case
cortisolsecret
adrenocort
tumor
suppress
effect
growth
desir
well
achiev
high
dosag
mitotan
howev
approach
associ
side
effect
concern
mitotan
toxic
household
pregnant
women
andor
children
steroidogen
orphan
nuclear
hormon
receptor
key
regul
adren
steroidogenesi
prolifer
modul
activ
could
possibl
interest
therapeut
target
canin
hypercortisol
aim
studi
investig
effect
invers
agonist
steroidogenesi
prolifer
canin
primari
adrenocort
cell
suspens
three
type
invers
agonist
test
isoq
isoqa
compound
compound
eight
adrenocort
cell
suspens
healthi
dog
three
patient
incub
four
concentr
per
compound
normal
adrenocort
cell
suspens
synthet
acth
ad
mimic
hypercortisol
effect
invers
agonist
determin
cortisol
measur
cultur
media
mrna
rel
express
steroidogen
enzym
melanocortin
type
receptor
rtqpcr
analysi
prolif
effect
assess
edu
assay
acthstimul
nonstimul
normal
adrenocort
cell
highest
concentr
significantli
p
p
respect
inhibit
cortisol
concentr
dmso
vehicl
control
respect
compound
isoqa
signific
effect
cortisol
product
nonstimul
adrenocort
suspens
significantli
reduc
mrna
express
p
p
import
enzym
cortisol
synthesi
three
suspens
effect
reduc
cortisol
product
mean
cortisol
concentr
highest
concentr
rang
compar
dmso
vehicl
control
edu
assay
demonstr
clear
effect
invers
agonist
adrenocort
cell
suspens
healthi
dog
minim
effect
cell
suspens
conclus
vitro
studi
demonstr
invers
agonist
effect
inhibitor
cortisol
product
effect
prolif
capac
cell
warrant
evalu
futur
studi
new
medic
treatment
option
hypercortisol
disclosur
disclosur
report
galac
receiv
fund
adrenocort
tumor
research
morri
anim
foundat
akc
canin
health
foundat
grant
dog
pituitari
hyperadrenocortic
hac
usual
treat
trilostan
reduc
hypercortisol
howev
surgic
remov
radiotherapi
pituitari
tumor
might
use
especi
anim
larg
tumor
radiosurgeri
perform
gamma
knife
equip
design
appli
singl
dose
distribut
converg
beam
stereotax
condit
propos
definit
treatment
dog
pituitari
hac
studi
approv
ethic
committe
anim
experiment
univers
complutens
madrid
includ
dog
diagnos
hac
dog
differ
breed
femal
male
age
rang
year
mean
ae
sd
ae
year
stereotax
condit
anesthet
anim
studi
high
magnet
field
mri
underw
radiosurgeri
ruber
intern
hospit
madrid
dog
followedup
radiosurgeri
clinic
laboratori
control
hac
evalu
everi
visit
time
caus
death
regist
result
mri
show
presenc
pituitari
microadenoma
dog
mass
greater
mm
diagnos
macroadenoma
anim
treatment
mean
ae
sd
dose
administ
ae
gy
rang
gy
good
control
hac
achiev
dog
microadenoma
month
treatment
without
trilostan
n
dog
macroadenoma
reduct
neurolog
sign
observ
within
first
week
treatment
trilostan
requir
control
hac
lower
dosag
radiosurgeri
short
time
midterm
secondari
effect
observ
one
dog
develop
hypothyroid
year
radiotherapi
one
dog
diagnos
macroadenoma
die
due
diencephal
radionecrosi
day
tumor
recurr
observ
day
n
mean
surviv
time
dog
diagnos
microadenoma
ae
day
rang
day
mean
surviv
time
dog
diagnos
macroadenoma
ae
day
rang
day
surviv
time
dog
microadenoma
longer
observ
studi
dog
hac
use
mitotan
mean
ae
day
trilostan
mean
ae
day
dog
macroadenoma
surviv
time
similar
report
fraction
radiotherapi
gamma
knife
radiosurgeri
noninvas
effect
procedur
treat
dog
pituitari
hac
especi
use
dog
macroadenoma
disclosur
disclosur
report
comparison
clinic
sign
na
k
concentr
na
k
ratio
made
zycortaltr
dog
previous
treat
fludrocortison
versu
new
case
treat
fludrocortison
multicentr
randomis
clinic
trial
investig
efficaci
safeti
new
prolongedreleas
suspens
docp
zycort
dechra
ltd
treatment
ph
case
n
retrospect
group
base
prestudi
treatment
histori
case
treat
longterm
fludrocortison
day
lt
n
case
treat
shortterm
fludrocortison
day
st
n
newli
diagnos
case
never
treat
fludrocortison
nf
n
dog
administ
zycort
initi
dose
mgkg
subcutan
subsequ
dose
administ
approxim
everi
day
month
treatment
success
day
occur
veterinarian
assess
case
improv
unchang
new
case
ph
compar
baselin
veterinarianassess
improv
na
k
concentr
na
k
ratio
within
refer
rang
dog
concurr
treat
prednisolon
prednison
major
dog
purebr
young
middl
age
mean
year
male
femal
equal
repres
treatment
success
similar
p
day
lt
st
nf
group
respect
day
p
respect
group
veterinarianassess
improv
group
day
lt
dog
normal
na
k
concentr
day
day
lt
dog
normal
concentr
na
k
day
st
nf
dog
normal
na
k
concentr
howev
day
dog
normal
na
k
concentr
advers
event
report
frequent
group
polyuriapolydipsia
vomit
zycort
equal
effect
manag
clinic
sign
electrolyt
concentr
newli
diagnos
case
ph
compar
case
previous
treat
fludrocortison
show
benefici
effect
electrolyt
normalis
dog
previous
receiv
fludrocortison
success
transit
zycort
disclosur
author
employe
dechra
ltd
manufactur
zycort
studi
fund
dechra
dog
sign
ce
serum
cbl
pmoll
refer
interv
pmoll
includ
supplement
prescrib
use
blockrandom
predesign
schedul
either
daili
oral
cbl
tablet
use
treatment
protocol
retrospect
studi
http
parenter
cbl
accord
current
protocol
http
vetmedtamuedugilabresearchcobalamininform
dose
studi
approv
local
ethich
committe
start
march
serum
mma
concentr
analyz
use
stabl
isotop
dilut
gcm
method
refer
interv
mmoll
dog
age
year
median
differ
breed
includ
po
group
pe
previous
report
serum
cbl
concentr
improv
significantli
dog
comparison
group
perform
use
mann
whitney
test
comparison
within
group
use
wilcoxon
matchedpair
sign
rank
test
inclus
statist
differ
mma
concentr
group
p
initi
median
rang
mma
concentr
mmoll
po
group
mmoll
pe
group
week
supplement
median
mma
concentr
decreas
significantli
mmoll
po
group
mmoll
pe
group
p
group
statist
differ
po
pe
group
week
p
furthermor
statist
differ
mma
concentr
week
treatment
either
po
group
n
p
pe
group
n
p
week
treatment
median
mma
serum
concentr
po
group
mmoll
mmoll
pe
group
statist
differ
group
p
result
suggest
oral
cbl
supplement
appear
effect
parenter
improv
cellular
cobalamin
statu
disclosur
disclosur
report
dog
treat
clinic
small
anim
medicin
ludwigmaximiliansuniversitaet
munich
cpv
infect
followup
least
month
avail
includ
studi
owner
complet
questionnair
presenc
chronic
gastrointestin
cutan
sign
cardiac
diseas
potenti
disord
ident
questionnair
sent
owner
breedand
agematch
control
group
time
period
fisher
exact
test
use
statist
analysi
seventyon
questionnair
dog
cpv
infect
control
dog
analyz
significantli
cpvinfect
dog
compar
control
dog
develop
chronic
gastrointestin
sign
later
life
p
signific
differ
could
observ
regard
dermatolog
cardiac
disord
result
studi
suggest
dog
surviv
cpv
infect
significantli
higher
risk
develop
chronic
gastrointestin
diseas
prospect
studi
assess
risk
assess
prevent
long
term
effect
need
disclosur
disclosur
report
fecal
sampl
obtain
healthi
dog
dog
chronic
diarrhea
test
interassay
variabl
fece
dog
divid
aliquot
analyz
separ
assess
daytoday
variabl
three
consecut
sampl
test
healthi
diseas
dog
fecal
sampl
also
expos
differ
storag
temperatur
also
underw
consecut
repeat
freezethaw
cycl
fecal
dna
extract
sampl
analyz
bacteri
group
use
quantit
pcr
qpcr
assay
result
bacteri
group
express
index
interassay
variabl
sampl
run
consecut
time
posit
neg
di
rang
reveal
classif
error
classif
error
rate
daytoday
variat
sampl
test
di
stabl
week
classif
error
sampl
three
freezethaw
cycl
alter
interpret
dysbiosi
index
conclus
qpcr
base
dysbiosi
index
analyt
valid
show
satisfactori
perform
stabil
data
analysi
clinic
sampl
disclosur
disclosur
report
dr
suchodolski
steiner
lidburi
employe
gastrointestin
laboratori
texa
univers
offer
dysbiosi
index
feeforservic
basi
mani
affect
cat
recent
studi
also
increas
serum
concentr
fpl
andor
ftli
although
neither
anorexia
vomit
notabl
clinic
featur
cat
etiolog
pancreat
pathophysiolog
unknown
object
studi
determin
serum
fpl
ftli
concentr
cat
ice
associ
chang
fecal
microbiom
serum
metabolom
studi
evalu
cat
older
year
age
fed
nutrit
complet
balanc
diet
thirtyon
cat
ice
demonstr
increas
fecal
fat
subnorm
fat
digest
subnorm
serum
cobalamin
increas
serum
methylmalon
acid
without
exocrin
pancreat
insuffici
assess
assay
serum
ftli
ftli
fpl
assay
gi
lab
texa
univers
usa
fecal
microbiom
evalu
roch
sequenc
analysi
qiim
quantit
insight
microbi
ecolog
serum
metabolom
analysi
done
use
lc
gcm
metabolon
durham
nc
usa
relationship
serum
fpl
ftli
evalu
use
oplsda
describ
ramadan
z
et
al
j
vet
int
med
valu
q
consid
signific
strongli
cat
neither
fpl
ftli
significantli
associ
fecal
microbiom
q
howev
signific
associ
serum
metabolom
ftli
q
fpl
q
enzym
sever
metabolit
either
posit
neg
correl
serum
concentr
r
r
littl
overlap
correl
metabolit
pancreat
marker
enzym
conclud
littl
direct
associ
fecal
microflora
serum
pancreat
enzym
numer
individu
metabolit
associ
fpl
ftli
relationship
differ
enzym
causal
relationship
remain
determin
cat
chronic
kidney
diseas
import
distinguish
anemia
due
lack
erythropoetin
anemia
due
gastrointestin
bleed
urem
gastroenter
human
screen
test
occult
faecal
blood
valid
cat
far
aim
studi
determin
impact
differ
renal
diet
result
two
haemoccult
test
healthi
cat
addit
sensit
two
test
detect
occult
blood
evalu
three
differ
commerci
avail
renal
diet
vetconcept
low
protein
hill
kd
royal
canin
renal
fed
nine
healthi
cat
seven
day
comparison
cat
fed
raw
meat
diet
hemoglobin
hb
form
felin
blood
ad
differ
concentr
start
day
faecal
sampl
analyz
daili
day
haemoccult
haemoccult
sensa
beckmanncoult
krefeld
germani
cat
fed
raw
meat
test
posit
occult
blood
test
haemoccult
cat
fed
respect
test
posit
mg
hb
per
kg
bodyweight
per
day
ad
diet
faecal
sampl
test
posit
cat
haemoccult
haemoccult
sensa
diet
suitabl
diet
diagnos
gastrointestin
bleed
cat
chronic
kidney
diseas
reliabl
detect
minim
amount
blood
haemoccult
sensa
use
disclosur
disclosur
report
frd
share
mani
similar
coeliac
diseas
cd
human
complet
respons
strict
elimin
diet
typic
histolog
find
shorten
small
intestin
villi
autoantibodi
use
test
cd
human
includ
antireticulin
antiendomysium
antiema
antideamid
gliadin
peptid
antibodi
aim
studi
test
hypothesi
antireticulin
antiema
deamid
gliadin
antibodi
use
diagnosi
frd
dog
hypothes
antiema
antibodi
would
detect
frequent
dog
frd
compar
healthi
dog
dog
srd
antibodi
detect
use
human
indirect
immunofluoresc
assay
adapt
use
canin
patient
tissu
biochip
tm
euroimmun
ltd
ge
assay
includ
primat
intestin
primat
oesophagu
primat
liver
synthet
deamid
gliadin
antigen
use
biochip
tm
yield
characterist
fluoresc
pattern
sampl
consid
posit
serum
evalu
healthi
control
dog
dog
frd
dog
srd
dog
underw
rigor
diagnost
investig
includ
clinic
stage
use
sever
score
ccecai
comprehens
laboratori
evalu
ultrasonograph
examin
abdomen
endoscopi
intestin
biopsi
healthi
control
dog
srd
dog
test
neg
autoantibodi
dog
frd
test
neg
antibodi
direct
endomysium
deamid
gliadin
peptid
howev
five
dog
frd
test
posit
antireticulin
antibodi
signific
associ
presenc
foodrespons
diseas
posit
immunofluoresc
respons
antireticulin
antibodi
compar
healthi
control
p
srd
group
p
although
immunofluoresc
pattern
visual
typic
antireticulin
pattern
usual
seen
cd
find
may
indic
presenc
autoantibodi
ema
dog
frd
may
warrant
studi
larger
cohort
disclosur
disclosur
report
grant
provid
research
compar
gastroenterolog
societi
multidrug
gene
polymorph
associ
develop
inflammatori
bowel
diseas
ibd
human
furthermor
propos
pgp
express
gener
resist
treatment
canin
human
be
aim
studi
investig
epitheli
lamina
propria
lp
express
pgp
cat
ibd
alimentari
lymphoma
al
correl
express
clinic
sign
histopatholog
score
cat
diagnos
ibd
n
al
n
includ
felin
chronic
enteropathi
activ
index
fceai
calcul
case
control
group
compos
healthi
indoor
femal
cat
sick
cat
die
euthan
nongastrointestin
ill
diagnosi
classif
ibd
al
establish
accord
wsava
gastrointestin
standard
group
templat
nation
cancer
institut
formul
respect
furthermor
modifi
wsava
templat
villou
stunt
epitheli
injuri
crypt
distens
lacteal
dilat
appli
low
grade
al
lgal
n
evalu
immunolabel
pgp
antibodi
perform
epitheli
pgp
immunoexpress
calcul
accord
apic
membran
continu
intens
label
lp
pgp
immunoexpresss
score
accord
percentag
stain
cell
intens
repres
segment
score
patient
wsava
modifi
wsava
use
statist
analysi
nonparametr
test
use
epitheli
pgp
express
show
intestin
segment
control
group
lp
epitheli
discontinu
immunoreact
observ
lymphoplasmacyt
enter
lpe
eosinophil
enter
ee
lgal
case
intermedi
high
gal
ihgal
n
case
express
lp
show
lpe
ee
lgal
ihgal
case
correl
found
fceai
valu
epitheli
lp
pgp
express
fceai
score
significantli
differ
ibd
al
group
differ
observ
regard
pgp
immunolabel
total
modifi
wsava
score
show
signific
correl
epitheli
lp
pgp
express
howev
statist
signific
differ
found
epitheli
lp
pgp
express
neither
control
ibd
group
ibd
al
group
nevertheless
al
group
statist
signific
increas
lp
express
compar
control
group
regard
epitheli
immunolabel
conclus
pgp
immunoexpress
lp
al
may
affect
respons
treatment
surviv
compar
ibd
disclosur
disclosur
report
acut
pancreat
ap
common
diseas
exocrin
pancrea
dog
ap
inflammatori
cytokin
releas
circul
lead
potenti
sever
system
complic
signific
morbid
mortal
goal
studi
investig
risk
factor
associ
shortterm
mortal
dog
diagnos
ap
medic
record
dog
evalu
review
dog
diagnos
ap
includ
diagnosi
ap
base
associ
least
two
clinic
sign
consist
ap
vomit
abdomin
pain
anorexia
lethargi
diarrhoea
present
less
day
serum
cpl
concentr
lgl
least
two
clinic
sign
consist
ap
present
less
day
serum
cpl
concentr
lgl
ultrasonograph
find
consist
ap
thicken
hypoecho
pancrea
blur
margin
surround
hyperecho
adipos
tissu
clinic
sign
admiss
laboratori
data
serum
cpl
concentr
date
death
within
day
diagnosi
record
surviv
analysi
use
cox
proport
hazard
model
perform
investig
variabl
associ
shortterm
day
mortal
dog
still
aliv
day
diagnosi
censor
one
hundr
thirtyeight
dog
includ
fortysix
dog
die
within
day
diagnosi
multivari
analysi
identifi
presenc
iri
grade
versu
acut
kidney
injuri
adjust
hazard
ratio
ahr
confid
interv
ci
p
serum
bilirubin
concentr
mgl
ahr
ci
p
hypercreatininemia
ahr
ci
p
hypocalcaemia
ahr
ci
p
metabol
acidosi
ahr
ci
p
serum
cpl
concentr
lgl
ahr
ci
p
significantli
associ
shortterm
mortal
studi
suggest
presenc
serum
bilirubin
concentr
mgl
hypercreatininemia
hypocalcaemia
metabol
acidosi
iri
grade
acut
kidney
injuri
increas
shortterm
mortal
dog
diagnos
ap
result
studi
add
relev
inform
current
literatur
allow
clinician
recogn
sever
case
develop
acut
kidney
injuri
case
ap
need
investig
disclosur
disclosur
report
resid
program
dr
v
fabr
partli
financ
royal
canin
unrel
subject
matter
abstract
author
knowledg
diamet
valu
pyloru
sphincter
cat
never
establish
pylor
stenosi
poorli
document
cat
diagnosi
current
base
clinic
sign
pylor
outflow
obstruct
abnorm
pylor
conform
detect
ultrasonographi
aim
studi
describ
endoscop
techniqu
allow
assess
pylor
diamet
report
measur
healthi
cat
adult
healthi
cat
year
old
weight
kg
prospect
recruit
met
follow
criteria
vomit
episod
last
week
histori
chronic
vomit
treatment
given
last
month
abnorm
blood
biochemistri
cat
exclud
gastric
inflamm
determin
superior
accord
wsava
criteria
endoscop
procedur
pylor
diamet
measur
speciallydesign
interchang
biocompat
oliv
rang
mm
insert
decreas
order
screw
biopsi
forcep
pass
work
channel
diamet
first
oliv
abl
pass
pyloru
consid
equival
pylor
diamet
durat
endoscop
procedur
record
influenc
age
sex
weight
breed
statist
assess
valu
express
mean
sd
twentytwo
cat
met
inclus
criteria
two
cat
exclud
mark
gastric
inflamm
mean
age
remain
cat
month
rang
month
mean
weight
kg
rang
kg
entir
male
entir
femal
spay
femal
domest
shorthair
siameserel
cat
mean
pylor
diamet
popul
mm
rang
mm
influenc
age
sex
weight
breed
mean
durat
endoscop
procedur
minut
rang
minut
studi
author
knowledg
first
one
describ
method
assess
pylor
diamet
cat
endoscop
techniqu
safe
short
durat
studi
base
healthi
cat
mean
diamet
pyloru
estim
mm
determin
refer
interv
warrant
order
help
diagnosi
pylor
stenosi
cat
disclosur
disclosur
report
howev
actual
mechan
hostmicrob
interact
remain
elus
furthermor
littl
inform
avail
differ
microbiota
dog
suffer
ibd
frd
therefor
aim
studi
defin
differ
microbiota
dog
ibd
frd
duodenum
colon
extract
dna
duoden
colon
biopsi
dog
frd
dog
ibd
use
illumina
sequenc
bacteri
rrna
gene
analyz
use
quantit
insight
microbi
ecolog
qiim
pipelin
analysi
similar
anosim
function
statist
softwar
packag
primer
primer
ltd
luton
uk
use
weight
unweight
unifrac
distanc
matrix
determin
group
sampl
contain
significantli
differ
bacteri
commun
linear
discrimin
analysi
lda
effect
size
lefs
perform
identifi
bacteri
group
significantli
associ
diseas
durat
colon
signific
differ
microbiota
structur
anosim
p
speci
rich
frd
ibd
duodenum
also
signific
differ
found
microbiota
structur
speci
rich
p
lefs
identifi
sever
bacteri
group
differenti
alter
group
enterococcu
neisseriacea
gemella
significantli
higher
ibd
group
lda
wherea
lactobacillu
cryocola
significantli
higher
frd
group
conclus
studi
reveal
differ
individu
bacteri
group
duodenum
dog
ibd
frd
addit
studi
need
valid
find
also
explor
signific
bacteri
group
play
pathophysiolog
ibd
frd
disclosur
disclosur
report
human
ibd
patient
signal
transduc
activ
transcript
stat
activ
epitheli
cell
correl
clinic
activ
although
canin
ibd
seem
involv
similar
pathogenet
mechan
littl
inform
exist
dog
aim
studi
investig
express
intestin
biopsi
dog
ibd
express
differ
subtyp
ibdpati
correl
clinic
histopatholog
activ
express
accord
clinic
sign
respons
therapi
ibddog
group
food
respons
dog
frd
n
steroid
respons
enteropathi
sre
n
proteinlos
enteropathi
ple
n
ten
healthi
beagl
serv
control
co
dog
clinic
assess
use
canin
chronic
enteropathi
activ
index
ccecai
score
system
duoden
mucos
biopsi
sampl
endoscop
retriev
histopatholog
examin
use
world
small
anim
veterinari
associ
wsava
grade
immunohistochemistri
detect
perform
group
signific
differ
histolog
clinic
score
compar
co
significantli
higher
express
sreand
pledog
detect
villu
epithelium
crypt
epithelium
ce
patient
group
signific
correl
wsava
express
ibd
dog
ce
could
detect
similarli
human
ibdpati
studi
show
signific
differ
subtyp
ibdpati
compar
co
studi
requir
investig
role
potenti
marker
ibdpati
disclosur
disclosur
report
canin
chronic
enteropathi
cce
summar
diseas
entiti
character
persist
gastrointestin
symptom
inflammatori
infiltr
lymphoplasmacellular
enter
lpe
common
form
base
respons
treatment
food
respons
diarrhoea
frd
inflammatori
bowel
diseas
ibd
steroidrespons
diarrhea
protein
loos
enteropathi
ple
differenti
differenti
lpe
intestin
lymphoma
diagnost
challeng
histopatholog
might
fail
yield
unequivoc
result
inflammatori
lymphocyt
infiltr
polyclon
origin
often
reliabl
differenti
clonal
prolifer
lymphoma
histopatholog
alon
clonal
test
detect
antigen
receptor
gene
rearrang
polymeras
chain
reaction
might
offer
use
solut
dilemma
retrospect
studi
clonal
test
histopatholog
sampl
cce
patient
lpe
perform
eventu
differ
clonal
pattern
ibd
frd
ple
intestin
lymphocyt
infiltr
six
healthi
beagl
dog
investig
canin
ibd
activ
index
cibdai
use
endoscop
duoden
colon
biopsi
evalu
histopatholog
clonal
test
base
clinic
data
respons
therapi
cce
dog
alloc
group
frd
n
ibd
n
ibd
secondari
ple
n
one
dog
frd
group
also
diagnos
histiocyt
ulcer
coliti
huc
clonal
test
perform
use
primer
target
complet
immunoglobulin
heavi
chain
variabl
region
ighv
tcellreceptor
gamma
tcrg
generearrang
size
separ
perform
highresolut
capillari
electrophoresi
cibdai
significantli
differ
group
improv
significantli
week
appropri
therapi
p
beagl
show
polyclon
electrophoret
pattern
band
tcell
primer
sampl
cce
patient
show
polyclon
pattern
bcell
primer
target
tcrg
patient
show
oligoclon
pattern
lymphocyt
infiltr
duodenum
two
dog
belong
frd
group
one
ple
group
frdhuc
patient
show
oligoclon
colon
differ
clonal
express
group
could
detect
despit
clinic
improv
group
oligoclon
lymphoid
popul
detect
four
dog
conclus
clonal
test
might
use
complementari
tool
investig
natur
lymphocyt
intestin
infiltr
result
clonal
must
interpret
context
clinic
sign
diagnost
find
respons
therapi
data
long
term
follow
need
decid
new
tool
might
help
detect
earli
lymphoma
patient
cce
disclosur
disclosur
report
acquir
pylor
stenosi
ap
poorli
report
cat
diagnost
challeng
partli
dimens
healthi
felin
pyloru
defin
howev
sinc
pyloru
usual
passabl
mm
diamet
endoscop
inabl
intub
pyloru
despit
sever
attempt
could
use
diagnost
indic
pylor
stenosi
ps
aim
retrospect
studi
compar
clinic
characterist
cat
possibl
ap
base
presenc
gastrointestin
sign
inabl
pass
endoscop
group
control
group
cat
gastrointestin
sign
pyloru
passabl
group
b
studi
conduct
two
referr
centr
cat
sign
gastrointestin
diseas
underw
upper
gastrointestin
endoscopi
part
diagnost
investig
perform
clinician
vf
group
compris
adult
cat
presumpt
diagnosi
ap
group
b
includ
cat
signal
clinic
paramet
statist
compar
group
chi
squar
test
fisher
exact
test
student
ttest
significantli
siames
siameserel
cat
group
group
b
p
howev
neither
age
weight
significantli
differ
group
chronic
vomit
main
present
complaint
defin
presenc
distribut
sever
gi
diseas
endoscop
biopsi
specimen
dog
inflammatori
bowel
diseas
ibd
difficult
prior
studi
fail
detect
convinc
associ
mucos
histopatholog
clinic
sign
respons
therapi
outcom
dog
ibd
reason
standard
grade
scheme
interpret
gi
histopatholog
find
introduc
wsava
grade
scheme
howev
larger
scale
studi
far
evalu
whether
clinic
score
system
linearli
correl
wsava
histopatholog
grade
scheme
inform
would
use
clinician
wsava
grade
could
use
monitor
treatment
respons
may
give
prognost
inform
aim
studi
evalu
whether
dog
diagnos
ibd
clinic
score
perform
use
canin
chronic
enteropathi
clinic
activ
index
ccecai
histopatholog
score
use
wsava
score
scheme
linearli
correl
one
anoth
electron
data
wsava
grade
endoscop
retriev
biopsi
score
assign
veterinari
pathologist
one
singl
centr
collect
maximum
five
site
evalu
per
anim
stomach
pyloru
n
fundu
n
duodenum
n
ileum
n
colon
n
one
hundr
two
dog
diagnos
ibd
includ
studi
wsava
score
compar
ccecai
score
assign
anim
time
diagnosi
linear
correl
assess
use
spearman
rank
test
linear
correl
score
weak
r
rang
gastric
fundu
r
gastric
pyloru
r
duodenum
r
ileum
r
colon
r
site
linear
correl
signific
duodenum
r
p
studi
indic
linear
correl
two
grade
system
weak
clinician
reli
one
system
predict
score
studi
correl
score
treatment
larg
number
dog
indic
evalu
predict
abil
wsava
score
microbi
commun
composit
gut
larg
influenc
diet
may
affect
health
human
diet
domin
red
meat
associ
colon
diseas
ibd
colorect
cancer
gut
bacteria
may
play
role
etiolog
whether
also
appli
dog
well
document
aim
studi
evalu
chang
fecal
bacteri
composit
healthi
clientown
dog
increas
inclus
minc
beef
mb
diet
eleven
dog
includ
sevenweek
studi
eight
dog
particip
dietari
period
first
two
week
dog
acclim
commerci
dri
food
cd
follow
three
week
increment
increas
dog
total
energi
requir
suppli
mb
expens
cd
mb
provid
low
lmb
medium
mmb
high
hmb
percent
energi
result
concomit
increas
protein
fat
decreas
starch
fiber
final
two
week
dog
fed
cd
bacteri
popul
express
oper
taxonom
unit
otu
character
fecal
sampl
dietari
period
use
illumina
miseq
base
region
rrna
gene
hmb
diet
induc
lower
speci
rich
even
anova
pvalu
differ
microbi
popul
genu
level
observ
hmb
cd
diet
group
permut
test
p
rel
abund
otu
classifi
clostridia
hiranoni
increas
wherea
otu
classifi
saccharolyt
bacteria
ruminococcacea
spp
faecalibacterium
prausnitzii
decreas
sampl
dog
fed
hmb
diet
revers
p
lda
score
fecal
ph
well
butyr
isovaler
level
also
affect
diet
conclus
mb
content
diet
dog
influenc
composit
divers
fecal
bacteri
popul
studi
need
assess
impact
gut
health
dog
especi
concern
role
clostridia
hiranoni
light
role
biotransform
primari
bile
acid
potenti
harm
secondari
bile
acid
reduc
rel
abund
butyrateproduc
saccharolyt
bacteria
consum
diet
lower
carbohydr
content
disclosur
studi
sponsor
labb
felleskjopet
escherichia
coli
e
coli
member
resid
intestin
microflora
howev
e
coli
divers
speci
strain
harbour
virul
determin
may
caus
intestin
diseas
favour
circumst
peopl
crohn
diseas
boxer
granulomat
coliti
evid
e
coli
strain
lack
virul
determin
typic
associ
diarrheagen
strain
involv
pathogenesi
chronic
intestin
inflamm
furthermor
german
shepherd
dog
gsd
lymphoplasmacyt
ibd
lpibd
frequent
respond
antibiot
treatment
howev
basi
clinic
respons
unknown
aim
present
studi
prospect
investig
presenc
virul
gene
associ
diarheagen
ecoli
intestin
mucosa
dog
lpibd
twelv
gsd
twenti
nongsd
evalu
march
octob
royal
veterinari
colleg
london
uk
includ
studi
diagnosi
lpibd
base
clinic
sign
intestin
histopatholog
exclus
known
caus
gastrointestin
sign
e
coli
cultur
endoscop
collect
mucos
biopsi
materi
sheep
blood
agar
macconkey
coloni
show
characterist
consist
e
coli
identifi
use
biom
erieux
dna
extract
strain
use
magna
pure
system
roch
follow
loopmedi
isotherm
pcr
amplif
lamp
detect
presenc
shigatoxin
und
heatstabl
enterotoxin
sta
attach
effac
intimin
gene
eae
total
number
mucosaassoci
ecoli
strain
isol
dog
higher
frequenc
ecoli
strain
isol
gsd
posit
cultur
per
dog
vs
dog
breed
posit
cultur
per
dog
p
none
ecoli
strain
posit
sta
eae
gene
found
strain
eaeposit
e
coli
frequent
isol
gsd
breed
lpibd
p
result
suggest
ecoli
carri
eae
gene
possibl
yet
investig
virul
factor
could
involv
pathogenesi
lpibd
gsd
disclosur
ye
disclosur
report
laboklin
ag
bad
kissingen
germani
partial
sponsor
project
intern
medicin
wherea
major
dog
immunemedi
haemolyt
anaemia
imha
regen
anaemia
mani
persist
nonregen
anaemia
possibl
indic
autoimmun
respons
direct
precursor
cell
bone
marrow
prognost
factor
includ
canin
haemolyt
anaemia
object
score
chao
identifi
dog
imha
clear
whether
factor
remain
valid
dog
present
nonregen
imha
nrimha
aim
studi
evalu
associ
clinicopatholog
variabl
surviv
dog
nrimha
compar
associ
composit
chao
electron
record
tertiari
referr
institut
search
identifi
dog
anaem
pack
cell
volum
less
least
one
follow
featur
spontan
agglutin
red
blood
cell
dilut
salin
spherocytosi
without
evid
shear
damag
evalu
fresh
blood
smear
titr
least
direct
antiglobulin
test
detect
erythrophagocytosi
myeloid
cell
bone
marrow
dog
consid
nrimha
absolut
reticulocyt
concentr
arc
increas
l
within
five
day
present
underli
caus
immunemedi
diseas
exclud
diagnost
imag
serum
biochemistri
test
vectorborn
diseas
urinalysi
chao
score
calcul
dog
score
incorpor
age
rectal
temperatur
serum
albumin
total
bilirubin
concentr
platelet
concentr
associ
clinicopatholog
variabl
surviv
evalu
cox
proport
hazard
analysi
initi
univari
analysi
follow
construct
multivari
model
separ
analysi
conduct
chao
sole
explanatori
variabl
fifti
dog
nrimha
includ
studi
mean
age
year
se
median
pack
cell
volum
present
interquartil
rang
iqr
median
arc
l
iqr
bone
marrow
sampl
obtain
dog
reveal
erythroid
hyperplasia
hypoplasia
prca
three
factor
serum
creatinin
albumin
total
bilirubin
concentr
significantli
associ
surviv
final
multivari
model
separ
model
chao
also
significantli
associ
surviv
studi
indic
prognost
factor
identifi
mix
popul
dog
imha
includ
serum
total
bilirubin
creatinin
concentr
also
appear
import
dog
nrimha
disclosur
disclosur
report
platelet
count
increas
within
day
dog
imt
treat
prednisolon
hivig
treatment
failur
death
may
still
occur
aim
studi
investig
shortterm
respons
hivig
manag
imt
twentyseven
dog
imtevanssyndrom
es
receiv
hivig
includ
dog
concurr
diseas
receiv
medicationvaccin
within
day
imt
diagnosi
classifi
secondari
imt
simt
remain
primari
imt
pimt
base
platelet
count
ae
hr
posthivig
infus
dog
divid
respond
n
nonrespond
n
posit
respons
defin
increas
platelet
compar
valu
hivig
infus
differ
nonrespond
respond
sex
presenc
type
bleed
type
diseas
ie
pimt
vs
simt
presenc
concurr
es
day
prednisolon
treatment
day
hospit
hivig
infus
platelet
count
hct
serum
igg
total
protein
tp
albumin
creactiv
protein
concentr
plasma
ddimer
concentr
hivig
administ
dose
nonrespond
sign
mucos
bleed
ie
melena
epistaxishaematuria
compar
respond
vs
p
older
month
vs
month
month
p
hr
posthivig
infus
nonrespond
compar
respond
lower
serum
albumin
g
dl
vs
gdl
p
serum
globulin
gdl
vs
gdl
p
serum
igg
mgdl
vs
mgdl
p
delta
igg
ie
mgdl
vs
mgdl
p
serum
tp
gdl
vs
gdl
p
expect
nonrespond
compar
respond
lower
platelet
count
vs
p
delta
platelet
count
ie
median
rang
vs
p
fourteenday
posthivig
infus
mortal
higher
nonrespond
compar
respond
vs
p
roc
curv
analysi
show
mgdl
predict
posit
respons
p
final
weak
correl
hivig
administ
dose
p
shortterm
respons
hivig
infus
dog
imt
may
occur
regardless
dog
pimt
simt
es
older
age
mucos
bleed
admiss
ongo
bleed
decreas
poor
prognost
indic
respons
nonrespond
increas
shortterm
mortal
mgdl
predict
respons
treatment
weak
posit
correl
hivig
receiv
dose
present
disclosur
disclosur
report
dog
refractori
recur
itp
treat
romiplostim
inclus
criteria
diagnosi
primari
secondari
itp
base
complet
medic
record
platelet
count
posit
plateletbound
antibodi
test
primari
itp
diagnos
evid
caus
might
trigger
platelet
destruct
discrimin
primari
secondari
form
itp
base
complet
diagnost
workup
complet
blood
count
blood
smear
evalu
test
erythrocyt
agglutin
clinic
chemistri
coagul
panel
diagnost
imag
test
infecti
diseas
immunolog
test
primari
secondari
itp
diagnos
evan
syndrom
dog
ehrlicha
cani
infect
respect
dog
pretreat
prednisolon
mycophenol
mofetil
cyclosporin
dexamethason
alon
combin
due
inadequ
respons
relaps
romiplostim
administ
addit
lgkg
median
lgkg
subcutan
dog
increas
platelet
count
note
day
first
romiplostim
inject
one
dog
primari
itp
increas
day
second
administr
lgkg
anoth
dog
secondari
itp
respond
lgkg
dog
lost
followup
one
dog
platelet
count
refer
rang
euthan
due
immunemedi
hemolyt
anemia
month
observ
period
week
median
dog
initi
given
dose
could
reduc
none
treat
dog
develop
side
effect
concomit
therapi
drug
gradual
reduc
halt
dog
platelet
count
stabl
interestingli
none
dog
relaps
observ
period
result
pilot
studi
suggest
human
drug
romiplostim
may
repres
novel
therapeut
option
dog
refractori
itp
disclosur
disclosur
report
role
bacteri
commun
canin
nasal
diseas
studi
far
use
next
gener
pyrosequenc
method
aim
studi
character
nasal
microbiom
healthi
dog
compar
dog
nasal
diseas
nasal
swab
collect
healthi
dog
n
dog
malign
nasal
neoplasia
n
dog
chronic
rhiniti
n
bacteri
dna
extract
sequenc
bacteri
rrna
gene
perform
data
analyz
use
quantit
insight
microbi
ecolog
qiim
total
bacteri
speci
phyla
detect
healthi
dog
moraxella
spp
common
speci
follow
phyllobacterium
spp
cardiobacteriacea
staphylococcu
spp
moraxella
spp
significantli
decreas
diseas
compar
healthi
dog
p
pasteurellacea
significantli
increas
p
shannon
divers
index
analysi
similar
use
unweight
unifrac
distanc
metric
significantli
differ
nasal
microbi
commun
healthi
dog
compar
dog
nasal
diseas
p
studi
show
canin
nasal
caviti
inhabit
highli
speciesrich
bacteri
commun
suggest
differ
nasal
microbiom
healthi
dog
dog
nasal
diseas
disclosur
disclosur
report
acut
phase
protein
app
sensit
marker
inflamm
serum
creactiv
protein
crp
shown
use
diagnost
biomark
dog
bacteri
pneumonia
bp
human
pneumonia
app
also
great
util
followup
biomark
order
investig
applic
app
biomark
treatment
respons
dog
bp
serum
creactiv
protein
crp
serum
amyloid
saa
haptoglobin
hp
follow
simultan
along
hematolog
serum
biochemistri
arteri
blood
ga
analysi
thorac
radiograph
natur
cours
bp
n
healthi
dog
includ
control
measur
app
initi
significantli
elev
dog
bp
compar
healthi
control
magnitud
elev
connect
diseas
sever
crp
saa
reflect
well
recoveri
process
declin
rapidli
initi
therapi
normal
serum
crp
appli
guid
length
antibiot
therapi
therapi
stop
day
crp
normal
dog
surviv
discharg
median
treatment
length
day
iqr
day
wherea
dog
treat
accord
convent
recommend
median
iqr
respect
crp
appli
guid
antibiot
therapi
treatment
length
significantli
p
reduc
without
increas
number
relaps
accord
studi
serum
crp
saa
may
use
biomark
treatment
respons
normal
serum
crp
may
appli
guid
length
antibiot
therapi
dog
bp
disclosur
sj
viitanen
receiv
research
grant
finnish
foundat
veterinari
research
finnish
veterinari
foundat
fund
sourc
influenc
studi
design
sampl
collect
interpret
result
laryng
collaps
commonli
associ
brachycephal
syndrom
bs
suspect
secondari
chronic
upper
airway
obstruct
although
laryng
collaps
suspect
consequ
lack
rigid
laryng
cartilag
chondromalacia
impact
possibl
laryng
dysfunct
laryng
paresi
yet
evalu
correct
surgic
treatment
mainli
aim
improv
airflow
rima
glottidi
howev
impact
laryng
collaps
postop
prognosi
still
controversi
object
present
studi
investig
laryng
function
anaesthet
dog
bs
use
pharmacolog
stimul
doxapram
hydrochlorid
dxp
laryngoscopi
investig
whether
surgeri
worsen
laryng
collaps
twentysix
dog
present
bs
includ
diagnosi
respiratori
clinic
sign
assess
well
degre
laryng
collaps
dxp
inject
mgkg
intraven
one
month
correct
surgeri
bs
respiratori
clinic
sign
degre
laryng
collaps
reevalu
respiratori
clinic
sign
score
base
frequenc
snore
inspiratori
effort
exercis
intoler
syncop
degre
laryng
collaps
assess
accord
classif
describ
leonard
wilcoxon
sign
rank
test
continu
correct
fisher
exact
test
use
statist
analysi
pug
significantli
frequent
present
grade
laryng
collaps
p
compar
french
bulldog
larynx
initi
appear
paret
dog
signific
abduct
laryng
cartilag
could
observ
dog
dxp
inject
moreov
signific
differ
mean
degre
laryng
collaps
dxp
inject
p
confirm
observ
signific
clinic
improv
observ
surgeri
vast
major
dog
mean
respiratori
clinic
score
surgeri
signific
differ
mean
degre
laryng
collaps
compar
surgeri
laryng
collaps
improv
remain
stabl
worsen
n
n
n
dog
respect
surgeri
conclus
laryng
collaps
brachycephal
dog
associ
absenc
laryng
abduct
preoper
degre
laryng
collaps
use
criterion
discourag
surgeri
bs
overal
clinic
improv
even
laryng
collaps
may
worsen
dog
surgeri
disclosur
disclosur
report
brachycephal
obstruct
airway
syndrom
boa
relat
congenit
flatten
facial
skull
anatomi
boa
caus
respiratori
distress
heat
exercis
intoler
gastrointestin
sign
english
bulldog
eb
one
brachycephal
breed
high
preval
boa
current
sever
boa
sign
subject
assess
improv
welfar
brachycephal
breed
object
easytous
tool
need
help
breeder
select
healthier
anim
exercis
test
walk
test
distanc
walk
measur
walk
test
time
complet
measur
could
use
assess
level
boa
exercis
intoler
impair
recoveri
key
featur
boa
studi
evalu
sever
sign
anatom
compon
boa
group
prospect
recruit
young
adult
eb
n
investig
well
result
walk
test
walk
test
correl
sever
boa
eb
sever
boa
walk
shorter
distanc
longer
time
recoveri
exercis
took
longer
mild
sign
boa
control
dog
differ
breed
n
perform
exercis
test
significantli
better
eb
bodi
temperatur
rise
exercis
significantli
higher
eb
control
result
studi
support
use
exercis
test
object
evalu
level
boa
disclosur
disclosur
report
sinoorbit
aspergillosi
soa
invas
felin
fungal
infect
high
mortal
caspofungin
echinocandin
use
successfuli
treat
sever
case
studi
aim
investig
caspofungin
pharmacokinet
healthi
adult
cat
singl
b
multipl
intraven
iv
infus
studi
caspofungin
mgkg
iv
administ
healthi
cat
h
day
studi
b
cat
receiv
mkg
caspofungin
iv
daili
addit
day
day
blood
collect
h
h
h
h
h
h
h
h
h
h
h
drug
administr
day
next
dose
day
h
final
dose
day
plasma
caspofungin
level
determin
time
point
use
liquid
chromatographi
mass
spectrometri
assay
valid
accord
us
fda
guidelin
industri
bioanalyt
method
valid
singl
iv
dose
mean
maximum
caspofungin
concentr
c
max
ae
mgml
reach
ae
h
termin
elimin
halflif
caspofungin
clearanc
cl
volum
distribut
v
ae
h
ae
ml
hkg
ae
lkg
respect
achiev
steadyst
mean
maximum
concentr
css
max
ae
mgml
reach
day
dose
estim
multipl
dose
clearanc
clss
volum
distribut
vss
ae
h
ae
mlhkg
ae
lkg
respect
accumul
ratio
mean
plasma
caspofungin
concentr
mgml
durat
h
sampl
period
exce
minimum
inhibitori
concentr
effect
aspergillu
speci
caspofungin
given
mgkg
iv
q
h
safe
like
effect
treat
aspergillu
infect
cat
disclosur
disclosur
report
publish
studi
identifi
caus
pyrexia
cat
primari
aim
studi
describ
featur
diagnos
popul
cat
refer
pyrexia
secondari
object
describ
evalu
util
diagnost
investig
perform
final
treatment
referr
possibl
effect
reach
diagnosi
assess
clinic
record
cat
pyrexia
document
least
twice
refer
andor
referr
practic
retrospect
review
case
assign
follow
diseas
categori
base
diagnosi
infecti
inflammatori
immunemedi
neoplast
miscellan
diagnosi
pyrexia
unknown
origin
puo
one
diagnosi
made
case
diagnosi
deem
like
caus
pyrexia
use
categoris
unclear
attribut
miscellan
differ
signal
peak
temperatur
referr
temperatur
present
presencesever
common
haematolog
serum
biochem
abnorm
outcom
evalu
diseas
categori
diagnost
investig
classifi
enabl
assist
help
achiev
diagnosi
effect
treatment
referr
assess
associ
temperatur
present
abil
reach
diagnosi
chisquar
test
use
categor
data
kruskallw
test
continu
data
infecti
diseas
common
categori
cat
felin
infecti
periton
inflammatori
condit
found
neoplasia
includ
cat
lymphoma
miscellan
caus
immunemedi
diseas
cat
despit
often
extens
diagnost
investig
puo
pedigre
versu
nonpedigre
statu
p
age
p
differ
significantli
diseas
categori
outcom
p
puo
associ
wors
outcom
categori
p
cytolog
includ
fluid
analysi
histopatholog
often
enabl
assist
reach
diagnosi
cat
receiv
treatment
referr
antimicrobi
administ
case
nonsteroid
antiinflammatori
administr
significantli
associ
lower
temperatur
present
p
abil
reach
diagnosi
associ
treatment
referr
p
first
studi
caus
pyrexia
cat
show
contrast
dog
infecti
diseas
common
immunemedi
diseas
compar
rare
puo
associ
wors
outcom
agreement
human
report
disclosur
disclosur
report
statement
disclosur
ir
ir
receiv
financi
support
hyperand
hypoadrenocortic
research
dechra
veterinari
product
ltd
bsava
petsav
past
ir
also
receiv
financi
support
endocrin
clinic
research
project
univers
glasgow
veterinari
fund
bsava
petsav
anipoc
ltd
ir
paid
provid
continu
profession
develop
wide
rang
commerci
compani
notforprofit
organis
around
world
serum
magnesium
exist
free
proteinbound
complex
fraction
sum
per
unit
volum
describ
total
magnesium
concentr
mg
relationship
free
magnesium
concentr
f
mg
describ
dog
abnorm
mg
associ
prolong
hospitalis
decreas
surviv
dog
remain
unclear
whether
magnesium
measur
offer
prognost
valu
beyond
valid
tool
acut
patient
physiolog
laboratori
evalu
appl
score
aim
studi
determin
relationship
f
mg
mg
dog
present
veterinari
emerg
centr
explor
associ
f
mg
surviv
dog
includ
studi
blood
obtain
initi
present
immedi
measur
plasma
f
mg
use
ionselect
electrod
subset
dog
serum
sampl
obtain
contemporan
measur
mg
separ
cell
pellet
within
two
hour
frozen
analys
singl
batch
ilab
analys
use
enzymat
reaction
method
primari
outcom
surviv
discharg
applefast
score
incorpor
glucos
albumin
lactat
concentr
mentat
platelet
count
calcul
dog
initi
present
correl
plasma
f
mg
serum
mg
assess
spearman
rho
coeffici
associ
f
mg
surviv
evalu
logist
regress
surviv
discharg
depend
variabl
applefast
score
fix
factor
classif
neoplasia
common
caus
present
companion
anim
veterinari
surgeon
uk
howev
nation
statist
character
either
present
manag
neoplasia
companion
anim
gener
practic
use
electron
health
record
ehr
gather
uk
small
anim
practic
small
anim
veterinari
surveil
network
savsnet
use
character
frequenc
present
neoplasia
common
tumour
locat
treatment
pursu
cat
dog
ehr
collect
novemb
octob
includ
anim
signal
result
short
questionnair
present
veterinari
surgeon
consult
neoplasia
identifi
main
reason
present
proport
confid
interv
calcul
use
robust
standard
error
allow
cluster
within
veterinari
practic
ehr
obtain
uniqu
anim
dog
cat
veterinari
practic
site
proport
dog
attend
veterinari
practic
least
one
neoplasiarel
consult
mean
ci
hdefmybox
vrule
depth
height
width
igher
proport
cat
ci
dog
cat
neuter
anim
frequent
present
neoplasia
entir
anim
total
neoplasia
questionnair
dog
cat
collect
dog
skin
subcutan
tissu
commonli
present
tumour
locat
respect
whilst
cat
skin
follow
intraabdomin
common
time
present
anim
neoplasia
within
one
month
dog
cat
howev
dog
cat
present
tumour
greater
one
year
treatment
plan
dog
cat
present
neoplast
condit
although
dog
cat
decis
treat
determin
time
consult
common
treatment
plan
surgeri
dog
analgesia
antiinflammatori
cat
mainli
perform
gener
practic
canin
patient
felin
patient
refer
treatment
neoplasia
result
demonstr
savsnet
power
tool
collect
epidemiolog
data
regard
neoplasia
small
anim
attend
uk
veterinari
practic
big
data
set
help
establish
outcom
patient
treat
gener
practic
provid
inform
acceler
revolution
understand
companion
anim
neoplasia
disclosur
disclosur
report
q
fournier
j
lawrenc
handel
jc
serra
univers
edinburgh
roslin
uk
complet
blood
count
cbc
routin
assess
prior
administr
chemotherapi
dog
effort
minim
clinic
ill
neutrophil
criteria
cutoff
suggest
safe
administ
chemotherapi
arbitrari
vari
across
clinician
chemotherapi
dose
intens
theoret
import
maxim
tumour
respons
suggest
determin
optim
neutrophil
cutoff
also
import
similarli
arbitrari
guidelin
util
administr
prophylact
antibiot
neutropen
dog
primari
object
studi
evalu
impact
variou
pretreat
absolut
neutrophil
count
anc
cutoff
chemotherapi
administr
determin
associ
pretreat
anc
incid
sever
toxic
secondari
object
evalu
current
util
neutrophil
criteria
algorithm
use
guid
prescript
prophylact
antibiot
afebril
clinic
well
neutropen
dog
six
hundredfifteen
cbc
dog
present
standard
multidrug
chemotherapi
follow
diagnosi
highgrad
lymphoma
evalu
stratifi
accord
anc
anc
class
includ
x
l
x
l
x
l
x
l
number
event
chemotherapi
would
administ
due
anc
valu
cutoff
determin
chemotherapyrel
toxic
grade
per
standard
criteria
mannwhitney
test
perform
determin
presenc
associ
pretreat
anc
class
toxic
address
secondari
object
afebril
clinic
well
neutropen
dog
anc
x
l
clinic
criteria
prophylact
antibiot
evalu
cbc
evalu
chemotherapi
would
administ
n
n
n
visit
anc
cutoff
x
l
x
l
x
l
respect
associ
pretreat
anc
class
grade
likelihood
toxic
dog
anc
x
l
prophylact
antibiot
dispens
consid
separ
dog
anc
x
l
n
anc
x
l
n
recov
spontan
without
medic
intervent
expect
pretreat
anc
cutoff
x
l
associ
lower
number
dog
requir
dose
delay
importantli
pretreat
anc
associ
increas
likelihood
toxic
preliminari
evalu
suggest
establish
anc
cutoff
near
x
l
prescrib
prophylact
antibiot
may
clinic
ration
disclosur
disclosur
report
besid
activ
telomeras
tumor
cell
use
altern
lengthen
telomer
alt
telomer
mainten
mechan
tmm
becom
immort
alt
found
often
human
mesenchym
epitheli
tumor
canin
tumor
character
alt
yet
aim
studi
evalu
tmm
variou
canin
sarcoma
subtyp
sixtyfour
canin
sarcoma
sampl
snapfrozen
ffpe
six
canin
sarcoma
cell
line
screen
alt
ccircl
assay
telomer
length
assess
via
qpcr
telomer
restrictionfrag
includ
pulsedfield
electrophoresi
altassoci
mutat
evalu
immunohistochemistri
telomeras
activ
ta
gene
express
analyz
trap
qpcr
eight
human
sarcoma
cell
line
dna
human
neuroblastoma
use
compar
control
alt
found
canin
sarcoma
includ
aggress
subtyp
hemangiosarcoma
osteosarcoma
histiocyt
sarcoma
select
sampl
characterist
alt
long
heterogen
telomer
loss
atrx
elev
express
high
level
coloc
daxx
telomer
demonstr
ta
detect
snapfrozen
sampl
tmm
coexist
one
histiocyt
sarcoma
absent
one
hemangiosarcoma
sarcoma
cell
line
taposit
altneg
canin
sarcoma
seem
share
mani
similar
human
counterpart
appear
attract
compar
telomer
research
human
alt
might
higher
preval
aggress
canin
sarcoma
subtyp
overal
besid
ta
also
alt
consid
potenti
target
therapeut
approach
disclosur
disclosur
report
etoposid
semisynthet
deriv
podophyllotoxin
cytotox
chemotherapi
drug
mediat
inhibit
topoisomeras
ii
etoposid
wide
use
variou
human
solid
hematopoiet
cancer
littl
data
avail
concern
potenti
antitumor
efficaci
dog
previou
studi
canin
lymphoma
treat
intraven
administr
etoposid
show
minim
therapeut
effect
associ
hematolog
toxic
sever
acut
hypersensit
reaction
probabl
associ
vehicl
use
parenter
formul
object
doseescal
clinic
trial
assess
safeti
toler
efficaci
intraven
etoposid
phosphat
etopopho
dog
multicentr
lymphoma
etopopho
etoposid
prepar
contain
iv
formul
expect
like
toler
dog
twentyseven
owneddog
stage
iiiv
multicentr
lymphoma
enrol
signal
clinic
find
histolog
complet
stage
result
respons
treatment
record
seven
dose
level
evalu
determin
recommend
dose
mgm
n
mgm
n
mgm
n
mgm
n
mgm
n
mgm
n
mgm
n
protocol
consist
three
cycl
etoposid
phosphat
etopopho
iv
inject
everi
week
inject
daili
consecut
day
advers
effect
grade
accord
veterinari
cooper
oncolog
group
criteria
complet
endstag
realiz
day
inclus
dose
level
mgm
minim
therapeut
effect
observ
n
dog
treat
dose
level
mgm
dog
achiev
pr
dog
cr
orr
dog
treat
dose
level
mgm
main
advers
event
observ
dog
revers
gastrointestin
toxic
grade
myelotox
rare
grade
dog
grade
neutropenia
report
one
dog
dose
level
mgm
dog
treat
dose
level
mgm
sever
gastrointestin
toxic
grade
sever
myelotox
grade
neutropenia
report
dog
acut
hypersensit
reaction
studi
recommend
dose
etoposid
phosphat
etopopho
dog
mgm
orr
moder
revers
gastrointestin
toxic
sever
myelotox
hypersensit
reaction
report
dose
level
disclosur
studi
conduct
oncovet
clinic
research
ocr
part
collabor
research
project
ocr
pierr
fabr
medica
mesothelioma
rare
tumor
dog
known
induc
effus
coelom
caviti
neoplast
tissu
biopsi
often
difficult
obtain
even
cytolog
diagnosi
straightforward
case
challeng
other
therefor
diagnosi
mesothelioma
complic
case
describ
literatur
studi
assess
casecontrol
manner
effici
surgeri
radiat
therapi
chemotherapi
aim
retrospect
casecontrol
studi
evalu
effici
chemotherapi
dog
cytolog
andor
histolog
diagnosi
mesothelioma
collect
medic
databas
dog
treat
intraven
iv
andor
intracavitari
ic
chemotherapi
includ
group
dog
receiv
cytotox
treatment
group
signal
type
durat
clinic
sign
anatom
locat
mesothelioma
result
stage
procedur
cytolog
andor
histolog
examin
type
treatment
surgeri
chemotherapi
collect
dog
followup
data
obtain
medic
record
telephon
interview
owner
refer
veterinarian
progressionfre
surviv
pf
defin
time
diagnosi
evid
diseas
progress
death
calcul
dog
pf
function
estim
use
kaplan
meier
method
compar
group
use
log
rank
test
sixteen
dog
includ
studi
march
decemb
pleural
pericardi
periton
concomit
pleural
pericardi
mesothelioma
signific
differ
age
weight
sex
ratio
two
group
ten
dog
treat
variou
chemotherapi
protocol
receiv
iv
carboplatin
doxorubicin
mitoxantron
mitomycin
c
ic
chemotherapi
carboplatin
cisplatin
chemotherapi
administr
associ
significantli
higher
pf
median
pf
rang
vs
day
rang
p
six
dog
also
underw
pericardiectomi
studi
show
first
time
dog
mesothelioma
could
benefit
cytotox
chemotherapi
howev
larger
prospect
studi
use
standard
chemotherapi
protocol
appli
specif
anatom
form
diseas
warrant
confirm
find
disclosur
disclosur
report
canin
malign
melanoma
aggress
neoplasm
highli
metastat
resist
convent
chemotherapi
treatment
previou
work
demonstr
canin
melanoma
cell
line
may
contain
activ
akt
mtor
pathway
well
sensit
mtor
inhibitor
rapamycin
aim
studi
assess
combin
treatment
use
dual
inhibit
mtor
compar
result
achiev
inhibit
pathway
individu
five
establish
primari
canin
melanoma
cell
line
grown
monolay
cultur
vitro
standard
condit
cell
line
deriv
canin
primari
oral
melanoma
primari
cutan
melanoma
metastat
lymph
node
subcutan
metastasi
cell
treat
inhibitor
mtor
inhibitor
rapamycin
dual
inhibitor
hour
cell
viabil
assess
use
resazurin
dye
absorb
read
spectrophotomet
western
blot
use
evalu
drug
treatment
impact
pathway
compon
includ
phosphoryl
total
akt
mtor
dosedepend
decreas
cell
viabil
observ
cell
line
dual
inhibit
mtor
potent
pathway
target
inhibit
result
lower
cell
viabil
valu
either
drug
test
dual
inhibit
mtor
may
efficaci
singl
pathway
target
canin
melanoma
cell
futur
studi
assess
potenti
target
strategi
sensit
chemotherapi
respons
notori
treatment
resist
tumour
type
disclosur
disclosur
report
nutrit
statu
patient
usual
evalu
record
bodi
weight
bw
assess
bodi
condit
score
bc
muscl
condit
score
mc
differ
score
could
exist
among
train
untrain
veterinari
personnel
aim
studi
assess
reproduc
score
techniqu
differ
oper
dog
seventyf
adult
dog
boxer
english
cocker
spaniel
golden
retriev
labrador
retriev
weight
blind
assess
bc
mc
five
differ
evalu
ie
internist
nutritionist
behaviorist
vet
student
dog
show
judg
accord
offici
nutrit
guidelin
particular
bc
score
evalu
use
scale
mc
score
consid
visual
examin
palpat
muscl
tempor
bone
scapula
rib
lumbar
vertebra
pelvic
bone
chisquar
test
perform
statist
signific
analysi
set
p
agreement
differ
oper
score
evalu
cohen
kappa
chisquar
test
perform
five
evalu
assess
signific
p
cohen
kappa
obtain
estim
bc
score
show
fair
moder
agreement
evalu
kappa
particular
higher
concord
detect
student
internist
kappa
compar
other
consid
mc
kappa
agreement
evalu
rang
best
agreement
nutritionist
judg
english
cocker
spaniel
difficult
breed
evalu
show
worst
level
concord
evalu
data
confirm
difficulti
obtain
uniqu
nutrit
evalu
lack
concord
could
due
differ
practic
area
evalu
mainli
involv
caution
taken
consider
bc
mc
score
practition
involv
clinic
manag
dog
order
reduc
limit
adequ
train
could
perform
involv
staff
disclosur
disclosur
report
dog
unit
state
consid
overweight
obes
mani
pet
owner
unsuccess
reduc
pet
bodi
weight
critic
compon
success
weight
loss
regimen
good
estim
bodi
composit
start
point
calcul
appropri
food
amount
weight
loss
newli
develop
method
call
bodi
fat
index
bfi
differenti
level
obes
establish
link
bfi
ideal
bodi
weight
dualenergi
xray
absorptiometri
dexa
provid
accur
way
measur
percent
bodi
fat
howev
readili
avail
gener
practition
current
studi
compar
percent
bodi
fat
determin
bfi
chart
dexa
scan
group
obes
dog
weight
loss
weight
mainten
fed
food
formul
help
dog
achiev
healthi
weight
contain
g
protein
g
fat
g
insolubl
fiber
g
solubl
fiber
mg
lcarnitin
per
kilocalori
protocol
procedur
approv
institut
anim
care
use
committe
thirteen
obes
dog
fed
weight
loss
achiev
ideal
bodi
weight
ibw
follow
weight
mainten
phase
dog
group
hous
allow
social
access
outdoor
run
three
anim
care
technician
independ
determin
bfi
dog
per
month
averag
bfi
calcul
bfi
chart
includ
imag
descriptor
use
determin
dog
percent
bodi
fat
dog
underw
monthli
dexa
scan
weight
loss
phase
everi
two
month
weight
mainten
phase
includ
entir
studi
popul
valu
percent
bodi
fat
determin
bfi
dexa
strongli
correl
r
dog
age
correl
stronger
r
dog
age
r
bfi
slightli
underestim
percent
bodi
fat
older
dog
older
dog
higher
percent
bodi
fat
ibw
compar
younger
dog
ibw
purpos
studi
evalu
use
new
bfi
risk
chart
repeatedli
estim
percent
bodi
fat
overweight
dog
weight
loss
period
stabl
normal
bodi
weight
result
show
new
method
excel
tool
determin
bodi
fat
practic
use
veterinari
clinic
disclosur
disclosur
report
present
coauthor
employe
hill
pet
nutrit
inc
bodi
fat
index
chart
use
studi
develop
hill
pet
nutrit
concept
metabol
syndrom
ms
gather
pathophysiolog
chang
deriv
excess
bodi
fat
human
obes
dog
share
compon
ms
hypercholesterolemia
hypertriglyceridemia
insulin
resist
howev
unlik
peopl
dog
seem
resist
obesityrel
diseas
like
atherosclerosi
typeii
diabet
mellitu
elucid
effect
bodi
composit
lipid
metabol
glucos
homeostasi
dog
may
allow
better
understand
ms
aim
studi
investig
healthi
dog
potenti
associ
bodi
condit
score
bc
biochem
paramet
involv
ms
data
dog
retriev
part
european
lupa
project
includ
male
boxer
belgian
shepherd
dog
cavali
king
charl
spaniel
dachshund
doberman
finnish
lapphund
german
shepherd
dog
labrador
retriev
femal
labrador
retriev
newfoundland
age
rang
year
old
dog
weigh
bc
assign
use
scale
exclud
dog
consid
healthi
base
histori
physic
examin
cbc
biochemistri
complet
cardiovascular
workup
circul
concentr
cholesterol
free
fatti
acid
ffa
triglycerid
creactiv
protein
crp
insulin
glucos
fructosamin
cortisol
aldosteron
measur
spearman
correl
bonferronicorrect
pvalu
comput
variabl
overal
group
within
breed
mannwhitney
test
use
compar
dog
categoris
lean
bc
overweight
bc
ancova
use
test
effect
breed
along
bc
take
dog
account
bc
posit
correl
cholesterol
triglycerid
fructosamin
cholesterol
triglycerid
fructosamin
ffa
triglycerid
insulin
crp
glucos
fructosamin
cortisol
glucos
aldosteron
correl
neg
age
posit
triglycerid
cortisol
correl
also
observ
test
within
breed
overweight
group
significantli
higher
cholesterol
ffa
triglycerid
fructosamin
aldosteron
significantli
older
lean
group
effect
bc
persist
cholesterol
insulin
age
despit
correct
differ
breed
metabol
chang
occur
associ
overweight
bodi
condit
otherwis
healthi
dog
although
breed
effect
also
contribut
characteris
interact
bodi
fat
deposit
glucos
lipid
metabol
may
provid
insight
canin
obesityrel
metabol
disturb
disclosur
disclosur
report
aj
german
hec
bamford
sl
holden
v
biourg
univers
liverpool
neston
uk
royal
canin
research
center
aimargu
franc
obes
common
medic
disord
dog
predispos
number
diseas
howev
inform
limit
clinicopatholog
chang
seen
result
obes
subsequ
weight
loss
well
whether
chang
could
predict
outcom
weight
manag
regim
clientown
dog
includ
observ
cohort
studi
dog
underw
control
weight
loss
programm
use
purposeformul
diet
routin
haematolog
serum
biochemistri
urinalysi
perform
weight
loss
associ
clinicopatholog
find
variou
outcom
assess
dog
success
reach
target
weight
base
postweight
loss
assess
dualenergi
xray
absorptiometri
dog
stop
programm
prematur
euthanas
unrel
diseas
dog
reach
target
weight
leucocyt
p
lymphocyt
p
monocyt
p
albumin
p
alp
p
calcium
p
creatinin
p
cholesterol
p
total
protein
p
decreas
weight
loss
regim
wherea
urea
concentr
increas
p
magnitud
chang
cholesterol
kendal
tau
p
albumin
kendal
tau
p
neg
associ
percentag
weight
lost
ie
weight
lost
greater
decreas
final
preweightloss
glucos
concentr
greater
p
whilst
sodium
p
creatinin
p
concentr
less
dog
fail
reach
target
weight
dog
subsequ
success
weight
loss
whilst
mani
clinicopatholog
paramet
chang
result
control
weight
loss
obes
dog
clinic
signific
unknown
work
requir
determin
whether
preweightloss
glucos
concentr
could
use
predict
outcom
weight
programm
disclosur
disclosur
report
diet
use
studi
manufactur
royal
canin
ajg
readership
fund
royal
canin
ajg
also
receiv
financi
remuner
gift
provid
educ
materi
speak
confer
consult
work
slh
post
univers
liverpool
also
fund
royal
canin
employ
compani
vb
employ
royal
canin
excess
bodi
weight
contribut
sever
clinic
sign
dog
osteoarthr
purpos
studi
determin
effect
new
dietet
food
ndf
achiev
weight
loss
improv
mobil
obeseoverweight
clientown
dog
osteoarthr
object
evalu
weight
loss
paramet
assess
clinic
sign
relat
osteoarthr
dog
fed
ndf
thirtyeight
dog
enrol
studi
initi
followup
evalu
monthli
month
includ
determin
bodi
weight
bodi
condit
score
bc
bodi
fat
index
bfi
evalu
osteoarthritisrel
paramet
assess
veterinarian
lame
weight
bear
pain
joint
palpat
owner
difficulti
rise
aggress
reluct
walk
play
inact
beg
behaviour
faecal
score
accept
food
also
evalu
initi
veterinari
consult
consist
physic
examin
nutrit
assess
determin
ideal
bodi
weight
ibw
develop
weightloss
feed
guidelin
der
x
ibw
kg
explan
assess
perform
statist
analysi
compris
scatterplot
regress
analysi
summari
statist
friedman
chisquar
test
mix
model
anova
assess
chang
time
statist
signific
p
eighti
nine
percent
dog
lost
weight
n
averag
weight
loss
sem
month
averag
weekli
weightloss
rate
sem
start
bodi
weight
mean
durat
weight
loss
day
sd
day
averag
day
sd
day
recheck
bc
bfi
dog
lost
weight
significantli
lower
compar
baselin
month
studi
difficulti
rise
reluct
play
improv
significantli
compar
baselin
start
month
studi
wherea
reluct
walk
inact
improv
significantli
compar
baselin
start
month
studi
similarli
lame
weight
bear
pain
palpat
improv
significantli
compar
baselin
start
month
studi
faecal
score
unaffect
beg
significantli
lower
month
compar
baselin
conclus
clinic
studi
confirm
effect
ndf
achiev
weight
loss
improv
clinic
sign
relat
osteoarthr
overweightobes
clientown
dog
owner
veterinarian
report
signific
improv
dog
weight
mobil
without
neg
side
effect
critic
ill
dog
character
mark
variat
energi
requir
aim
studi
evalu
retrospect
effect
earli
oral
voluntari
nutrit
mortal
length
hospit
anorex
dog
sir
medic
record
anorex
dog
admit
criteria
sir
hauptman
ospedal
veterinario
gregorio
vii
ovud
univers
teramo
januari
august
review
sever
anorexia
defin
time
onset
durat
anorexia
prior
present
mild
hour
moder
hour
sever
anorexia
hour
medic
treatment
sir
institut
depend
underli
diseas
mainli
consist
fluidtherapi
support
analgesia
antibiot
antithrombot
therapi
blood
plasma
transfus
requir
antiemet
therapi
maropit
mgkg
q
h
sc
metoclopramid
mgkg
q
h
cri
given
anorex
dog
independ
concurr
presenc
vomit
nutrit
requir
calcul
basal
metabol
rate
bmr
x
bw
kg
recoveri
diet
royal
canin
ad
hill
given
via
oral
voluntari
friendli
eat
partial
parenter
nutrit
x
bmr
given
dog
sever
anorexia
chi
squar
test
util
statist
analysi
categor
data
mann
whitney
test
independ
non
parametr
data
medcal
onehundredthirtyseven
dog
includ
fourteen
mildli
anorex
moder
anorex
sever
anorex
fiftysix
dog
diagnos
acut
gastroenter
septic
periton
pyometra
acut
pancreat
fortysix
dog
start
eat
voluntarili
within
hour
admiss
dog
hour
admiss
dog
never
ate
food
voluntarili
fiftynin
dog
die
dog
never
resum
eat
two
dog
start
eat
hour
admiss
signific
differ
mortal
rate
found
sever
anorex
group
moder
anorex
group
p
signific
differ
found
mortal
rate
length
hospit
among
differ
diseas
process
statist
signific
differ
observ
length
hospit
dog
gain
voluntari
eat
within
hour
ae
day
hour
ae
day
admiss
p
conclus
earli
oral
voluntari
nutrit
anorex
dog
sir
associ
lower
mortal
rate
shorter
length
hospit
disclosur
disclosur
report
lungworm
infect
potenti
lifethreaten
parasit
infect
dog
cat
might
repres
underestim
diseas
urban
suburban
area
aim
studi
report
occurr
lungworm
infect
dog
cat
belong
urban
suburban
area
rome
present
ospedal
veterinario
gregorio
vii
juli
march
twenti
cat
nineteen
dsh
cat
one
siames
cat
mean
age
month
month
includ
twelv
cat
male
cat
stray
cat
main
clinic
sign
cough
dyspnea
three
cast
asymptomat
fourteen
cat
radiolog
examin
character
mild
moder
sever
mix
bronchoalveolarinterstiti
pattern
cat
three
posit
baermann
result
identif
aelurostrongylu
abstrusu
cat
receiv
fenbendazol
mgkg
week
fulli
recov
twentyon
dog
mean
age
month
month
includ
thirteen
dog
intact
male
three
dog
mixedbre
dog
other
belong
differ
breed
dog
histori
risk
exposur
main
durat
clinic
sign
day
day
cough
dog
dyspnea
main
symptom
three
dog
neurolog
sign
eight
dog
mean
hematocrit
concurr
dissemin
intravascular
coagul
dog
one
thorac
radiograph
character
diffus
moder
sever
mix
alveolarbronchialinterstiti
pattern
thirteen
dog
posit
baermann
result
two
test
posit
angiostrongylu
vasorum
idexx
angiodetecttest
one
neg
overal
nine
dog
test
angiostrongylu
v
eight
test
posit
two
dog
neg
fecal
result
diagnos
post
mortem
lung
mix
infect
dissemin
aelurostrongylu
infect
respect
one
dog
diagnos
bal
one
lung
cytolog
five
dog
die
other
recov
therapi
fenbendazol
mgkg
week
depend
clinic
statu
lungworm
infect
might
underestim
diseas
urban
suburban
area
consid
differenti
diagnosi
dog
cat
present
respiratori
diseas
limit
studi
retrospect
view
dog
posit
baermann
lungworm
infect
type
small
number
dog
test
angiostrongylu
v
due
late
introduct
inclin
test
cat
uncertain
proven
routin
screen
disclosur
disclosur
report
age
rang
one
year
median
year
major
dog
n
pure
bred
n
belong
larg
breed
boxer
labrador
n
small
breed
yorkshir
terrier
french
bull
dog
three
larg
mixedbre
dog
also
diagnos
interestingli
male
n
frequent
diagnos
femal
n
common
clinicopatholog
find
ulcer
nodular
cutan
lesion
lymphadenomegali
lame
mild
moder
nonregen
anemia
hypergammaglobulinemia
proteinuria
renal
azotemia
serolog
base
immunofluoresc
quantit
elisa
time
diagnosi
posit
dog
except
one
dog
neg
dog
receiv
full
vaccin
protocol
although
case
vaccin
administ
veterinari
center
clinic
leishmaniosi
diagnos
dog
appar
healthi
time
vaccin
consid
seroneg
base
rapid
serolog
test
interestingli
major
dog
diagnos
clinic
leishmaniosi
prior
first
annual
revaccin
mean
ae
standard
deviat
time
vaccin
appear
clinic
ill
ae
month
rang
month
conclus
studi
describ
first
time
clinicopatholog
data
dog
leishmaniosi
vaccin
moreov
major
dog
diagnos
month
vaccin
highlight
import
use
accur
screen
diagnost
test
prior
vaccin
dog
live
endem
area
disclosur
disclosur
report
studi
aim
determin
frequenc
infecti
agent
found
fcov
whole
blood
cat
fuo
use
realtim
pcr
despit
low
viral
load
spike
gene
fusion
peptid
base
genotyp
achiev
isol
fipv
associ
fusion
peptid
mutat
found
isol
wherea
case
determin
wildtyp
fecv
clinic
followup
genotyp
case
success
fipv
fecv
case
fipv
case
review
show
quick
clinic
detori
despit
empiri
therapi
attempt
euthanasia
case
within
averag
day
day
two
fecv
case
could
follow
one
case
euthan
within
day
high
clinic
suspis
fip
second
case
euthan
month
day
respiratori
distress
polylymphadenopathi
studi
suggest
consid
system
circul
fcov
detect
whole
blood
fuo
cat
earli
indic
progress
fip
disclosur
disclosur
report
author
employe
idexx
laboratori
tickborn
enceph
zoonot
diseas
transmit
tick
caus
agent
tickborn
enceph
viru
tbev
member
genu
flaviviru
sinc
antitbev
canin
vaccin
avail
seroposit
dog
indic
natur
exposur
flaviviru
dog
serv
sentinel
identifi
risk
area
human
natur
flaviviru
foci
seropreval
healthi
dog
shown
fluctuat
depend
area
dog
may
resist
develop
clinic
sign
clinic
case
often
fatal
studi
two
aim
assess
tbevseropreval
dog
show
neurolog
sign
relationship
regard
gender
age
breed
ii
evalu
possibl
concord
tbevseropreval
specif
area
suspect
flaviviru
foci
accord
rki
robertkoch
institut
berlin
germani
classif
risk
counti
analys
blood
sampl
obtain
dog
variou
unspecifi
neurolog
sign
suspect
tbevinfect
major
sampl
came
germani
austria
czech
republ
sweden
switzerland
norway
iggantibodi
tbev
assay
use
commerci
avail
elisa
base
antibodytitr
result
dog
could
classifi
follow
abposit
uml
borderlin
rang
uml
abneg
uml
breed
dog
abposit
dog
follow
decreas
order
golden
retriev
labrador
retriev
yorkshir
terrier
mongrel
bernes
mountain
dog
genderdepend
could
detect
median
age
abposit
dog
year
dog
germani
abposit
came
risk
area
bavaria
badenwuerttemberg
hess
thuringia
saarland
dog
countri
present
follow
abposit
austria
czech
republ
norway
switzerland
present
studi
show
retriev
predomin
breed
respect
tbevseroposit
ii
high
concord
confirm
seroposit
dog
neurolog
sign
tbevrisk
area
germani
defin
classif
rki
data
also
suggest
although
seropreval
could
low
tbe
consid
potenti
use
differenti
diagnosi
dog
neurolog
sign
dog
histori
travel
live
risk
area
case
serolog
diagnosi
confirm
pair
sampl
taken
two
week
apart
disclosur
disclosur
report
author
breu
guthardt
j
employ
laboklin
gmbh
co
kg
germani
mueller
ownermanag
laboklin
gmbh
co
kg
germani
felin
morbilliviru
fmopv
recent
gain
import
sinc
consid
associ
tubuleinterstiti
nephriti
chronic
kidney
diseas
cat
studi
perform
investig
frequenc
histopatholog
phylogeni
felin
morbilliviru
fmopv
cat
istanbul
turkey
cat
clinic
examin
presenc
fmopvrna
determin
n
unhealthi
n
dead
histopatholog
perform
fmopv
phylogenet
analysi
undertaken
fmopv
rna
detect
rtpcr
six
cat
three
unhealthi
three
die
tissu
three
dead
cat
also
posit
immunohistochemistri
antibodi
n
protein
fmopv
phylogenet
analysi
fmopv
posit
cat
show
strain
group
cluster
high
similar
fmopv
strain
japan
germani
three
fmopvrna
posit
cat
sign
respiratori
urinari
digest
system
observ
well
weight
loss
fever
depress
cat
fmopvrna
posit
unhealthi
cat
proteinuria
bilirubinuria
nitrituria
glucosuria
one
cat
bacteriauria
residu
urin
cat
found
histopatholog
fmopvrna
posit
dead
cat
tubulointerstiti
nephriti
characteris
sever
granular
vacuolar
degener
epitheli
cell
cortic
medullari
tubul
well
mononuclear
cell
infiltr
widespread
lymphoid
cell
infiltr
observ
renal
cortex
medullari
region
kidney
cellular
infiltr
cholangiohepat
focal
necrosi
liver
also
found
conclus
first
studi
show
presenc
felin
morbilliviru
infect
cat
turkey
sick
cat
particularli
one
kidney
diseas
test
viru
genotyp
found
studi
similar
previous
report
strain
indic
circul
morbillivirus
turkey
conserv
disclosur
disclosur
report
microbi
popul
felin
nose
assess
use
sequenc
bacteri
rrna
gene
far
aim
studi
describ
nasal
microbiom
healthi
cat
cat
nasal
diseas
furthermor
influenc
signal
environ
investig
bacteri
dna
extract
nasal
swab
healthi
cat
n
cat
nasal
neoplasia
n
cat
felin
upper
respiratori
tract
diseas
furtd
n
use
pyrosequenc
rrna
gene
data
analysi
perform
use
quantit
insight
microbi
ecolog
qiim
total
bacteri
speci
phyla
identifi
group
moraxella
spp
common
speci
follow
pasteurella
spp
cat
furtd
shannon
divers
index
analysi
similar
use
unweight
unifrac
distanc
matrix
significantli
differ
nasal
microbi
commun
healthi
cat
compar
age
p
indooroutdoor
statu
p
studi
demonstr
felin
nose
inhabit
variabl
divers
microbi
commun
suggest
differ
nasal
microbiom
healthi
cat
depend
age
indooroutdoor
statu
disclosur
disclosur
report
aim
studi
provid
insight
parasit
occurr
berlinbrandenburg
area
clinic
sign
laboratori
radiograph
chang
well
treatment
outcom
medic
record
dog
diagnos
vasorum
evalu
retrospect
inclus
criterion
diagnosi
vasorum
infect
base
detect
larva
fecal
sampl
tracheal
wash
fluid
andor
via
antigen
test
idexx
angio
detecttm
serum
dog
consist
differ
breed
crossbre
dog
angiostrongylosi
diagnos
median
age
year
rang
dog
male
femal
twenti
dog
came
berlin
eight
dog
known
travel
histori
never
left
germani
common
sign
admiss
cough
tachypneadyspnea
vomitu
neurolog
sign
hematolog
chang
includ
leukocytosi
eosinophilia
neutrophilia
monocytosi
thrombocytopenia
anemia
biochemistri
abnorm
hyperproteinemia
hypoalbuminemia
azotemia
hypercalcemia
four
dog
prolong
activ
partial
thromboplastin
time
thorac
radiograph
abnorm
detect
dog
twentytwo
dog
treat
moxidectin
dog
receiv
fenbendazol
addit
one
dog
treat
fenbendazol
addit
medic
includ
prednisolon
theophyllin
antimicrobi
therapi
eight
dog
need
hospit
two
dog
die
admiss
anesthesia
due
progress
neurolog
sign
bleed
diathesi
nineteen
dog
recov
lost
followup
median
time
anthelmint
treatment
week
rang
vasorum
infect
emerg
diseas
consid
import
differenti
diagnosi
variou
clinic
sign
berlinbrandenburg
area
disclosur
studi
partial
sponsor
idexx
laborati
ludwigsburg
idexx
laboratori
produc
angio
detect
tm
coauthor
e
huisinga
employe
idexx
laboratori
aim
studi
describ
retrospect
clinic
radiograph
therapeut
featur
cat
itali
diagnos
lungworm
infect
twentysix
cat
infect
lungworm
veterinari
teach
hospit
univers
teramo
underw
physic
examin
laboratori
analysi
thorac
radiographi
fecal
examin
parasit
element
identifi
floatat
baermannwetzel
method
result
confirm
pcr
anim
treat
differ
anthelmint
followedup
everi
week
recoveri
cat
male
femal
median
age
month
live
allow
roam
outdoor
infect
aelurostrongylu
abstrusu
n
troglostrongylu
brevior
n
capillaria
aerophila
n
coinfect
breviora
abstrusu
n
breviorc
aerophila
n
diagnos
cat
harbor
brevior
n
less
four
month
respiratori
sign
record
cough
n
increas
vesicular
sound
n
dyspnoea
n
tachypnoea
n
abdomin
breath
n
oculonas
discharg
n
sneez
n
wheez
n
crackl
n
one
cat
asymptomat
haematobiochem
abnorm
anemia
n
neutrophilia
n
eosinopenia
n
eosinophilia
n
monocytosi
n
radiograph
featur
interstiti
n
bronchial
n
alveolar
n
vascular
n
pattern
twentyf
cat
show
complet
recoveri
within
week
one
kitten
die
day
diagnosi
cat
infect
abstrusu
cours
oral
fenbendazol
n
one
n
two
n
three
n
topic
moxidectin
two
week
apart
recov
within
day
anim
troglostrongylosi
recov
day
singl
administr
moxidectin
n
emodepsid
n
cat
coinfect
breviora
abstrusu
receiv
singl
topic
emodepsid
n
singl
oral
milbemycin
oxim
n
two
n
three
n
administr
moxidectin
five
cat
healthi
day
one
treat
milbemycin
oxim
die
acut
onset
dyspnoea
two
cat
infect
c
aerophila
tbreviorc
aerophila
receiv
singl
administr
eprinomectin
emodepsid
respect
healthi
two
week
lungworm
alway
includ
differenti
diagnos
cat
live
endem
area
present
respiratori
radiograph
sign
copromicroscop
examin
consid
first
step
radiograph
chang
may
evid
onset
clinic
sign
radiograph
examin
mandatori
lungworm
suspect
fact
case
time
therapi
guarante
recoveri
variou
compound
effect
felid
lungworm
disclosur
disclosur
report
purpos
investig
evalu
diagnost
sensit
specif
point
care
later
flow
test
lepto
zoeti
detect
igm
leptospira
use
wellcharacter
canin
sera
archiv
freie
berlin
test
requir
serum
plasma
whole
blood
result
obtain
minut
total
sampl
collect
dog
four
differ
group
test
dog
acut
clinic
leptospirosi
confirm
one
follow
acut
mat
serolog
titer
nonvaccin
serovar
convalesc
mat
serolog
blood
pcr
urin
pcr
convalesc
sera
nine
dog
collect
approxim
two
week
acut
sampl
also
test
ii
dog
clinic
sign
compat
leptospirosi
differ
final
diagnosi
iii
healthi
dog
iv
recent
vaccin
dog
sampl
week
postvaccin
wpv
six
anim
also
test
wpv
wit
test
detect
infect
anim
group
high
diagnost
titer
acut
mat
fals
neg
sampl
wit
test
high
diagnost
acut
mat
titer
seroconvers
group
convalesc
sampl
evid
nine
witnessposit
compar
witnessposit
acut
sampl
group
group
dog
neg
wit
popul
dog
wit
diagnost
sensit
specif
therefor
ci
respect
wit
test
also
detect
vaccinegener
igm
wpv
initi
rapid
increas
posit
test
wpvonli
remain
posit
wpv
dog
return
neg
wit
statu
wpv
conclus
lepto
reliabl
test
diagnosi
acut
leptospirosi
capabl
detect
igm
ealier
mat
neg
result
interpret
leptospirosisneg
howev
suspicion
remain
confirmatori
test
necessari
posit
test
indic
leptospirosi
must
consid
within
context
clinic
present
time
recent
leptospira
vaccin
disclosur
disclosur
report
zoeti
partial
sponsor
studi
joshua
lizer
employe
zoeti
zoeti
produc
wit
lepto
test
aim
studi
detect
quantifi
presenc
blactamas
produc
gramneg
bacteria
resist
third
gener
cephalosporin
intestin
tract
dog
treat
surgic
identifi
possibl
risk
factor
respons
colon
increas
bacteri
quantif
fecal
sampl
collect
veterinari
teach
hospit
vth
faculti
veterinari
medicin
univers
lisbon
januari
juli
two
group
dog
enrol
dog
submit
surgic
procedur
surgeri
group
dog
live
close
contact
hospitalhospit
staff
environment
control
group
bacteria
isol
quantifi
macconkey
plate
contain
cefotaxim
suscept
test
perform
disk
diffus
method
accord
clsi
guidelin
esblpampc
gene
detect
pcr
potenti
risk
factor
esblpampcproduc
bacteria
faecal
carriag
obtain
questionnair
owner
regard
age
gender
cohabit
anim
antimicrobi
treatment
within
last
year
hospitalis
resid
dog
hospit
staff
veterinari
medicin
student
kennel
environment
control
group
also
consid
contact
time
year
frequenc
contact
hospit
data
analys
logist
regress
model
sa
softwar
result
consid
statist
signific
p
fecal
sampl
collect
dog
belong
environment
control
group
dog
surgeri
group
admiss
hospit
surgeri
n
surgeri
n
number
dog
colon
isol
significantli
higher
n
compar
p
p
bacteria
number
significantli
higher
p
group
p
group
compar
p
resid
risk
factor
one
signific
p
increas
number
colon
anim
contact
time
vth
signific
p
risk
factor
increas
bacteri
quantif
group
escherichia
coli
preval
bacteria
blactxm
frequent
blactamas
identifi
group
n
n
n
pampc
gene
detect
group
two
blacmyproduc
ecoli
isol
studi
enhanc
import
nosocomi
colon
infect
control
system
judici
antimicrobi
therapi
order
improv
anim
health
safeguard
public
health
disclosur
indocyanin
green
icg
fluoresc
dye
exclus
elimin
liver
bile
icg
clearanc
determin
use
success
evalu
hepat
function
laboratori
dog
howev
rare
use
clinic
set
analysi
serum
icg
concentr
requir
advanc
laboratori
techniqu
high
perform
liquid
chromatographi
recent
studi
healthi
beagl
dog
reveal
good
correl
icg
clearanc
transcutan
method
determin
icg
plasma
disappear
rate
icgpdr
min
near
infrar
spectroscopi
probe
place
tail
http
human
medicin
main
indic
measur
icgpdr
prognost
assess
liver
failur
liver
transplant
present
studi
evalu
daytoday
variat
icgpdr
healthi
beagl
dog
assess
repeat
test
studi
six
healthi
laboratori
beagl
dog
undergo
icgpdr
test
three
consecut
day
standard
condit
icg
given
intraven
mgkg
icgpdr
determin
use
pulsioflex
monitor
platform
limon
modul
probe
pulsion
munich
germani
daili
icgpdr
valu
dog
compar
coeffici
intrasubject
variat
cv
calcul
mean
icgpdr
ae
min
day
one
ae
min
day
two
ae
min
day
three
signific
differ
day
mean
icgpdr
similar
previous
report
data
ae
min
howev
mean
cv
icgpdr
high
ae
ighest
individu
cv
limit
number
anim
repeat
transcutan
icgpdr
current
form
rather
poor
seem
unlik
test
method
use
repeat
assess
mild
moder
chang
canin
liver
function
howev
futur
studi
warrant
assess
prognost
valu
icgpdr
canin
patient
sever
acut
chronic
end
stage
liver
failur
compar
current
indic
human
medicin
disclosur
ah
diagnos
accur
sv
anatomi
obtain
periop
ct
intraop
portographi
imag
associ
hyperammonemia
leftsid
ihpss
visual
four
anim
two
cat
present
seizur
episod
previou
surgeri
two
dog
cat
previous
undergon
partial
shunt
ligat
posterior
recurr
hyperammonemia
mean
age
time
diagnosi
nine
month
rang
five
twelv
month
french
multipurpos
cathet
insert
mesenter
vein
pv
advanc
shunt
site
guidewir
transperiton
approach
coil
anchor
insert
sv
dog
ak
cat
rb
previou
coil
embol
procedur
pss
attenu
requir
deploy
addit
coil
due
persist
shunt
flow
dog
pushabl
coil
use
occlud
pss
dog
low
probabl
coil
migrat
detach
microcoil
use
occlud
pss
cat
due
adapt
irregular
sv
possibl
retriev
devic
case
instabl
coil
deploy
pv
pressur
measur
determin
preand
postocclus
plausibl
chang
preoper
serum
ammonia
rang
lmoll
lmoll
postop
period
serum
liver
enzym
remain
elev
followup
period
patient
howev
neurolog
gastrointestin
abnorm
gradual
improv
shortterm
postop
period
residu
pss
flow
expect
gradual
ceas
due
blood
clot
around
coil
nevertheless
longterm
followup
recommend
pss
attenu
risk
involv
coil
disloc
shunt
recan
followup
sign
liver
dysfunct
manag
use
low
protein
diet
hepatoprotect
drug
disclosur
disclosur
report
extrem
tachycardia
via
rapid
ventricular
pace
caus
abrupt
reduct
cardiac
output
use
peopl
improv
balloon
stabil
intervent
procedur
purpos
studi
determin
safeti
rapid
pace
dog
optim
pace
rate
requir
procedur
hypothes
rapid
right
ventricular
pace
result
ventricular
arrhythmia
pace
rate
beat
min
necessari
decreas
systol
blood
pressur
percutan
access
jugular
vein
obtain
adult
research
dog
temporari
pace
lead
posit
right
ventricl
fluoroscop
guidanc
pace
protocol
initi
second
rate
beatsmin
pace
rate
increas
increment
beat
drop
systol
blood
pressur
record
dog
allow
recov
minut
pace
protocol
decreas
systol
blood
pressur
achiev
heart
rate
beatsmin
dog
arrhythmia
complic
rapid
pace
note
techniqu
subsequ
appli
success
valvuloplasti
procedur
one
dog
sever
subaort
stenosi
one
dog
sever
pulmon
stenosi
rapid
ventricular
pace
success
reduc
blood
pressur
systol
blood
flow
use
increas
balloon
stabil
valv
dilat
appear
induc
ventricular
arrhythmia
addit
studi
need
evalu
rapid
ventricular
pace
improv
success
balloon
valvuloplasti
dog
disclosur
disclosur
report
effect
benazepril
serum
angiotensinconvert
enzym
ace
activ
evalu
healthi
beagl
dog
aim
studi
compar
effect
twice
day
versu
day
administr
benazepril
evalu
effect
pimobendan
ace
inhibit
benazepril
total
dog
randomis
four
group
n
femal
male
per
group
prospect
parallelgroup
design
studi
four
group
control
placebo
twice
daili
b
mgkg
benazepril
daili
morn
c
mgkg
benazepril
twice
daili
mgkg
benazepril
mgkg
pimobendan
twice
daili
test
item
administ
oral
day
serum
ace
activ
measur
use
commerci
radioenzymat
assay
blood
sampl
taken
baselin
time
postdos
day
day
steadi
state
group
b
c
associ
signific
reduct
serum
ace
activ
compar
baselin
day
test
overal
treatment
effect
postdos
group
b
c
associ
significantli
lower
ace
activ
compar
control
group
p
differ
group
b
c
noninferior
shown
group
c
versu
b
versu
b
versu
c
conclus
mgkg
benazepril
twice
daili
produc
equival
inhibit
serum
ace
activ
compar
mgkg
benazepril
daili
furthermor
addit
mgkg
pimobendan
twice
daili
signific
effect
inhibit
serum
ace
activ
produc
mgkg
benazepril
twice
daili
result
support
use
benazepril
either
twice
daili
dog
combin
benazepril
pimobendan
disclosur
disclosur
report
studi
sponsor
time
studi
author
employ
elanco
anim
health
market
benazepril
benazeprilpimobendan
combin
tricuspid
annular
systol
plane
excurs
taps
propos
measur
right
ventricular
rv
systol
function
decreas
refer
interv
dog
sever
pulmonari
hypertens
howev
taps
linear
measur
tricuspid
annular
movement
scale
nonlinearli
bodyweight
dog
examin
whether
taps
could
normal
linear
aortic
measur
creat
bodyweightindepend
measur
rv
systol
function
echocardiograph
evalu
perform
healthi
dog
dog
includ
previou
studi
taps
dog
heart
diseas
pulmonari
hypertens
tricuspid
regurgit
veloc
ms
dog
pulmonari
hypertens
variou
etiolog
sever
tricuspid
regurgit
veloc
ms
taps
ao
regress
bodyweight
dog
pulmonari
hypertens
tricuspid
veloc
taps
scale
nonlinearli
bodyweight
previous
report
taps
ao
larg
remov
effect
bodyweight
nonparametr
determin
lower
refer
limit
healthi
dog
taps
ao
dog
heart
diseas
pulmonari
hypertens
show
slight
neg
associ
taps
ao
bodyweight
dog
taps
ao
dog
pulmonari
hypertens
taps
ao
neg
associ
tricuspid
veloc
howev
dog
taps
ao
dog
tr
veloc
ms
taps
ao
specif
sensit
identifi
dog
sever
pulmonari
hypertens
taps
ao
bodyweight
independ
measur
rv
systol
function
dog
normal
dog
taps
ao
howev
appear
sensit
indic
pulmonari
hypertens
disclosur
disclosur
report
aim
studi
assess
effect
electr
cardiovers
chosen
red
blood
cell
paramet
studi
carri
larg
giant
breed
dog
weigh
kg
lone
atrial
fibril
lone
af
electr
cardiovers
carri
gener
anaesthesia
infus
propofol
fentanyl
premed
use
medetomidin
midazolam
cardiovers
carri
biphas
j
cardiovers
use
lifepak
medtron
defibril
blood
collect
atrial
fibril
prior
cardiovers
found
electr
cardiovers
dog
lead
statist
signific
clinic
red
blood
cell
lysi
conflict
interest
author
list
project
cofinanc
nation
scientif
leadership
centr
wroclaw
biotechnolog
centr
disclosur
disclosur
report
heart
rate
variabl
hrv
known
risk
factor
mortal
healthi
dog
heart
failur
healthi
human
refer
normal
valu
shortterm
measur
hrv
sthrv
publish
appendix
paper
heart
rate
variabl
standard
measur
physiolog
interpret
clinic
use
circul
healthi
dog
refer
valu
sthrv
publish
pol
j
vet
sci
aim
studi
compar
normal
valu
shortterm
hrv
healthi
dog
h
n
dog
sick
sinu
syndrom
sss
n
ecg
record
continu
least
min
dark
clam
room
qr
complex
ecg
first
edit
automat
manual
care
inspect
rr
interv
data
atrial
ventricular
prematur
complex
signal
transform
spectrum
fast
fourier
transform
heart
rate
variabl
paramet
measur
fix
time
number
sampl
min
separ
frequenc
hz
compon
hrv
obtain
includ
low
frequenc
vlf
low
frequenc
lf
high
frequenc
hf
total
power
tp
lf
hf
ratio
research
new
biomark
detect
myocardi
injuri
crucial
medicin
although
whole
blood
serum
cholin
suggest
emerg
biomark
patient
myocardi
ischemia
avail
data
use
predict
cardiac
event
dog
cat
thu
studi
aim
evalu
use
serum
cholin
concentr
potenti
biomark
myocardi
ischemia
determin
whether
correl
cardiac
troponin
ctni
serum
cholin
dog
cat
heart
diseas
dog
congest
heart
failur
n
cat
either
hypertroph
cardiomyopathi
n
dilat
cardiomyopathi
n
use
cardiac
group
heart
diseas
diagnos
base
clinic
radiolog
electrocardiograph
ecg
echocardiograph
find
myocardi
injuri
determin
elev
serum
ctni
level
dog
ngml
cat
ngml
healthi
ageand
breedmatch
dog
n
cat
n
use
control
dog
cat
select
studi
seroneg
common
vectorborn
pathogen
felin
infecti
diseas
respect
serum
freecholin
concentr
sampl
analyz
high
perform
liquid
chromatographi
triplic
result
express
micromolar
lm
ecg
reveal
strain
pattern
left
ventricular
lv
hypertrophi
dilat
statist
signific
differ
found
echocardiograph
measur
lv
size
eg
lvdd
lvd
function
ef
fs
control
affect
dog
cat
serum
ctni
concentr
dog
cat
median
rang
ngml
ng
ml
control
group
ngml
ngml
cardiac
group
significantli
differ
p
group
respect
serum
cholin
concentr
dog
lm
control
group
lm
cardiac
group
serum
cholin
concentr
cat
lm
control
group
lm
cardiac
group
serum
cholin
concentr
cardiac
group
higher
p
healthi
control
posit
correl
serum
level
cholin
ctni
serum
cholin
level
correl
significantli
geometr
function
paramet
lv
serum
marker
hepatoren
diseas
alt
bun
cr
data
suggest
serum
cholin
concentr
might
use
biomark
diagnosi
myocardi
ischemia
dog
cat
variou
heart
diseas
therebi
may
contribut
differenti
ischem
nonischem
etiolog
ctni
elev
disclosur
disclosur
report
assess
right
ventricular
rv
systol
function
remain
challeng
complex
morpholog
tricuspid
annular
plane
excurs
fraction
area
chang
tissu
doppler
imag
speckletrack
echocardiographi
use
assess
rv
systol
function
healthi
dog
dog
pulmonari
arteri
hypertens
pah
hypothes
rv
outflow
tract
rvot
function
might
provid
simpl
use
estim
rv
function
pah
specif
measur
rvot
fraction
shorten
rvotf
determin
index
help
identifi
rv
dysfunct
dog
pah
tricuspid
regurgit
velocitytrv
msec
one
hundr
fifteen
dog
healthi
dog
dog
mitral
valv
diseas
mvd
without
pah
dog
pah
underw
complet
echocardiograph
evalu
acquir
guid
mmode
record
rv
outflow
tract
parastern
short
axi
view
level
aortic
root
place
mmode
line
perpendicular
rvot
parallel
commissur
aortic
valv
noncoronari
leftcoronari
cup
rvotf
calcul
rvot
dimens
enddiastoleendsystol
enddiastol
mean
measur
dog
use
statist
analysi
healthi
dog
mvd
dog
without
pah
higher
rvotf
dog
pah
p
dog
rvotf
pah
dog
trv
msec
rvotf
cutoff
specif
sensit
identifi
pah
relationship
bodi
weight
leftatrialtoaort
ratio
heart
rate
rvotf
could
identifi
p
data
suggest
rvotf
might
help
identifi
subset
dog
pah
rvotf
significantli
modifi
dog
sever
moder
pah
suggest
rv
systol
dysfunct
class
pah
disclosur
disclosur
report
assess
left
atrial
la
size
crucial
cat
cardiomyopathi
la
dilat
result
increas
diastol
fill
pressur
predispos
toward
develop
congest
heart
failur
arteri
thromboembol
addit
la
dilat
shown
neg
prognost
factor
cat
affect
hypertroph
cardiomyopathi
aim
studi
evalu
agreement
mmode
twodimension
echocardiographi
assess
la
size
cat
studi
retrospect
observ
cat
without
heart
diseas
includ
la
aorta
ao
measur
mmode
use
standard
right
parastern
short
axi
view
aortic
valv
level
left
atrium
aorta
ratio
laao
consid
indic
la
enlarg
cohen
kappa
agreement
calcul
blandaltman
plot
obtain
total
clientown
cat
includ
heart
diseas
without
heart
diseas
la
ao
dimens
mmode
ae
mm
ae
mm
respect
ae
mm
ae
mm
respect
blandaltman
plot
show
mean
differ
evalu
ao
dimens
mmode
ae
mm
la
ae
mm
laao
measur
mmode
ae
ae
respect
median
differ
two
method
ae
cohen
kappa
yield
good
agreement
two
method
interpret
laao
ratio
kappa
ci
agreement
conclus
echocardiographi
result
slightli
higher
estim
la
ao
diamet
comparison
mmode
laao
good
agreement
document
mmode
evalu
laao
two
method
use
interchang
measur
echocardiograph
index
cat
disclosur
disclosur
report
restrict
cardiomyopathi
rcm
approxim
account
refer
felin
cm
primari
myocardi
disord
character
diastol
dysfunct
poor
prognosi
larg
studi
focus
rcm
cat
scant
aim
retrospect
studi
describ
epidemiolog
characterist
analyz
prognost
factor
affect
surviv
cat
rcm
clinic
archiv
clinica
veterinaria
gran
sasso
itali
cardiolog
unit
dimevet
univers
milan
itali
review
cat
diagnos
rcm
base
echocardiograph
exam
diagnosi
base
distinct
echocardiograph
phenotyp
left
atrialbiatri
enlarg
normal
left
ventricular
lv
wall
thick
restrict
lv
fill
pattern
puls
doppler
echocardiographi
inclus
criteria
patient
complet
case
record
echocardiograph
diagnosi
rcm
cat
diagnos
anoth
form
cardiomyopathi
cm
congenit
heart
diseas
hypertens
hyperthyroid
incomplet
case
record
exclud
followup
statu
caus
death
determin
review
medic
record
phone
interview
owner
one
hundr
three
cat
male
femal
includ
studi
mean
age
year
sd
median
weight
kg
iqr
kg
cat
domest
shorthair
persian
almost
cat
show
clinic
sign
dyspnea
common
clinic
sign
evid
cat
dyspnea
attribut
pleural
effus
pe
cat
pulmonari
edema
cat
cat
hind
limb
paresi
paralysi
due
aortic
thromboembol
evid
cat
followup
inform
avail
cat
median
surviv
time
mst
cat
rcm
day
statist
signific
differ
p
mst
identifi
cat
dyspnea
day
cat
without
dyspnea
day
likewis
statist
signific
p
differ
mst
identifi
cat
pe
day
cat
without
pe
day
mst
cat
dyspneap
studi
significantli
shorter
mst
cat
without
dyspneap
present
result
confirm
cat
rcm
short
surviv
time
mst
day
wors
prognosi
prospect
owner
cat
dyspnea
pe
better
prognosi
may
prospect
cat
without
dyspnea
disclosur
disclosur
report
decreas
level
coenzym
coq
plasma
myocardium
found
cardiovascular
diseas
human
patient
moreov
low
level
coq
found
independ
predictor
mortal
chronic
heart
failur
human
patient
aim
studi
investig
surviv
refer
popul
canin
cardiovascular
patient
regard
therapi
yesno
plasma
coq
concentr
first
visit
seventytwo
clientown
dog
includ
present
studi
healthi
control
dog
refer
cardiovascular
patient
variou
diseas
classifi
isachc
class
intern
small
anim
cardiac
health
council
isachc
cardiovascular
diseas
confirm
basi
histori
clinic
examin
thorac
radiograph
electrocardiogram
echocardiographi
effect
therapi
surviv
studi
advanc
stage
class
ii
iii
plasma
coq
determin
use
hplcatmospher
pressur
chemic
ionizationtandem
mass
spectrometri
method
cardiac
biomark
ntprobnp
elisa
test
analys
screen
diseas
sever
kaplanmei
analysi
use
estim
surviv
sinc
group
receiv
cardiac
therapi
significantli
higher
coq
concentr
patient
without
therapi
variabl
taken
account
use
cox
proport
hazard
regress
model
result
kaplanmei
analysi
show
significantli
longer
surviv
group
alreadi
receiv
therapi
p
analys
cox
model
hazard
ratio
patient
therapi
ci
p
indic
also
better
surviv
compar
group
without
therapi
model
coq
signific
effect
p
conclus
import
start
cardiac
therapi
soon
possibl
earli
therapi
signific
effect
surviv
result
coq
warrant
studi
conclud
effect
surviv
canin
cardiovascular
patient
disclosur
disclosur
report
report
cytokin
contribut
pathogenesi
congest
heart
failur
chf
human
canin
cardiovascular
patient
human
studi
reveal
increas
circul
level
tumour
necrosi
factoralpha
tnfalpha
heart
failur
patient
addit
increas
creactiv
protein
crp
concentr
found
human
dog
congest
heart
failur
aim
studi
investig
whether
level
circul
cytokin
tnfalpha
crp
elev
dog
variou
heart
diseas
heart
failur
addit
effect
therapi
measur
paramet
evalu
advanc
stage
diseas
intern
small
anim
cardiac
health
council
isachc
ii
iii
cardiac
biomark
ntprobnp
analys
screen
diseas
sever
fiftyeight
clientown
dog
enrol
studi
dog
confirm
cardiovascular
diseas
healthi
dog
cardiovascular
patient
classifi
isachc
class
cardiovascular
diseas
confirm
basi
histori
clinic
examin
thorac
radiograph
electrocardiogram
echocardiographi
patient
diseas
exclud
studi
serum
concentr
inflammatori
marker
determin
elisa
kit
plasma
ntprobnp
secondgener
probnp
level
analys
idexx
laboratori
kruskalw
analysi
follow
mannwhitney
u
test
bonferroni
adjust
p
use
comparison
measur
paramet
among
group
patient
healthi
dog
effect
therapi
test
mannwhitney
u
test
tnfalpha
concentr
differ
significantli
among
isachc
group
control
group
isachc
group
highest
tnfalpha
concentr
found
isachc
iii
median
pgml
versu
pgml
isachc
ii
crp
concentr
significantli
higher
isachc
iii
mgl
isachc
ii
mgl
control
group
mgl
howev
signific
differ
crp
concentr
found
among
isachc
group
result
show
signific
differ
measur
paramet
patient
withouth
therapi
posit
signific
correl
found
ntprobnp
isachc
ii
correl
tnfalpha
crp
signific
neither
group
patient
increas
crp
concentr
advanc
stage
heart
failur
signific
posit
correl
ntprobnp
indic
system
inflamm
dog
chf
therapi
effect
measur
inflammatori
marker
futher
studi
larger
group
canin
cardiovascular
patient
might
confirm
cytokin
respons
progress
heart
failur
disclosur
disclosur
report
contemporari
data
detail
cardiac
chamber
patholog
felin
cardiomyopathi
aim
character
measur
contrast
gross
morpholog
involv
atrial
ventricular
chamber
felin
hcm
dcm
fiftytwo
felin
heart
section
rightparasternallongaxi
echocardiograph
plane
lv
inflowoutflow
ifof
n
fourchamb
n
use
stereomicroscopi
heart
examin
chamber
morpholog
infarct
photograph
digit
measur
multipl
level
la
ra
lv
rv
wall
age
bodi
weight
mean
rang
hcm
yr
yr
versu
dcm
yr
yr
hcm
kg
kg
versu
dcm
kg
kg
ns
p
respect
lv
shortaxi
intern
dimens
hcm
ae
mm
ifof
ae
mm
dcm
ae
mm
ifof
ae
mm
iv
thick
compar
chordalvspapillaryvsannular
level
hcmifof
chordal
ae
mm
papillari
ae
mm
annular
ae
mm
p
relationship
held
view
iv
dcmifof
thick
greater
papillari
median
mm
versu
annular
median
mm
p
relationship
lvw
chordal
level
hcm
ae
mm
ifof
versu
ae
mm
dcm
ae
mm
ifof
versu
ae
mm
rv
hcmbase
ae
mm
versu
midrv
wall
ae
mm
p
rvapex
mm
ae
mm
p
dcmat
base
median
mm
versu
midrv
median
mm
versu
rvapex
median
mm
p
wall
thick
rang
la
mm
ra
mm
ns
per
respect
measur
locat
p
transmur
lv
myocardi
infarct
occur
hcm
apicallv
n
midlvw
n
dcm
apicallv
n
midlvw
n
mm
long
data
provid
context
echocardiograph
examin
assist
patholog
assess
necropsyassess
necropsi
disclosur
english
bull
terrier
ebt
may
well
high
preval
murmur
presum
predispos
mitral
valv
dysplasia
mitral
valv
stenosi
left
ventricular
outflow
tract
obstruct
lvoto
cardiac
disord
could
lead
congest
heart
failur
syncop
sudden
death
aforement
disord
congenit
might
hereditari
rel
preval
heart
diseas
dutch
belgian
ebt
breed
popul
report
mani
ebt
present
kliniek
voor
gezelschapsdieren
eersel
kvgd
echocardiographi
prior
breed
aim
studi
report
echocardiograph
find
dutch
belgian
breed
popul
ebt
case
record
ebt
underw
echocardiograph
screen
prior
breed
kvgd
januari
april
review
retrospect
n
ebt
underw
routin
physic
examin
subsequ
mmode
doppler
transthorac
echocardiographi
continu
ecg
monitor
perform
anim
dog
consid
asymptomat
owner
dog
entir
male
entir
femal
age
vari
month
averag
month
weight
rang
kg
averag
kg
murmur
detect
anim
maximum
intens
averag
left
ventricular
diamet
diastol
systol
cm
cm
respect
compar
publish
breed
specif
refer
rang
well
refer
rang
gener
dog
popul
index
bodi
weight
measur
within
limit
averag
aortic
diamet
measur
cm
compar
dog
breed
weight
valu
lower
normal
refer
rang
maxim
aortic
veloc
vmaxao
measur
dog
ms
subcost
measur
averag
ms
dog
vmaxao
ms
popul
appar
healthi
ebt
increas
vmaxao
smaller
aortic
diamet
found
physiolog
mitral
regurgit
jet
quit
common
mitral
valv
dysplasia
mitral
valv
stenosi
seen
prospect
observ
studi
need
determin
specif
ebt
refer
rang
true
preval
natur
histori
hered
heart
diseas
ebt
breed
disclosur
disclosur
report
sudden
death
sd
commonli
occur
dog
breed
high
predisposit
vpd
like
doberman
pinscher
boxer
irish
wolfhound
iw
high
preval
dilat
cardiomyopathi
dcm
atrial
fibril
af
recent
perform
longitudin
studi
iw
dcm
iw
initi
lone
af
reveal
sd
occur
dog
object
studi
compar
ecg
find
iw
cardiomyopathi
cm
without
iw
n
f
examin
physic
examin
echocardiographi
electrocardiographi
av
dog
longitudin
follow
owner
instruct
report
date
circumst
death
dcm
diagnos
dog
f
associ
sinu
rhythm
f
af
f
af
abnorm
f
addit
diagnos
dog
valvular
diseas
vpd
one
occas
record
iw
dcm
normal
dog
doubl
triplet
bigeminu
run
found
normal
iw
dcm
multifoc
vpd
seen
dog
dcm
svpd
singl
detect
dog
dcm
normal
iw
sv
tachycardia
present
iw
without
dog
dcm
develop
af
later
rbbb
diagnos
iw
without
dcm
iw
one
without
dcm
lbbb
lafb
common
iw
without
dcm
versu
dcm
abnorm
qr
complex
like
notch
splinter
form
common
group
dog
dcm
normal
iw
studi
sd
occur
femal
iw
dcm
af
one
shown
vpd
earlier
male
iw
die
sd
vpd
record
multifoc
vpd
run
singl
conclus
af
common
ecg
abnorm
iw
sd
occur
signific
proport
dog
dcm
af
male
iw
vpd
record
sd
occur
disclosur
disclosur
report
pulmonaryveintopulmonaryarteri
ratio
pv
pa
propos
method
identifi
variou
stage
cardiovascular
diseas
includ
congest
heart
failur
chf
pulmonari
hypertens
ph
howev
studi
exist
examin
diagnost
util
pv
pa
pv
pa
measur
diagnosi
chf
ph
mmode
echocardiograph
evalu
perform
dog
mitral
valv
diseas
mmvd
ph
tricuspid
regurgit
veloc
ms
right
ostium
pv
pa
measur
maxim
minim
diamet
mechan
time
peak
qr
end
twave
ecg
time
left
atrium
aorta
measur
onset
diastol
dog
classifi
subclin
chf
c
variou
indic
pv
pa
calcul
indic
examin
subset
dog
similar
la
ao
differ
clinic
classif
n
versu
c
n
determin
clinic
util
pv
pa
identifi
chf
pv
pa
indic
also
examin
dog
n
without
n
ph
determin
clinic
util
identifi
ph
ecgtim
pv
pa
obtain
peak
qr
differ
subclin
chf
dog
similar
la
ao
pv
paqr
optim
cutoff
sensit
specif
detect
chf
pa
ao
measur
smallest
diamet
qr
approxim
sensit
specif
identifi
moder
ph
tr
veloc
ms
pa
distens
index
perform
better
identifi
moder
ph
pv
pa
echocardiograph
indic
might
use
discrimin
subclin
chf
dog
similar
degre
cardiac
enlarg
identifi
dog
moderatesever
ph
disclosur
disclosur
report
btype
natriuret
peptid
bnp
endogen
cardioprotect
natriuret
vasodilatori
diuret
peptid
mediat
action
cyclic
gmp
cgmp
bnp
produc
myocardiocyt
respons
stress
overwhelm
neurohormon
system
heart
failur
human
acut
congest
heart
failur
exogen
intraven
bnp
help
allevi
sign
dyspnea
addit
bnp
longerterm
antiremodel
properti
develop
method
chronic
administ
bnp
human
dog
heart
diseas
subject
interest
administr
exogen
bnp
previous
report
privatelyown
dog
sought
determin
feasibl
safeti
toler
subcutan
synthet
canin
btype
natriuret
peptid
syncbnp
phoenix
pharmaceut
burlingam
ca
perform
modifi
intrapati
dose
escal
studi
dog
includ
healthi
dog
dog
stage
myxomat
mitral
valv
diseas
mmvd
stage
involv
administ
subtherapeut
dose
mcgkg
syncbnp
dog
follow
second
therapeut
dose
mcgkg
hour
later
stage
administ
baselin
dose
mcgkg
follow
maximum
dose
mcgkg
hour
later
addit
dog
syncbnp
inject
welltoler
dog
concentr
statist
signific
differ
blood
pressur
heart
rate
rhythm
serum
creatnin
bun
syncbnp
administr
median
plasma
cgmp
concentr
significantli
higher
minut
mcgkg
dose
compar
baselin
baselin
pmolml
min
min
p
signific
differ
serum
aldosteron
plasma
renin
activ
urin
specif
graviti
urinari
fraction
excret
sodium
urinari
cgmp
concentr
singl
subcutan
inject
syncbnp
mcgkg
caus
advers
reaction
associ
increas
bnp
secondari
messeng
cgmp
studi
investig
clinic
util
acut
chronic
syncbnp
dog
naturallyoccur
heart
diseas
warrant
disclosur
disclosur
report
torasemid
loop
diuret
potent
greater
persist
furosemid
torasemid
potenti
use
treatment
dog
cat
congest
heart
failur
chf
licens
use
dog
uk
aim
studi
describ
use
oral
torasemid
cat
natur
occur
chf
report
toler
advers
effect
two
hospit
databas
search
cat
cardiac
diseas
receiv
torasemid
march
clientown
cat
suitabl
record
subsequ
retrospect
evalu
collect
data
includ
signal
present
sign
diagnosi
concurr
medic
maximum
dose
furosemid
transit
torasemid
start
torasemid
dose
maximum
torasemid
dose
reach
chf
therapi
surviv
time
commenc
torasemid
comparison
renal
paramet
electrolyt
priorto
commenc
torasemid
advers
reaction
record
boardcertifi
cardiologist
retrospect
review
case
owner
sign
consent
form
permit
use
offlicens
drug
cat
includ
chf
acquir
cardiomyopathi
congenit
cardiac
diseas
confirm
echocardiographi
initi
treat
furosemid
oral
therapi
intraven
therapi
variou
concurr
therapi
includ
ace
inhibitor
spironolacton
antithrombot
pimobendan
diltiazem
atenolol
carbimazol
famotidin
mirtazapin
initi
torasemid
cat
either
poorli
respons
oral
furosemid
n
manag
deem
appropri
torasemid
n
median
dose
furosemid
hr
rang
hr
prior
commenc
torasemid
median
initi
dose
torasemid
hr
mgkg
hr
administ
divid
twice
daili
dose
first
recheck
trend
toward
increas
creatinin
urea
decreas
potassium
azotaemia
observ
mark
patient
receiv
higher
dose
torasemid
chronic
therapi
torasemid
reduc
cat
due
increas
azotaemia
time
write
cat
still
aliv
mortal
due
euthanasia
refractori
chf
n
progress
azotemia
start
torasemid
n
cat
lost
follow
median
surviv
time
median
final
torasemid
dose
hr
hr
oral
torasemid
toler
popul
cat
chf
main
advers
clinic
effect
worsen
azotaemia
prospect
studi
need
evalu
use
torasemid
cat
disclosur
disclosur
report
savares
probo
c
locatelli
g
traini
pg
brambilla
paltrinieri
univers
milan
milano
itali
peopl
anemia
serum
iron
si
defici
sid
frequent
comorbid
chronic
heart
failur
chf
recent
studi
show
sid
alon
reduc
qualiti
life
surviv
mitral
valv
diseas
mvd
common
acquir
heart
diseas
dog
lead
chf
best
knowledg
studi
examin
iron
statu
mvd
dog
aim
determin
preval
characterist
sid
si
dog
mvd
analyz
differ
si
among
acvim
class
symptomat
asymptomat
patient
studi
associ
sid
surviv
fifti
privat
own
mvd
dog
admit
cardiolog
servic
dimevet
januari
complet
physic
evalu
chest
xray
echocardiograph
examin
serum
biochem
panel
includ
patient
heart
system
diseas
exclud
blood
sampl
collect
routin
clinic
evalu
complet
cbc
routin
biochemistri
perform
use
autom
laser
hematolog
analyz
autom
spectrophotomet
excess
serum
frozen
analysi
iron
statu
evalu
measur
si
total
ironbind
capac
tibc
percentag
transferrin
satur
sat
calcul
median
age
dog
year
iqr
median
bodi
weight
kg
iqr
intact
male
repres
breed
mongrel
twenti
dog
acvim
class
c
nonsymptomat
symptomat
dog
respect
n
n
preval
sid
mvd
dog
symptomat
nonsymptomat
patient
present
anemia
hct
tibc
within
refer
rang
nv
lgdl
dog
sid
except
one
reduc
tibc
sat
minimum
level
nv
dog
differ
si
found
acvim
class
symptomaticnonsymptomat
patient
logrank
analysi
show
shorter
surviv
mvd
dog
sid
p
valu
nevertheless
multivari
cox
analysi
show
symptom
presenc
affect
surviv
result
show
sid
although
appear
influenc
surviv
common
symptomat
dog
occasion
present
without
anemia
dog
mvd
tibc
sat
valu
suggest
sid
frequent
true
primari
sid
function
secondari
inflammatori
condit
disclosur
disclosur
report
postcapillari
pulmonari
hypertens
common
dog
degen
mitral
valv
diseas
dmvd
preval
increas
sever
dmvd
presenc
predictor
wors
outcom
left
atrial
la
function
size
prognost
indic
dmvd
dog
la
contractil
function
shown
decreas
sever
dmvd
human
chronic
mitral
regurgit
la
function
import
correl
right
ventricular
systol
pressur
aim
studi
assess
la
dysfunct
associ
ph
dog
dmvd
dog
dmvd
measur
tricuspid
regurgit
tr
retrospect
recruit
maxim
la
diamet
la
diamet
onset
p
wave
minim
la
diamet
measur
anatom
mmode
cineloop
aortic
short
axi
view
left
atrial
reservoir
la
expans
index
total
la
shorten
fraction
conduit
passiv
la
shorten
fraction
contractil
function
activ
la
shorten
fraction
indic
deriv
measur
nineti
three
dog
includ
acvim
stage
c
includ
dog
assign
pulmonari
hypertens
group
ph
tr
pressur
gradient
mmhg
n
median
mmhg
rang
pulmonari
normotens
group
pn
n
mmhg
la
reservoir
contractil
function
indic
reduc
acvim
stage
c
compar
asymptomat
stage
p
tr
pressur
gradient
higher
symptomat
dog
p
compar
asymptomat
dog
tr
gradient
posit
correl
la
size
measur
differ
time
interv
p
neg
correl
la
reservoir
p
contractil
p
variabl
la
reservoir
variabl
p
activ
la
shorten
fraction
p
lower
ph
group
compar
pn
ancova
use
test
categor
effect
acvim
stage
along
effect
la
function
indic
tr
pressur
gradient
acvim
stage
strong
effect
tr
gradient
p
la
function
paramet
persist
correct
acvim
stage
studi
confirm
dog
dmvd
ph
strongli
associ
stage
heart
failur
fail
show
independ
relationship
la
dysfunct
develop
ph
reason
may
lack
accuraci
one
dimension
variabl
assess
la
phasic
function
absenc
causal
link
la
dysfunct
develop
pulmonari
hypertens
dmvd
dog
disclosur
disclosur
report
mineralis
heart
great
vessel
report
incident
radiograph
find
dog
preval
report
thorac
radiographi
thorac
comput
tomographi
ct
imag
use
frequent
dog
recent
year
ct
preval
mineralis
unreport
may
higher
increas
sensit
ct
compar
radiographi
aim
studi
therefor
describ
preval
locat
cardiac
great
vessel
mineralis
dog
evalu
associ
age
sex
concurr
diseas
thorac
ct
studi
dog
carri
veterinari
teach
hospit
review
poor
qualiti
ct
exclud
result
dog
avail
inclus
singl
train
oper
systemat
review
ct
studi
panel
three
boardcertifi
cardiologist
one
boardcertifi
diagnost
imag
review
abnorm
case
group
sex
malefemal
age
year
year
year
concurr
diseas
process
neoplasia
cardiorespiratori
neurolog
intern
medicin
surgic
soft
tissu
orthopaed
miscellan
mineralis
heart
andor
great
vessel
document
dog
frequent
localis
aortic
bulb
seen
dog
follow
localis
area
ascend
aorta
dog
mineralis
cranial
vena
cava
intracardiac
mineralis
present
dog
dog
younger
year
less
mineralis
older
dog
p
statist
differ
observ
dog
year
dog
year
old
associ
mineralis
sex
concurr
diseas
type
detect
conclus
mineralis
heart
andor
great
vessel
present
dog
thorac
ct
aortic
bulb
frequent
site
observ
account
mineralis
dog
year
old
like
demonstr
mineralis
younger
dog
associ
diseas
state
suggest
incident
find
despit
remark
higher
preval
detect
ct
plain
radiographi
disclosur
disclosur
report
author
conflict
interest
disclosur
declar
regard
studi
cardioren
syndrom
new
entiti
veterinari
medicin
drawn
attent
import
constant
interplay
two
system
kidney
heart
failur
two
main
mechan
present
activ
renninangiotensinaldosteron
axi
increas
sympathet
tone
sympathet
overdr
hard
ass
clinic
condit
cardiac
autonom
modul
parasympathet
sympathet
compon
easili
evalu
real
time
use
heart
rate
variabl
techniqu
hvr
knowledg
research
made
regard
evalu
hrv
dog
chronic
kidney
diseas
ckd
purpos
studi
ass
sympathet
activ
dog
chronic
kidney
diseas
use
heart
rate
variabl
analysi
hrv
short
time
ecg
monitor
minut
includ
dog
variou
age
breed
chronic
kidney
diseas
ckd
group
diagnos
accord
iri
classif
evalu
time
domain
frequenc
domain
paramet
estim
overal
hrv
sdnn
vagal
tone
activ
hf
sympathet
tone
lf
lfhf
use
kubio
hrv
softwar
compar
result
includ
hrv
data
healthi
dog
heart
kidney
diseas
present
match
age
weight
gender
result
show
signific
decreas
overal
hrv
sdnn
p
ckd
group
associ
signific
decreas
vagal
tone
hf
p
p
moreov
sympathet
tone
increas
p
p
ckd
group
compar
healthi
group
studi
show
dog
ckd
increas
sympathet
tone
associ
low
vagal
activ
autonom
imbal
known
predict
bad
outcom
dog
heart
diseas
human
hrv
analysi
use
marker
evolut
treatment
outcom
patient
kidney
failur
studi
need
includ
autonom
imbal
tool
monitor
clinic
evolut
dog
ckd
disclosur
disclosur
report
left
atrial
size
clinic
import
paramet
reflect
sever
chronic
cardiac
disord
myxomat
valv
degener
common
cardiac
diseas
dog
first
opinion
veterinari
practic
lack
easi
standard
method
assess
left
atrial
size
reliabl
though
twodimension
echocardiographi
would
excel
modal
purpos
perform
cardiac
ultrasonographi
requir
advanc
train
quit
experi
furthermor
ultrasonographi
less
wide
avail
radiographi
though
vertebr
heart
scale
vh
simpl
quantit
method
assess
cardiac
size
thorac
radiograph
vh
say
noth
specif
size
left
atrium
describ
new
standard
method
estim
left
atrial
size
later
thorac
radiograph
dog
principl
method
draw
straight
line
dorsal
border
tracheal
bifurc
point
ventral
border
caudal
vena
cava
cross
cranial
cru
diaphragm
anatom
landmark
easi
recogn
similar
use
determin
vh
hypothes
cardiac
silhouett
exce
line
dorsal
left
atrium
enlarg
normal
ten
veterinari
student
appli
linemethod
radiograph
select
clinic
archiv
period
year
inclus
criterion
echocardiogram
perform
cardiologist
day
radiograph
made
serv
golden
standard
student
use
ordin
scale
score
left
atrial
size
receiv
oper
characterist
curv
show
discrimin
abil
mean
moder
accuraci
test
mark
posit
student
absolut
sure
left
atrial
enlarg
linemethod
sensit
specif
correl
linemethod
echocardiograph
left
atrial
aortic
ratio
mean
moder
posit
correl
multipl
logist
regress
analysi
show
new
linemethod
valuabl
test
radiologist
unavail
expect
simpl
standard
method
would
help
practic
veterinarian
decid
whether
left
atrium
radiograph
enlarg
normal
result
absenc
radiologist
opinion
use
linemethod
could
facilit
rapid
differenti
cardiogen
pulmonari
edema
primari
respiratori
disord
dog
tachypnea
dyspnea
disclosur
disclosur
report
debat
valu
quantif
method
studi
report
compar
valu
goal
studi
compar
method
quantifi
regv
regurgit
fraction
rf
asymptomat
anatolian
shepherd
dog
ash
dmvd
sever
heart
diseas
classifi
use
chief
system
base
radiograph
heart
echocardiograph
left
atrium
la
size
control
group
consist
healthi
ash
ash
dmvd
sever
mr
assess
arjlaa
subtract
method
sever
mitral
regurgit
determin
arjlaa
significantli
p
higher
group
group
regv
dog
ae
ml
statist
p
differ
dog
ae
ml
rf
dog
ae
statist
p
differ
dog
ae
arjlaa
posit
correl
left
atrial
aortic
root
ratio
laao
ntermin
probnp
ntprobnp
regv
rf
regv
posit
correl
laao
ntprobnp
rf
rf
posit
correl
laao
ntprobnp
regv
observ
agreement
assay
arjlaa
versu
regv
arjlaa
versu
rf
kappa
statist
valu
arjlaa
versu
regv
arjlaa
versu
rf
substanti
agreement
moder
agreement
respect
hand
arjlaa
easi
obtain
oppos
subtract
method
result
indic
quantif
method
valuabl
assess
sever
diseas
ash
mr
good
accord
echocardiograph
heart
size
ntprobnp
level
therefor
noninvas
method
may
use
serial
assess
sever
mr
dmvd
order
monitor
progress
diseas
futur
studi
evalu
use
predict
risk
time
decompens
asymptomat
dog
disclosur
disclosur
report
diet
alon
suffici
necessari
supplement
diet
ckd
cat
specif
substanc
phosphat
binder
alkalin
agent
aim
retrospect
studi
evalu
effect
feed
supplement
contain
mix
substanc
bind
phosphat
correct
metabol
acidosi
cat
ckd
iri
intern
renal
interest
societi
stage
cat
median
bw
kg
bc
year
fed
balanc
renal
diet
involv
retrospect
analysi
treatment
consist
oral
administr
product
renal
candioli
pharma
contain
calcium
carbon
calcium
lactat
glucon
sodium
bicarbon
chitosan
given
day
anim
evalu
begin
studi
day
bw
bc
food
intak
blood
pressur
routin
hematochem
biochem
urinari
paramet
statist
analys
perform
use
sa
softwar
check
normal
data
analyz
use
kruskalw
wilcoxon
test
result
express
median
interquartil
rang
letter
show
differ
among
row
p
statist
signific
reduct
serum
phosphoru
concentr
obtain
studi
reduct
versu
also
statist
signific
increas
bicarbon
seen
also
record
increas
ioniz
calcium
level
howev
normal
rang
also
detect
statist
signific
differ
albuminglobulin
ratio
day
day
even
mani
studi
phosphat
binder
conduct
healthi
anim
import
evalu
efficaci
also
cat
ckd
fact
addit
phosphoru
binder
may
reduc
food
intak
azotem
cat
effect
seen
present
studi
feed
supplement
effect
reduc
blood
phosphat
level
increas
blood
bicarbon
level
thu
improv
cat
clinic
condit
durat
studi
disclosur
candioli
farmaceutici
fund
sponsor
write
manuscript
feed
produc
candioli
renal
human
urin
osmol
uosm
better
specif
graviti
usg
assess
renal
function
usg
uosm
correl
well
concentr
urin
nonperfus
healthi
cat
cat
suspect
earli
chronic
kidney
diseas
ckd
receiv
intraven
iv
infus
decreas
usg
difficult
intepret
reflect
either
tubular
injuri
urin
dilut
follow
infusioninduc
diuresi
date
consequ
iv
infus
usg
uosm
relationship
remain
unknown
evalu
individu
variat
relationship
usg
uosm
healthi
cat
receiv
iv
infus
hour
nonfast
healthi
cat
year
belong
student
veterinari
teach
hospit
receiv
iv
infus
mlkgh
lactat
ringer
rl
nacl
sampl
cystocentesi
baselin
target
number
sampl
baselin
urin
dipstick
sediment
normal
three
student
blind
measur
other
evalu
usg
measur
correspond
uosm
measur
random
order
interand
intraobserv
variabl
assess
pearson
coeffici
pc
relationship
studi
variat
median
uosm
usg
compar
baselin
wilcoxonmannwhitney
test
effect
solut
infus
assess
institut
ethic
committe
approv
protocol
sixteen
cat
includ
among
femal
male
median
age
month
median
weight
kg
half
receiv
rl
remaind
nacl
sampl
treat
complic
occur
minor
variat
usg
measur
support
excel
analyt
precis
optic
refractometri
median
usg
uosm
correl
well
sampl
pc
median
usg
significantli
decreas
baselin
wherea
median
uosm
significantli
decreas
baselin
p
paramet
vari
similarli
regardless
solut
infus
usg
uosm
correl
strongli
regardless
either
urin
dilut
type
infus
solut
probabl
use
isoton
solut
close
osmol
clinician
keep
use
usg
reliabl
surrog
renal
function
uosm
usg
significantli
decreas
hour
iv
infus
respect
remain
unknown
whether
observ
healthi
cat
relev
practic
cat
suspect
earli
ckd
clinician
would
hour
begin
iv
infus
sampl
urin
evalu
usg
reliabl
disclosur
disclosur
report
human
urin
osmol
uosm
better
urin
specif
graviti
usg
assess
hydrat
statu
renal
function
veterinari
medicin
uosm
use
routin
clinic
equip
osmomet
studi
provid
formula
estim
serum
osmol
cat
use
concentr
major
cation
sodium
chlorid
unchang
molecul
urea
glucos
public
propos
estim
uosm
aim
deriv
formula
estim
urinari
osmol
healthi
cat
receiv
intraven
iv
infus
period
nonfast
healthi
cat
year
belong
student
veterinari
teach
hospit
normal
clinic
find
sampl
cystocentesi
baselin
begin
iv
infus
mlkgh
isoton
solut
baselin
urin
dipstick
sediment
analysi
normal
chronic
kidney
diseas
exclud
accord
iri
guidelin
three
student
blind
measur
other
evalu
uosm
random
order
separ
occas
use
freez
point
depress
osmomet
roeblingosmomet
giessen
germani
urin
sampl
submit
measur
urea
creatinin
sodium
chlorid
potassium
glucos
concentr
use
autom
analyz
konelab
thermo
scientif
cergi
pontois
franc
visual
inspect
quantilequantil
plot
confirm
normal
distribut
relationship
urinari
metabolit
effect
uosm
studi
linear
regress
subsequ
evalu
pearson
correl
coeffici
pc
institut
ethic
committe
approv
protocol
five
cat
femal
male
median
age
month
median
weight
kg
sampl
five
time
hour
sampl
treat
complic
occur
median
minimummaximum
uosm
mosmkg
statist
analys
use
reliabl
paramet
includ
median
urea
mmoll
sodium
mmoll
potassium
mmoll
glucos
mmoll
result
follow
formula
pc
popul
healthi
cat
uosm
best
estim
use
formula
describ
uosm
accur
usg
formula
use
clinic
practic
help
veterinarian
inde
practition
nt
need
sophist
osmomet
standard
biochemistri
analyz
adequ
handl
dilut
urin
evalu
uosm
deriv
formula
need
valid
futur
research
disclosur
disclosur
report
risk
function
impair
kidney
ckd
aki
common
problem
cancer
due
infiltr
nephrotox
chemotherapeut
human
lymphoma
patient
known
compromis
kidney
function
affect
patient
diagnos
creatinin
remain
requir
biopsi
diagnost
accuraci
studi
human
patient
varieti
solid
tumor
demonstr
preval
reduc
gfr
advanc
ckd
stage
given
increas
incid
cancer
new
therapi
develop
frenet
pace
lead
increas
need
identifi
kidney
diseas
earli
highlight
demand
effect
sensit
biomark
time
detail
inform
nonexist
veterinari
patient
howev
reason
think
differ
methyl
arginin
signal
process
asymmetr
methyl
activ
transcript
express
symmetr
methyl
repress
signal
import
understand
increas
protein
turnov
malign
lead
increas
product
dimethylarginin
human
studi
includ
differ
type
cancer
adma
sdma
shown
significantli
increas
cancer
cohort
compar
control
observ
increas
sdma
like
due
impair
kidney
cancer
relat
increas
product
sdma
increas
adma
like
due
increas
protein
turnov
result
transcript
activ
look
caus
behind
increas
sdma
veterinari
patient
cancer
investig
sdma
canin
felin
patient
use
bank
sampl
correl
histopatholog
studi
look
total
patient
dog
cat
varieti
malign
includ
lymphoma
hemangiosarcoma
osteosarcoma
lymphosarcoma
pancreat
carcinoma
prostat
tcc
mammari
tumor
colon
adenocarcinoma
hepatocellular
carcinoma
sdma
concentr
rang
ugdl
patient
refer
limit
ugdl
necropsi
perform
patient
along
histopatholog
seven
patient
increas
sdma
histopatholog
find
indic
kidney
diseas
neoplast
infiltr
renal
find
report
patient
normal
sdma
retrospect
evalu
cat
dog
increas
sdma
elev
creatinin
conclud
patient
neoplasia
increas
sdma
correl
histopatholog
find
support
compromis
kidney
disclosur
disclosur
report
murthi
yerramilli
mahalakshmi
yerramilli
giosi
farac
jane
robertson
roberta
relford
employe
idexx
laboratori
inc
denni
jewel
employe
hill
pet
nutrit
inc
despit
progress
earli
diagnosi
recognit
acut
renal
failur
attribut
leptospirosi
remain
challeng
condit
intens
care
costli
procedur
includ
renal
replac
therapi
frequent
recquir
retrospect
studi
focus
dog
present
intermitt
haemodialysi
treatment
diagnosi
acut
renal
failur
secondari
confirm
leptospirosi
conduct
epidemiolog
clinic
paraclin
data
diagnosi
record
surviv
discharg
long
term
outcom
record
total
dog
includ
studi
year
period
mean
weight
kg
differ
breed
dyspnoea
present
diagnosi
case
wherea
dog
present
neurolog
sign
seizur
coma
mean
erum
urea
creatinin
valu
markedli
elevalt
diagnosi
gl
mgl
respect
dog
initi
oligur
anur
diagnosi
leptospirosi
reli
mat
dog
identifi
pr
edomin
reaction
australi
serogroup
dog
dog
diagnosi
leptosirosi
infect
reli
pcr
examin
blood
urin
five
dog
die
euthanazi
shortli
first
dialysi
treatment
four
dog
present
acut
hemoptysi
one
dog
present
persist
anuria
hyperkaliemia
twenti
remain
dog
surviv
discharg
howev
three
dog
present
chronic
renal
failur
follow
initi
acut
crisi
polypnea
diagnosi
anuria
neurolog
sign
neg
impact
surviv
wherea
urea
creatinin
valu
disclosur
disclosur
report
aim
prospect
studi
compar
three
method
urin
sampl
ejacul
regard
bacteri
growth
studi
perform
norwegian
univers
life
scienc
novemb
march
twenti
healthi
intact
dog
age
year
femal
male
includ
studi
three
urin
sampl
collect
within
hour
order
dog
void
ii
void
clean
extern
genit
clean
void
iii
cystocentesi
urin
sampl
analys
urin
dipstick
microscopi
sediment
bacteri
cultur
clean
prepuc
ejacul
also
collect
male
dog
cultur
nine
dog
bacteri
growth
sampl
seven
femal
two
male
bacteri
growth
found
void
sampl
three
femal
four
male
clean
void
one
one
femal
three
male
bacteria
cultur
cystocentesi
sampl
ejacul
bacteri
growth
three
femal
bacteri
growth
void
urin
one
remain
posit
clean
four
male
bacteria
void
sampl
one
growth
clean
void
sampl
growth
ejacul
two
dog
posit
cultur
clean
void
sampl
ejacul
fourth
dog
bacteria
grown
either
clean
void
urin
ejacul
three
male
dog
neg
cultur
three
urin
sampl
grew
bacteria
ejacul
one
dog
neg
bacteri
cultur
void
urin
posit
cultur
clean
void
urin
ejacul
two
male
dog
neg
cultur
sampl
bacteria
grown
differ
sampl
mycoplasma
cani
pasteurella
spp
pasteurella
multocida
enterococcu
faecium
mix
flora
studi
show
larg
proport
neg
cultur
void
urin
sampl
clinic
relev
sinc
neg
cultur
use
regardless
sampl
method
consist
pattern
relationship
cultur
result
differ
sampl
method
ejacul
unexpectedli
ejacul
show
larg
proport
posit
cultur
result
could
suggest
prostat
origin
bacteria
caus
bacteriuria
void
sampl
healthi
intact
dog
disclosur
disclosur
report
canin
felin
serum
sampl
use
evalu
accuraci
precis
two
commerci
avail
sdma
assay
idexx
sdmatm
test
veterinari
valid
clsi
guidelin
nonveterinari
valid
research
use
human
sdmaelisa
test
test
conduct
per
manufactur
standard
procedur
sampl
sourc
felin
canin
serum
submit
idexx
refer
laboratori
gener
chemistri
test
accuraci
assess
assay
thirtyseven
felin
twentynin
canin
serum
sampl
duplic
sdma
assay
compar
mean
result
gold
standard
lcm
sdma
result
nineteen
canin
twenti
felin
sampl
test
within
lcm
refer
rang
canin
felin
sampl
also
test
normal
idexx
sdmatm
test
two
felin
discrep
sampl
cutoff
sampl
averag
ugdl
higher
lcm
sdma
valu
twelv
normal
canin
felin
normal
sampl
return
elev
result
sdmaelisa
canin
discrep
sampl
averag
ugdl
higher
lcm
valu
rang
ugdl
felin
discrep
sampl
averag
ugdl
higher
lcm
valu
rang
ugdl
precis
determin
assay
replic
felin
canin
normal
serum
pool
use
sdma
assay
idexx
sdmatm
test
canin
felin
pool
sd
sdmaelisa
sd
respect
idexx
sdmatm
test
show
superior
accuraci
precis
human
sdmaelisa
posit
bia
poor
precis
sdmaelisa
test
sever
limit
clinic
util
diagnos
stage
ckd
dog
cat
disclosur
disclosur
report
potenti
indirect
disclosur
report
author
work
idexx
run
laboratori
servic
perform
assay
discuss
abstract
upper
lower
urinari
tract
disord
small
anim
commonli
seen
countri
kidney
becom
dysfunct
clinic
sign
appar
present
patient
studi
enzymuria
microalbuminuria
evalu
eighti
dog
lower
urinari
tract
symptom
pollakiuria
dysuriastranguria
hematuria
urinari
incontin
polyuria
polydipsia
excess
lick
urogenit
area
refer
istanbul
univers
veterinari
teach
research
hospit
intern
medicin
clinic
blood
urin
sampl
collect
asept
dog
specif
paramet
detect
studi
urin
microalbumin
concentr
heska
erdhealthscreen
canin
urin
test
urin
protein
creatinin
ratio
upc
urin
cultur
enzym
urin
nacetylbetadglucosaminidas
nag
alkalin
phosphates
alp
gamma
glutamyl
transferas
ggt
lactat
dehydrogenas
ldh
alanin
aminopeptidas
aap
blood
pressur
measur
high
definit
oscillometr
devic
memodiagnost
statist
analysi
gener
linear
model
base
gender
age
nutrit
microalbuminuria
urinari
tract
disord
dog
comparison
urin
dipstick
urin
proteincreatinin
ratio
microalbuminuria
test
result
agre
microalbuminuria
test
trustabl
practic
method
small
anim
practic
also
determin
microalbuminuria
level
could
affect
mani
factor
like
age
nutrit
except
microalbuminuria
enzym
especi
nag
aap
markedli
elev
dog
lower
urinari
tract
disord
thu
approv
paramet
control
studi
easili
use
sdma
biomark
aki
human
medicin
aim
studi
investig
sdma
dog
aki
assess
sdma
discrimin
aki
ckd
blood
sampl
store
previou
studi
investig
renal
biomark
dog
aki
ckd
analyz
sdma
period
year
sdma
measur
dog
renal
azotemia
aki
ckd
healthi
control
dog
sdmacreatinin
ratio
calcul
median
rang
plasma
creatinin
concentr
healthi
dog
dog
aki
dog
ckd
mgdl
mg
dl
mgdl
mgdl
mgdl
mg
dl
respect
median
plasma
sdma
concentr
dl
respect
median
sdmacreatinin
ratio
dog
aki
ckd
respect
plasma
sdma
concentr
significantli
higher
dog
aki
p
ckd
p
comparison
healthi
dog
sdma
concentr
dog
aki
ckd
similar
p
although
consider
overlap
sdmacreatinin
ratio
dog
aki
ckd
significantli
higher
dog
ckd
compar
dog
aki
p
sdma
suitabl
identifi
dog
affect
aki
ckd
research
necessari
investig
use
sdmacreatinin
ratio
aki
disclosur
yerramilli
e
obar
employe
idexx
laboratori
measur
sdma
concentr
perform
idexx
laboratori
free
charg
microalbuminuria
term
use
describ
urin
albumin
level
detect
dipstick
test
ie
lower
mgl
similarli
urinari
protein
measur
spot
urin
albumin
concentr
usual
normal
urinari
creatinin
valu
upper
normal
valu
spot
urinari
albumin
concentr
determin
dog
thu
laboratori
often
use
human
refer
valu
mg
urinari
albuminmg
urinari
creatinin
author
also
quot
human
refer
valu
mgl
urinari
albumin
concentr
upper
normal
level
albuminuria
healthi
dog
whether
valu
obtain
without
normal
urin
concentr
specif
graviti
alway
clear
descript
method
sighthound
claim
higher
arteri
blood
pressur
higher
urinari
albumin
concentr
dog
breed
aim
studi
determin
urinari
albumin
concentr
albumincreatinin
ratio
spot
urin
sampl
healthi
dog
includ
sighthound
client
own
nonlact
nonpregn
dog
underw
complet
physic
exam
abdomin
ultrasound
blood
work
urinalysi
includ
sediment
analysi
total
protein
determin
urin
obtain
cystocentesi
microalbumin
measur
commerci
human
immunoturbidimetr
method
formerli
valid
use
speci
blood
pressur
greyhound
measur
tail
high
definit
oscillometr
method
exclus
criteria
histori
current
diseas
hypertens
proteinuria
urinari
protcrea
ratio
elev
creatinin
level
abnorm
find
physic
ultrasound
exam
elev
wbc
tp
crp
level
suggest
inflammatori
diseas
origin
sixti
five
dog
recruit
laboratori
data
becom
avail
dog
exclud
proteinuria
thu
studi
eventu
includ
dog
sight
hound
nonsighthound
statist
differ
age
bodyweight
degre
proteinuria
microalbuminuria
two
group
median
microabuminuria
mgl
rang
mgl
median
urinari
albumincreatinin
ratio
urin
albumin
concentr
without
normal
specif
graviti
creatinin
level
suitabl
identifi
dog
albuminuria
human
refer
valu
urinari
albumin
creatinin
ratio
seem
also
appropri
use
dog
one
clinic
healthi
dog
valu
studi
disclosur
disclosur
report
urinari
lesion
urinari
bladder
repres
tumour
polyp
eosinophil
cystiti
chronic
urinari
bladder
inflamm
resembl
urinari
bladder
growth
definit
diagnosi
cytolog
histopatholog
examin
requir
fine
needl
aspir
associ
metastat
tract
along
needl
path
brush
traumat
catheter
use
variabl
result
cystoscopi
surgeri
effect
techniqu
collect
sampl
urinari
bladder
lesion
procedur
expens
cystoscopi
size
limit
male
dog
compar
femal
dog
aim
work
evalu
effect
transurethr
ultrasound
guid
biopsi
urinari
bladder
lesion
male
dog
author
hypothes
passag
atraumat
flexibl
endoscop
biopsi
forcep
mm
diamet
urethra
male
dog
would
allow
collect
suitabl
size
sampl
cytolog
histopatholog
diagnosi
six
male
dog
differ
size
diagnos
urinari
bladder
lesion
enrol
studi
one
dog
kg
labrador
retriev
one
dog
kg
welsh
terrier
four
dog
cross
breed
dog
weigh
kg
kg
kg
kg
respect
mean
age
year
year
five
dog
exhibit
recurr
haematuria
mean
durat
week
one
dog
histori
urinari
incontin
week
durat
dog
underw
gener
anaesthesia
local
urethra
anaesthesia
endoscop
biopsi
forcep
pass
urethra
biopsi
perform
ultrasound
guidanc
minimum
number
six
biopsi
taken
sampl
submit
cytolog
histopatholog
evalu
five
dog
full
agreement
cytolog
histopatholog
evalu
diagnosi
transit
cell
carcinoma
tcc
one
dog
procedur
repeat
discord
cytolog
histopatholog
diagnosi
first
sampl
cytolog
consist
tcc
histopatholog
eosinophil
cystiti
second
sampl
histopatholog
consist
tcc
two
dog
follow
month
period
extens
tcc
along
urethra
detect
subsequ
control
transurethr
ultrasound
guid
biopsi
urinari
bladder
lesion
male
dog
repres
effect
minim
invas
nonexpens
procedur
diagnosi
urinari
bladder
lesion
male
dog
allow
avoid
size
limit
evalu
larger
number
case
recommend
disclosur
disclosur
report
proteinuria
cat
associ
diagnosi
prognosi
monitor
sever
condit
includ
chronic
kidney
diseas
urin
dipstick
test
udt
common
method
use
assess
proteinuria
practic
urin
proteintocreatinin
ratio
upcr
help
confirm
quantifi
purpos
studi
assess
udt
togeth
urin
specif
graviti
usg
possibl
predictor
upcr
cat
author
knowledg
previous
describ
dog
studi
cat
record
januari
march
mix
first
opinion
referr
hospit
retrospect
review
sixtyeight
normal
color
urin
sampl
obtain
cystocentesi
includ
undergon
complet
urinalysi
includ
udt
result
inact
sediment
statist
analys
perform
use
statist
packag
sa
upcr
use
indic
absenc
proteinuria
accord
iri
classif
scheme
sampl
group
usg
analyz
compar
versu
trace
neg
result
agreement
two
method
measur
cohen
j
good
trace
consid
dipstickneg
sampl
usg
j
coeffici
p
data
analyz
consid
dipstickneg
regardless
usg
sensit
p
specif
p
sensit
p
obtain
consid
neg
result
sampl
usg
specif
group
p
studi
show
poor
correl
two
assess
diagnost
method
result
match
previous
describ
high
sensit
poor
specif
diagnosi
proteinuria
udt
cat
higher
sensit
achiev
consid
dipstickneg
result
sampl
usg
although
greater
popul
would
need
perform
repres
assess
result
show
poor
agreement
two
test
cat
compar
previou
studi
perform
dog
despit
conclud
cat
result
udt
sampl
usg
high
sensit
rule
proteinuria
classifi
upcr
disclosur
disclosur
report
repeat
urinalysi
quantif
proteinuria
central
import
manag
canin
kidney
diseas
although
natur
void
nt
affect
urin
proteintocreatinin
ratio
upc
sediment
inact
cystocentesi
recommend
decreas
contamin
genitourinari
tract
reliabl
interpret
upc
prospect
studi
aim
investig
influenc
differ
collect
techniqu
presenc
inflammatori
sediment
upc
dog
present
nation
veterinari
school
toulous
need
urinalysi
includ
urin
collect
dog
within
hour
freecatch
fc
freecatch
perin
clean
fcc
cystocentesi
cy
order
urin
sediment
examin
within
hour
collect
upc
determin
within
hr
store
supernat
effect
collect
techniqu
presenc
inflammatori
sediment
andor
wbc
andor
epitheli
cellshpf
upc
assess
binari
logist
regress
anova
respect
pvalu
consid
signific
twentyseven
dog
includ
median
delay
fc
cy
minut
inflammatori
sediment
found
sampl
collect
fc
fcc
cy
respect
presenc
activ
sediment
significantli
associ
method
collect
p
urin
collect
fc
rather
cy
increas
probabl
observ
inflammatori
sediment
oddsratio
upc
affect
method
collect
p
fc
might
use
reliabl
followup
proteinuria
dog
regardless
presenc
inflamm
disclosur
disclosur
report
veterinari
practic
inclin
measur
total
thyroxin
tt
commonli
done
diagnosi
monitor
although
accuraci
analyz
tt
quantif
question
recent
idexx
laboratori
introduc
novel
immunoassay
method
measur
tt
catalyst
one
chemistri
analyz
pointofcar
instrument
previous
valid
chemistri
test
purpos
studi
valid
method
tt
measur
sampl
cat
wide
rang
valu
compar
result
obtain
inclin
method
obtain
veterinari
refer
laboratori
vrl
idexx
vrl
use
autom
enzym
immunoassay
method
tt
dri
microgen
corpor
previous
valid
use
cat
blood
sampl
tt
determin
obtain
cat
examin
anim
endocrin
clinic
aec
cat
hyperthyroid
high
tt
evalu
treatment
normal
low
tt
serum
sampl
first
analyz
inhous
use
catalyst
tt
slide
analyz
aliquot
sampl
submit
vrl
day
lab
blind
result
median
serum
tt
concentr
report
vrl
nmoll
interquartil
rang
iqr
total
rang
nmoll
median
tt
nmoll
iqr
rang
nmoll
statist
differ
exist
tt
valu
obtain
method
p
mannwhitney
u
test
catalyst
total
assay
also
show
excel
correl
refer
method
r
p
mean
differ
blandaltman
plot
nmoll
limitsofagr
loa
plot
show
fix
proport
bia
increas
variat
higher
end
dynam
rang
region
clinic
decis
loa
plot
normal
differ
show
loa
approxim
ae
tt
method
cat
serum
tt
concentr
also
classifi
low
nmoll
high
nmoll
withinreferenceinterv
nmoll
establish
aec
use
clinicallynorm
cat
year
strong
agreement
sampl
base
classif
result
group
conclus
result
show
catalyst
tt
assay
provid
accur
reliabl
serum
tt
concentr
wide
clinic
use
rang
cat
provid
inclin
result
equival
obtain
veterinari
refer
laboratori
disclosur
disclosur
report
primari
second
author
noth
disclos
form
direct
financi
support
given
first
author
clinic
work
done
research
studi
support
studi
reagent
inclin
test
suppli
charg
idexx
laboratori
manufactur
test
kit
third
author
employe
idexx
laboratori
inc
compani
make
inclin
test
test
evalu
studi
none
data
analysi
perform
individu
howev
result
modifi
way
compani
benefit
arrang
made
prior
initi
studi
acth
stimul
test
acthst
commonli
use
screen
dog
spontan
hyperadrenocortic
hac
studi
aim
evalu
contribut
baselin
cortisol
interpret
acthst
studi
includ
sampl
dog
submit
referr
laboratori
evalu
hac
acthst
complet
questionnair
refer
veterinarian
rdvm
interpret
result
rdvm
report
whether
test
result
consid
confirmatori
hac
baselin
poststimul
cortisol
interpret
final
decis
whether
dog
hac
rdvm
consid
baselin
b
poststimul
p
cortisol
interpret
either
differ
pb
ratio
pb
receiv
oper
characterist
roc
analys
use
assess
predict
accuraci
baselin
cortisol
alon
poststimul
cortisol
alon
pb
pb
area
roc
curv
auc
baselin
cortisol
pb
pb
poststimul
cortisol
respect
outcom
confirmatori
result
respect
outcom
final
diagnosi
hac
poststimul
cortisol
auc
significantli
higher
auc
exclud
pb
auc
predict
confirmatori
result
hac
conclus
poststimul
cortisol
demonstr
good
discriminatori
abil
interpret
acthst
final
diagnosi
made
rdvm
either
superior
compar
pb
baselin
cortisol
p
b
ineffect
baselin
cortisol
addit
valu
interpret
acthst
result
diagnos
hac
rdvm
disclosur
disclosur
report
felin
hyperthyroid
emerg
metabol
diseas
middleag
older
cat
seem
shown
mark
increas
worldwid
incid
within
last
three
decad
well
mark
geograph
variat
preval
exact
pathogenesi
diseas
still
remain
obscur
despit
plethora
epidemiolog
studi
clear
risk
factor
identifi
purpos
studi
determin
preval
felin
hyperthyroid
south
africa
identifi
potenti
risk
factor
associ
diseas
geograph
locat
serum
total
thyroxin
ctsh
free
thyroxin
measur
cat
age
year
older
present
variou
veterinari
clinic
south
africa
time
blood
sampl
questionnair
complet
regard
vaccin
histori
intern
extern
parasit
control
diet
environ
univari
associ
potenti
risk
factor
assess
use
twotail
fisher
exact
test
multipl
logist
regress
model
use
estim
effect
risk
hyperthyroid
associ
present
clinic
sign
hyperthyroid
assess
univari
level
use
twotail
fisher
exact
test
preval
hyperthyroid
nmoll
nmoll
tsh
ngml
pmol
l
within
popul
ci
signific
differ
preval
healthi
sick
cat
cat
year
age
ci
p
cat
can
food
diet
ci
p
like
diagnos
hyperthyroid
statist
signific
relationship
vaccin
parasit
control
indoor
environ
hyperthyroid
observ
hyperthyroid
cat
like
present
weight
loss
ci
p
heart
rate
bpm
ci
p
cat
without
diseas
preval
felin
hyperthyroid
south
africa
appear
similar
previous
document
cat
japan
portug
less
document
cat
unit
kindgdom
germani
risk
factor
hyperthyroid
previous
found
epidemiolog
studi
specif
older
age
presenc
can
food
diet
also
appear
present
studi
popul
disclosur
disclosur
report
felin
hyperthyroid
current
treat
antithyroid
drug
surgeri
andor
radiotherapi
recent
iodinedefici
diet
hill
prescript
diet
yd
yd
emerg
altern
treatment
limit
data
avail
therapeut
effect
larg
cohort
sixtysix
cat
retrospect
includ
base
diagnosi
hyperthyroid
clinic
sign
free
thyroxinemia
pmoll
receiv
iodinedefici
diet
firstlin
treatment
exclus
food
aim
assess
clinic
biolog
effici
diet
fortyseven
femal
spay
male
neuter
mainli
domest
short
hair
rang
year
median
year
retrospect
includ
studi
main
clinic
sign
diagnosi
weight
loss
polyuropolydipsia
polyphagia
tachycardia
digest
sign
palpabl
thyroid
nodul
main
biolog
sign
high
median
pmoll
rang
uremia
mmoll
cat
creatininemia
lmoll
alt
ul
cat
receiv
dri
yd
can
form
major
cat
accept
eat
yd
accept
spontan
first
place
first
control
median
time
day
clinic
effici
consid
praction
satisfactori
cat
partial
poor
bodi
weight
significantli
chang
yd
kg
iodinedefici
diet
hill
yd
associ
satisfactori
clinic
improv
cat
signific
decreas
two
month
begin
treatment
longterm
followup
studi
current
conduc
assess
yd
palat
clinic
biolog
chang
particularli
creatininemia
alt
activ
surviv
cohort
disclosur
disclosur
report
aim
studi
identifi
frequenc
bacteri
uti
dog
dm
orand
hac
character
caus
microorgan
antimicrobi
suscept
relationship
control
endocrin
disord
medic
record
dog
present
intern
medicin
servic
veterinari
teach
hospit
complutens
madrid
januari
decemb
diagnos
dm
hac
review
case
urin
cultur
perform
includ
n
dog
classifi
consid
type
control
endocrin
diseas
dog
uti
treat
appropri
antibiot
base
cultur
sensit
anim
follow
respons
treatment
evalu
urin
cultur
dog
classifi
follow
dog
diagnos
dm
dog
hac
dog
diseas
uti
observ
dog
uti
present
dog
dog
uti
dog
uti
signific
relationship
uti
control
endocrin
diseas
escherichia
coli
common
organ
isol
consid
antimicrobi
agent
aa
test
urinari
cultur
marbofloxacin
ciprofloxacin
aa
highest
vitro
suscept
respect
follow
trimethoprimesulfamethoxazol
nitrofurantoin
amoxicillinclavulan
acid
enrofloxacin
effect
antimicrobi
present
elev
percentag
bacteri
resist
aa
highest
percentag
resist
nalidix
acid
firstgener
cephalosporin
follow
possibl
dog
three
persist
uti
bacteria
isol
second
urin
cultur
resist
aa
previous
use
appropri
treatment
persist
uti
new
cultur
perform
nt
grow
microorgan
frequenc
uti
dog
dm
andor
hac
lower
expect
howev
bacteria
isol
tend
resist
aa
commonli
use
fluoroquinolon
suscept
antibiot
howev
enrofloxacin
commonli
prescrib
higher
percentag
resist
suggest
uti
dog
endocrin
disord
difficult
elimin
tradit
antimicrobi
treatment
fluoroquinolon
might
use
case
disclosur
disclosur
report
commonli
use
drug
reduc
cholesterolemia
human
statin
reduc
cholesterol
biosynthesi
modifi
lipid
metabol
antiatherosclerot
effect
treatment
hyperlipidemia
dog
base
control
underli
diseas
dietari
manag
effect
statin
reduc
cholesterolemia
dog
report
aim
studi
know
efficaci
simvastatin
dog
hypercholesterolemia
respond
dietari
manag
evalu
toxic
effect
qualiti
life
consid
underli
disord
diabet
mellitu
hyperadrenocortic
hypothyroid
ten
dog
hyperlipidemia
prospect
includ
studi
consent
dog
kidney
diseas
iri
iii
iv
andor
cardiac
diseas
c
andor
sever
hepat
pancreat
diseas
exclud
manag
one
month
low
fat
diet
treatment
underli
disord
diabet
mellitu
hyperadrenocortic
hypothyroid
combin
treatment
simvastatin
start
mgkgday
sid
vo
dog
cholesterol
mgdl
followup
perform
one
three
six
month
simvastatin
administr
age
dog
rang
year
old
differ
breed
treatment
n
plasma
cholesterol
level
rang
mgdl
mean
ae
sd
ae
one
month
simvastatin
treatment
n
plasma
cholesterol
level
rang
mgdl
ae
p
three
month
n
plasma
cholesterol
level
rang
ae
moment
three
dog
reevalu
six
month
treatment
mild
transitori
advers
effect
observ
three
dog
solv
gastric
acid
inhibitor
advers
effect
vomit
n
soft
fece
n
reduc
appetit
n
transitori
increas
liver
enzym
n
one
addit
dog
kidney
diseas
iri
ii
year
age
die
two
month
treatment
due
acut
kidney
failur
advers
effect
observ
previous
statin
use
experiment
studi
dog
evalu
toxic
higher
dosag
howev
achiev
lipidlow
effect
statin
might
use
lower
dosag
similar
describ
human
preliminari
studi
use
simvastatin
might
use
reduc
cholesterol
level
dog
hypercholesterolemia
even
though
use
safe
dog
use
dog
sever
kidney
diseas
studi
larger
number
dog
need
disclosur
disclosur
report
canin
felin
serum
sampl
select
sampl
sent
refer
laboratori
test
concentr
measur
use
microgen
assay
sampl
therebi
assign
four
concentr
rang
speci
ensur
dynam
spread
across
rang
sampl
store
assay
sampl
measur
use
assay
method
technician
blind
group
assign
pairwis
pearson
correl
linear
regress
blandaltman
method
agreement
perform
statatm
canin
felin
sampl
canin
sampl
rang
nmoll
rvalu
r
proport
bia
rang
ci
mean
differ
standard
deviat
blandaltman
differ
nmol
l
respect
felin
sampl
rang
nmoll
rvalu
r
proport
bia
rang
ci
mean
differ
sd
blandaltman
differ
nmoll
respect
strong
correl
assay
bia
canin
felin
sampl
signific
bia
unknown
absenc
gold
standard
system
hypertens
common
dog
hyperadrenocortic
hac
howev
preval
factor
associ
frequent
report
aim
studi
determin
preval
sever
hypertens
dog
hac
time
diagnosi
potenti
relat
systol
blood
pressur
sbp
differ
paramet
age
sex
reproduct
statu
durat
clinic
sign
diagnosi
bodi
condit
score
concurr
diseas
type
hac
acth
stimul
test
result
fortythre
dog
newli
diagnos
hac
veterinari
teach
hospit
complutens
madrid
januari
decemb
evalu
blood
pressur
measur
use
doppler
ultrasonographi
sbp
calcul
averag
consecut
read
hypertens
defin
sbp
mm
hg
subclassifi
accord
risk
target
organ
damag
rtod
acvim
guidelin
dog
concurr
diseas
know
affect
sbp
chronic
kidney
diseas
iri
cardiac
diseas
stage
cd
diagnosi
exclud
signific
valu
consid
p
forti
dog
hac
includ
pituitari
hac
adren
hac
age
rang
year
dog
intact
dog
neuter
twenti
eight
dog
hypertens
sever
rtod
mmhg
higher
preval
hypertens
higher
mean
valu
sbp
observ
intact
dog
ae
mm
hg
neuter
ae
mm
hg
p
p
higher
preval
sever
rtod
also
observ
intact
dog
versu
p
posit
correl
sbp
durat
clinic
sign
diagnosi
observ
p
dog
sever
rtod
clinic
sign
longer
period
time
diagnosi
ae
month
anim
moderatemild
rtod
normotens
ae
month
p
signific
correl
observ
sbp
rest
variabl
list
preval
hypertens
among
untreat
dog
hac
high
similar
previous
report
preval
sever
rtod
similar
previous
report
differ
observ
other
probabl
reflect
differ
popul
studi
therefor
blood
pressur
measur
perform
part
initi
investig
dog
suspect
hac
relationship
reproduct
statu
sbp
previous
report
experiment
studi
rat
show
higher
blood
pressur
intact
rat
neuter
disclosur
disclosur
report
multicentr
randomis
clinic
trial
compar
safeti
efficaci
new
prolongedreleas
suspens
docp
zycort
dechra
ltd
usapprov
control
product
percortenv
elanco
anim
health
treatment
ph
dog
ph
diagnos
presenc
clinic
sign
consist
ph
na
k
ratio
basal
post
acthstimul
test
cortisol
concentr
nmoll
clientown
dog
n
ph
randomis
ratio
treat
initi
dose
mgkg
bodi
weight
either
zycort
subcutan
percortenv
intramuscularli
subsequ
dose
administ
approxim
monthli
month
adjust
dose
dosag
regimen
permit
dog
evalu
monthli
physic
examin
clinic
assess
evalu
serum
na
k
concentr
na
k
ratio
haematolog
chemistri
evalu
day
primari
endpoint
day
treatment
success
occur
veterinarian
assess
case
improv
unchang
new
case
ph
compar
baselin
day
veterinarianassess
improv
na
k
na
k
ratio
within
refer
rang
noninferior
treatment
success
zycort
compar
percortenv
calcul
use
twosid
confid
interv
use
glimmix
procedur
sa
sa
institut
field
safeti
assess
review
abnorm
clinic
sign
day
group
veterinarianassess
improv
dog
na
k
ratio
dog
na
k
concentr
within
refer
rang
dog
zycort
percortenv
group
respect
zycort
percortenv
treatment
success
respect
zycort
noninferior
percortenv
abnorm
clinic
sign
report
frequent
group
polydipsia
polyuria
vomit
polyphagia
diarrhoea
major
sign
mild
transient
new
formul
docp
zycort
well
toler
effect
use
replac
therapi
mineralocorticoid
defici
dog
ph
compar
control
product
percortenv
disclosur
author
employe
dechra
ltd
manufactur
zycort
studi
fund
dechra
therapeut
option
felin
hyperthyroid
antithyroid
drug
thyroidectomi
radioiodin
therapi
iodinerestrict
diet
prospect
studi
conduct
franc
analys
firstlin
therapeut
choic
privat
practic
felin
hyperthyroid
biolog
clinic
efficaci
safeti
owner
complianc
follow
one
year
treatment
set
septemb
june
cat
privat
practic
clinic
suspicion
hyperthyroid
total
thyroxin
concentr
superior
nmoll
measur
veterinari
laboratori
recruit
patient
practition
receiv
survey
close
question
therapeut
option
discuss
owner
final
therapeut
choic
reason
choic
repeat
monitor
freeli
propos
voluntari
basi
week
treatment
set
everi
month
one
year
one
year
treatment
set
satisfact
survey
sent
owner
regard
clinic
efficaci
treatment
cat
male
femal
ae
year
old
concentr
time
diagnosi
vari
nmoll
nmoll
ae
inclus
veterinarian
survey
fulfil
cat
sole
therapeut
option
antithyroid
drug
case
propos
cat
two
therapeut
option
propos
case
antithyroid
drug
iodinerestrict
diet
propos
case
respect
total
iodinerestrict
diet
propos
cat
final
chosen
cat
prescrib
habit
medic
conveni
reason
commonli
cite
partial
complet
followup
one
year
avail
cat
receiv
antithyroid
drug
eat
iodinerestrict
diet
euthyroid
appear
rapidli
achiev
versu
week
less
stabl
cat
receiv
antithyroid
drug
compar
cat
eat
special
diet
even
outdoor
cat
side
effect
uncommon
medicin
dietet
treatment
respect
one
year
owner
survey
avail
owner
satisfi
satisfi
treatment
issu
studi
revers
treatment
option
felin
hyperthyroid
larg
prefer
irrevers
option
rare
propos
efficaci
safeti
owner
complianc
high
dietet
medicin
option
iodinerestrict
diet
although
less
popular
antithyroid
drug
provid
promis
compar
result
disclosur
disclosur
report
cush
syndrom
cs
one
commonli
recogn
endocrin
disord
dog
knowledg
one
epidemiolog
studi
publish
evalu
incid
diseas
studi
canin
cs
frequent
report
appar
predisposit
femal
gender
none
studi
prove
lack
control
popul
aim
multicent
retrospect
studi
investig
epidemiolog
characterist
cs
italian
canin
popul
data
deriv
clientown
dog
select
electron
databas
veterinari
clinic
scatter
throughout
italian
territori
evalu
septemb
septemb
calcul
preval
dog
popul
one
center
univers
refer
center
cs
evalu
separ
popul
four
clinic
refer
center
cs
total
dog
identifi
cs
basi
histori
clinic
laboratori
find
posit
ldd
test
andor
acth
stimul
test
preval
clinic
ci
significantli
differ
compar
refer
center
ci
mean
sd
age
dog
cs
ae
year
dog
year
use
mix
breed
dog
control
popul
risk
develop
cs
significantli
higher
standard
schnauzer
p
fox
terrier
p
cavali
king
charl
spaniel
p
boxer
p
shihtzu
p
bolognes
p
pit
bull
p
jack
russel
terrier
p
maltes
p
miniatur
dachshund
p
miniatur
poodl
p
yorkshir
terrier
p
result
studi
identifi
preval
cs
italian
canin
popul
data
support
exist
sex
predisposit
develop
cs
highest
risk
neuter
femal
observ
studi
breed
predispos
develop
cs
disclosur
disclosur
report
diabet
common
endocrinopathi
cat
resembl
type
diabet
human
etiolog
pathogenesi
felin
diabet
fulli
understood
combin
genet
environment
factor
believ
contribut
obes
report
import
risk
factor
diabet
cat
human
aim
studi
assess
associ
environment
risk
factor
felin
diabet
webbas
questionnair
larg
casecontrol
studi
letter
invit
particip
web
survey
sent
mail
owner
cat
previou
ongo
insur
agria
anim
insur
studi
popul
includ
cat
diagnosi
diabet
year
n
control
group
cat
n
without
diagnosi
match
birth
year
diabet
cat
web
survey
contain
question
eg
signal
cat
environ
activ
level
access
outdoor
feed
regim
type
diet
eat
habit
bodi
condit
health
medic
vaccin
statu
anim
household
chang
occur
cat
life
diagnosi
diabet
total
complet
repli
acquir
diabet
cat
control
cat
answer
frequenc
respect
result
multivari
logist
regress
show
signific
associ
diagnosi
diabet
sever
respons
questionnair
burmes
breed
male
indoor
cat
greedi
eat
habit
overweight
independ
associ
increas
odd
diabet
result
far
largest
casecontrol
studi
diabet
cat
verifi
previou
report
overweight
live
indoor
import
risk
factor
diabet
cat
greedi
eater
new
potenti
risk
factor
diabet
cat
disclosur
disclosur
report
hypertens
frequent
dog
hyperadrenocortic
hac
even
adequ
control
hac
achiev
aim
studi
evalu
systol
blood
pressur
sbp
first
month
trilostan
treatment
dog
newli
diagnos
hac
determin
whether
associ
control
diseas
fortythre
clientown
dog
diagnos
hac
veterinari
teach
hospit
complutens
madrid
januari
decemb
follow
acvim
consensu
guidelin
trilostan
treatment
initi
start
dose
mgkg
bid
dog
evalu
one
n
three
n
six
n
month
treatment
mat
histori
physic
exam
hematolog
biochemistri
acth
stimul
blood
pressur
use
doppler
ultrasonographi
assess
everi
visit
dog
chronic
kidney
cardiac
diseas
stage
cd
receiv
antihypertens
medic
diagnosi
exclud
hypertens
defin
sbp
mm
hg
follow
acvim
guidelin
hypertens
anim
subclassifi
accord
risk
target
organ
damag
rtod
antihypertens
treatment
benazepril
andor
amlodipin
administ
deem
appropri
twentysix
dog
includ
femal
male
age
rang
year
twenti
dog
hypertens
diagnosi
sever
rtod
preval
hypertens
similar
throughout
studi
whilst
percentag
hypertens
anim
sever
rtod
decreas
treatment
significantli
normotens
dog
diagnosi
remain
normotens
becam
hypertens
mild
rtod
mm
hg
hypertens
dog
diagnosi
remain
hypertens
sever
rtod
mmhg
signific
correl
good
control
hac
good
control
sbp
mmhg
decreas
rtod
classif
sever
moderatemoder
mild
preval
hypertens
dog
hac
decreas
first
month
treatment
trilostan
also
report
peopl
slight
increas
sbp
observ
normotens
patient
treatment
start
control
hac
trilostan
correl
control
blood
pressur
hypertens
dog
monitor
close
hyperadrenocortic
progress
diseas
treatment
may
complet
normal
deleteri
effect
hypercortisol
disclosur
disclosur
report
canin
addisonian
crisi
occur
due
defici
cortisol
typic
associ
concurr
defici
aldosteron
glucocorticoid
dexamethason
commonli
use
emerg
parenter
treatment
crisi
drug
neglig
mineralocorticoid
activ
use
hydrocortison
sodium
succin
hss
describ
human
medicin
besid
glucocorticoid
activ
potent
mineralocorticoid
activ
potenti
make
superior
dexamethason
treatment
addisonian
crisi
aim
describ
treatment
addisonian
crisi
use
hss
cohort
dog
furthermor
compar
therapi
dog
treat
dexamethason
period
record
singl
referr
hospit
search
identifi
dog
diagnos
addisonian
crisi
serum
cortisol
concentr
nmoll
administr
tetracosactrin
requir
hospit
emerg
stabilis
dog
exclud
alreadi
receiv
glucocorticoid
andor
mineralocorticoid
therapi
prior
admiss
incomplet
data
concern
treatment
laboratori
test
outcom
seven
dog
treat
hss
continu
rate
infus
rang
mgkgh
group
eight
dog
treat
intraven
dexamethason
dose
rang
mgkg
group
b
none
dog
group
requir
treatment
dexamethason
none
dog
group
b
receiv
hss
stage
treatment
hss
dexamethason
associ
adequ
manag
acut
adrenocort
insuffici
everi
case
patient
surviv
discharg
signific
differ
found
two
group
regard
age
weight
gender
admiss
na
k
concentr
length
median
cost
hospitalis
median
time
k
concentr
normalis
time
spontan
eat
amount
crystalloid
colloid
fluid
use
median
time
na
concentr
normalis
significantli
shorter
group
compar
group
b
p
one
dog
group
b
treat
vasopressor
dopamin
wherea
none
dog
group
treat
vasopressor
result
suggest
hss
effect
manag
canin
addisonian
crisi
prospect
studi
larger
cohort
dog
warrant
assess
potenti
benefit
hss
compar
dexamethason
disclosur
disclosur
report
diagnosi
confirm
laparotomi
recent
studi
show
gastric
foreign
bodi
signific
risk
factor
develop
gastric
dilat
volvulu
dog
purpos
studi
correl
cat
dog
gi
foreign
bodi
underli
gi
diseas
hypothesi
cat
dog
gi
foreign
bodi
primari
underli
gastrointestin
diseas
result
pica
subsequ
ingest
foreign
bodi
record
privat
own
cat
dog
diagnos
gastrointestin
foreign
bodi
histopatholog
done
gastrointestin
tract
retrospect
evalu
inclus
criteria
diagnosi
gi
foreign
bodi
togeth
histopatholog
gi
tract
biopsi
taken
time
surgic
remov
foreign
bodi
case
cat
dog
mean
age
cat
year
rang
dog
year
rang
cat
classifi
dsh
dog
breed
vari
male
femal
within
cat
group
male
femal
within
dog
group
histopatholog
diagnosi
cat
lymphoplasmacyt
enter
lymphoma
carcinoma
wherea
dog
histopatholog
diagnosi
lymphoplasmacyt
enter
lymphoma
necrot
enter
carcinoma
eosinophil
enter
find
indic
cat
dog
gi
foreign
bodi
underli
primari
gi
diseas
presenc
foreign
bodi
may
thu
indic
seriou
gi
diseas
therefor
cat
dog
gi
foreign
bodi
biopsi
gastrointestin
done
time
surgeri
ensur
underli
diseas
identifi
correctli
manag
disclosur
disclosur
report
mammalian
intestin
inhabit
set
microorgan
ie
bacteria
virus
fungi
archaea
name
microbiota
variou
differ
condit
influenc
microbiota
one
diet
present
studi
investig
effect
barf
diet
fecal
microbiom
fecal
function
gene
content
predict
compar
two
group
four
czechoslovakian
wolfdog
fed
either
barf
commerci
diet
barf
diet
dog
fed
kibbl
month
group
compos
dog
male
femal
commerci
diet
group
compos
dog
male
femal
puppi
litter
mother
puppi
within
barf
group
parent
also
father
live
environ
differ
within
group
dna
extract
use
commerci
kit
analyz
next
gener
sequenc
rrna
gene
data
analyz
use
freewar
qiim
picrust
use
predict
function
gene
content
linear
discrimin
analysi
lda
effect
size
lefs
use
identifi
significantli
alter
bacteri
taxa
lefs
analysi
show
fed
barf
diet
associ
higher
proport
fusobacteria
epsilonproteobacteria
carnobacterium
genera
within
clostridiacea
fed
commerci
diet
associ
increas
proport
variou
bacteri
group
includ
bifidobacterium
lactobacillal
turicibact
lactobacillu
preval
dog
commerci
diet
group
p
adjust
qvalu
signific
fusobacterium
significantli
higher
abund
barf
group
p
adjust
qvalu
signific
rarefact
analysi
indic
barf
group
signific
lower
microbi
divers
group
p
lefs
analysi
function
gene
content
predict
reveal
total
differenti
enrich
bacteri
function
two
group
result
suggest
bone
raw
food
diet
could
influenc
canin
fecal
microbiom
similarli
factor
age
genet
related
could
also
result
differ
abund
function
gene
studi
larger
group
unrel
dog
need
better
character
influenc
disclosur
disclosur
report
year
old
male
neuter
cat
refer
chronic
intermitt
hematochezia
fecal
incontin
month
durat
weight
loss
report
cat
keep
good
appetit
symptomat
treatment
includ
deworm
metronidazol
hypoallergen
diet
tri
without
clinic
improv
physic
examin
complet
blood
count
biochemistri
panel
includ
folat
cobalamin
within
normal
limit
fecal
flotat
pcr
tritrichomona
giardia
neg
abdomin
sonographi
reveal
colon
wall
thick
colonoscopi
show
irregular
thicken
colon
wall
multipl
eros
compat
ulcer
coliti
infiltr
neoplasia
histopatholog
analysi
reveal
multifoc
ulcer
epithelium
mark
pa
posit
cell
moder
diffus
lymphoplasmacyt
infiltr
lamina
propria
toluidineblu
fitefaraco
stain
show
mast
cell
infiltr
mycobacterialik
bacteria
respect
rectal
wall
cultur
posit
ecoli
neg
salmonella
yersinia
campylobact
antimicrobi
suscept
test
broadli
posit
fluoresc
situ
hibrid
colon
biopsi
reveal
multifoc
cluster
intracellular
ecoli
treatment
enrofloxacin
mgkg
sid
week
led
complet
resolut
clinic
sign
remiss
sustain
month
date
find
reveal
ecoli
associ
gc
also
affect
cat
consid
differenti
diagnosi
chronic
hematochezia
studi
need
assess
molecular
genet
immun
pathway
beneath
intracellular
invas
ecoli
cat
gc
disclosur
disclosur
report
cat
includ
least
two
clinic
sign
consist
cp
weight
loss
dysorexia
vomit
diarrhea
week
fpl
valu
consist
abdomin
ultrasonograph
find
hypoecho
pancrea
peripancreat
steatiti
left
limb
thicken
local
effus
initi
present
histopatholog
perform
accept
owner
associ
condit
initi
present
list
valu
express
median
interquartil
rang
associ
age
weight
clinic
sign
durat
surviv
investig
use
kaplanmei
surviv
curv
nineteen
cat
male
femal
includ
domest
shorthair
commonli
affect
breed
median
age
year
median
weight
kg
median
durat
clinic
sign
inclus
day
median
fpl
valu
overal
median
st
day
surviv
curv
differ
cat
fpl
valu
versu
plogrank
median
st
cat
fpl
valu
day
reach
end
studi
cat
fpl
valu
eleven
case
still
aliv
initi
present
rang
day
presenc
weight
loss
n
dysorexia
n
vomit
n
diarrhea
n
present
significantli
associ
shorter
st
concurr
cholang
chronic
enter
often
suggest
ultrasonograph
find
histolog
confirm
case
cp
confirm
histolog
three
case
conclus
cat
cp
may
long
surviv
time
fpl
valu
initi
present
associ
mortal
none
clinic
sign
present
time
admiss
could
predict
mortal
preliminari
find
confirm
prospect
studi
disclosur
disclosur
report
diagnosi
pancreat
base
histori
physic
exam
pancreasspecif
lipas
assay
ultrasonographi
retrospect
studi
analys
agreement
felin
canin
pancreasspecif
lipas
pancreat
ultrasonograph
find
dog
cat
clinic
suspicion
pancreat
also
assess
sensit
se
specif
sp
ultrasonograph
paramet
use
diagnosi
pancreat
cat
dog
clinic
suspicion
pancreat
present
veterinari
teach
hospit
underw
quantit
spec
spec
cutoff
cat
dog
qualit
snap
assess
pancreasspecif
lipas
combin
abdomin
ultrasonographi
cohen
kappa
use
compar
agreement
pancreat
lipas
ultrasonographi
sensit
specif
ultrasonograph
paramet
size
echogen
margin
pancrea
peripancreat
fluid
increas
echogen
around
pancrea
diagnos
pancreat
determin
use
pancreasspecif
lipas
gold
standard
cat
male
femal
ae
year
old
among
pancreat
lipas
suggest
pancreat
ultrasonograph
diagnosi
pancreat
dog
male
femal
ae
year
old
among
pancreat
lipas
suggest
pancreat
ultrasonograph
diagnosi
pancreat
agreement
pancreat
lipas
ultrasonographi
low
cat
k
low
dog
k
increas
size
pancrea
sensit
paramet
detect
pancreat
cat
dog
se
respect
increas
echogen
around
pancrea
specif
paramet
detect
pancreat
cat
dog
sp
respect
case
clinic
suspicion
pancreat
low
agreement
pancreat
lipas
ultrasonographi
pancrea
observ
studi
accord
conclus
two
recent
studi
use
cut
valu
lipas
could
due
fals
posit
result
ultrasonographi
relat
anterior
bout
pancreat
subclin
chronic
pancreat
anatom
chang
relat
age
associ
pancreat
enzym
releas
ultrasonograph
data
therefor
consid
caution
case
clinic
suspicion
pancreat
dog
cat
disclosur
disclosur
report
defin
dog
respond
treatment
immunosuppress
drug
antibiot
treatment
discontinu
without
relaps
group
defin
dog
respond
treatment
immunosuppress
drug
diseas
relaps
interrupt
treatment
group
defin
dog
respond
diet
antibiot
immunosuppress
drug
kaplanmei
surviv
curv
obtain
group
surviv
curv
group
compar
use
logrank
test
two
stageanalysi
also
appli
first
univari
stage
variabl
screen
use
x
test
second
stage
factor
screen
p
evalu
use
multivari
logist
regress
odd
ratio
confid
interv
ci
calcul
final
model
one
hundr
four
dog
met
inclus
criteria
dog
group
median
surviv
longer
dog
group
day
rang
day
rang
versu
day
rang
respect
univari
regress
analysi
statist
differ
dog
group
respect
dog
group
follow
variabl
observ
previou
treatment
steroid
weight
loss
preval
small
bowel
diarrhoea
decreas
haematocrit
serum
albumin
total
protein
creatinin
cholesterol
increas
concentr
aspart
amino
transferas
ast
alanin
aminotransferas
alt
receiv
treatment
immunosuppress
drug
steroid
diagnosi
multivari
model
analysi
previou
treatment
steroid
ci
p
decreas
total
protein
ci
p
independ
variabl
associ
belong
group
conclus
respons
treatment
dog
ibd
correl
time
surviv
previou
treatment
steroid
along
decreas
total
protein
neg
prognost
factor
associ
lack
respons
treatment
disclosur
disclosur
report
cyclooxigenas
induc
isoform
cellular
activ
proinflammatori
cytokin
growth
factor
tumour
promot
mediat
prostaglandin
gener
resist
apoptosi
one
felin
report
show
detect
immunoexpress
alimentari
lymphoma
al
tumour
grade
specifi
aim
studi
evalu
epitheli
lamina
propria
lp
immunoexpress
felin
inflammatori
bowel
diseas
ibd
low
grade
al
lgal
correl
clinic
sign
histopatholog
score
cat
diagnos
ibd
n
lgal
n
includ
felin
chronic
enteropathi
activ
index
fceai
calcul
case
control
group
compos
healthi
indoor
cat
sick
cat
die
euthan
nongastrointestin
ill
diagnosi
classif
ibd
lgal
establish
accord
wsava
gastrointestin
standard
group
templat
nation
cancer
institut
formul
respect
furthermor
modifi
wsava
templat
villou
stunt
epitheli
injuri
crypt
distens
lacteal
dilat
appli
lgal
evalu
immunolabel
polyclon
rabbit
antimurin
antibodi
perform
epitheli
lp
inflammatori
neoplast
cell
immunolabel
calcul
accord
grade
neg
cell
stain
posit
intens
neg
weak
stain
moder
mark
posit
control
felin
foetal
macula
densa
repres
segment
score
patient
wsava
modifi
wsava
use
statist
analysi
nonparametr
test
use
immunoreact
epitheli
cell
intens
show
signific
differ
control
ibd
group
well
lgal
group
ibd
lgal
group
cat
group
present
immunoreact
epitheli
cell
therebi
differ
found
differ
found
immunoexpress
intens
percentag
cell
lp
group
howev
cat
lgal
group
show
moder
mark
intens
posit
neoplast
cell
lp
correl
epitheli
lp
express
fceai
histolog
alter
conclus
increas
intens
epitheli
cell
found
ibd
lgal
group
might
like
inflammatori
respons
though
role
intestin
repar
might
exclud
conclus
express
lp
lgal
could
obtain
low
number
patient
posit
express
disclosur
disclosur
report
ibd
pathogenesi
remain
poorli
defin
although
hypothes
influenc
immunolog
environment
genet
factor
canin
lymphocyticplasmacyt
coliti
clpc
form
ibd
mucos
cytokin
seem
involv
diseas
pathogenesi
howev
suffici
data
lack
aim
current
studi
evalu
mrna
express
level
proinflammatori
cytokin
interleukin
il
tnfalpha
mucosa
associ
epitheli
chemokin
colon
mucosa
mucu
dog
clpc
correl
canin
ibd
activ
index
cibdai
endoscop
activ
score
quantit
qualit
canin
ibd
colon
mucosa
mucu
dog
clpc
histolog
diagnosi
healthi
dog
obtain
endoscop
biopsi
cytolog
brush
respect
total
rna
extract
colon
mucosa
mucu
cdna
synthes
mrna
tnfalpha
measur
use
realtim
quantit
revers
transcriptas
polymeras
chain
reaction
realtim
qrtpcr
result
normal
use
gapdh
housekeep
gene
tnfalpha
mrna
express
colon
mucosa
clpc
nt
differ
signif
control
dog
mrna
express
statist
significantli
increas
colon
mucosa
compar
control
dog
colon
mucu
mrna
express
cytokin
clpc
dog
nt
differ
control
dog
tnfalpha
mrna
express
colon
mucosa
nt
differ
signif
among
differ
cibdai
group
normal
mild
moder
sever
contrast
mrna
express
level
colon
mucu
differ
statist
among
differ
cibdai
group
level
tnfalpha
mrna
express
nt
differ
signif
among
differ
group
endoscop
activ
score
quantit
qualit
colon
mucosa
mucu
studi
indic
clpc
dog
signific
increas
mrna
express
colon
mucosa
howev
express
level
correl
clpc
clinic
endoscop
sever
larger
number
dog
requir
clarifi
role
clpc
dog
investig
signific
clpc
pathogenesi
sever
disclosur
disclosur
report
gastrin
peptid
hormon
produc
gastric
duoden
g
cell
stimul
gastric
acid
secret
exert
trophic
effect
gastric
mucosa
hypergastrinemia
suggest
use
diagnos
canin
gastrinoma
increas
upper
refer
limit
url
hypergastrinemia
also
caus
antacid
therapi
lymphoplasmacyt
enter
effect
antacid
therapi
hypergastrinemia
dog
chronic
enteropathi
ce
biolog
variat
bv
serum
gastrin
concentr
unknown
aim
current
studi
evalu
serum
gastrin
concentr
antacidtr
ce
dog
test
associ
serum
gastrin
concentr
microscop
find
stomachduodenum
evalu
bv
serum
gastrin
concentr
ce
dog
serum
sampl
collect
dog
undergo
routin
diagnost
evalu
chronic
gastrointestin
sign
diagnos
ce
serum
gastrin
concentr
measur
chemiluminesc
immulit
gastrin
assay
sever
gastricduoden
histolog
lesion
assess
bv
serum
gastrin
concentr
evalu
use
serial
sampl
ce
dog
statist
analys
includ
nonparametr
group
comparison
likelihood
ratio
spearman
correl
test
nest
anova
serum
gastrin
concentr
significantli
higher
antacidtr
ce
dog
p
significantli
higher
gastrin
level
proton
pump
inhibitor
ppi
compar
h
antihistaminetr
dog
p
antacid
therapi
associ
hypergastrinemia
p
frequenc
gastrin
concentr
url
p
ppithan
h
antihistaminetr
dog
gastrin
concentr
p
url
serum
gastrin
concentr
numer
higher
dog
moderatesever
gastricduoden
lesion
mildno
lesion
differ
reach
signific
gastrin
concentr
correl
sever
gastric
antral
epitheli
injuri
p
duoden
lesion
p
presencenumb
spiral
bacteria
gastric
biopsi
intra
interindividu
bv
serum
gastrin
concentr
antacidtr
individu
index
critic
differ
ngl
ngl
respect
result
suggest
addit
effect
antacid
particularli
ppi
treatment
hypergastrinemia
seen
ce
dog
especi
dog
sever
gastricduoden
lesion
also
hypergastrinemia
associ
ce
antacid
therapi
unlik
compromis
diagnosi
gastrinoma
dog
use
populationbas
url
serum
gastrin
current
use
url
dog
ngl
appropri
disclosur
disclosur
report
nova
scotia
duck
toll
retriev
nsdtr
dog
predispos
immunemedi
disord
particularli
disord
character
chronic
stiff
pain
multipl
joint
indic
noneros
polyarthr
dog
affect
disord
call
immunemedi
rheumat
diseas
imrd
commonli
display
antinuclear
antibodi
ana
indirect
immunofluoresc
iif
noneros
polyarthr
ana
commonli
present
system
lupu
erythematosu
sle
system
rheumat
diseas
human
well
dog
imrd
may
describ
slerel
diseas
diagnosi
monitor
imrd
primarili
base
clinic
sign
presenc
ana
object
quick
costeffect
test
would
highli
valuabl
acut
phase
protein
creactiv
protein
crp
use
diagnos
monitor
system
inflamm
human
dog
consid
quantit
marker
inflamm
diseas
human
sle
crp
concentr
mildli
moder
increas
correl
degre
inflamm
aim
studi
investig
crp
concentr
nsdtr
imrd
hypothesi
crp
concentr
would
mildli
moder
increas
imrd
compar
healthi
dog
similar
report
human
sle
serum
crp
concentr
measur
imrd
affect
nsdtr
iifana
posit
iifana
neg
healthi
control
nsdtr
use
two
caninespecif
immunoturbidimetr
assay
gentian
ccrp
assay
highsensit
crp
assay
gentian
moss
norway
none
dog
treat
antiinflammatori
medic
time
sampl
dog
imrd
higher
crp
concentr
compar
control
dog
welch
two
sampl
ttest
logtransform
data
p
differ
observ
group
imrd
dog
without
posit
iifana
respect
p
median
crp
concentr
mgl
imrd
dog
mgl
control
dog
crp
concentr
low
moder
increas
major
imrd
dog
seen
human
sle
crp
concentr
lower
observ
exampl
studi
immunemedi
polyarthr
dog
breed
higher
canin
osteoarthr
two
disord
resembl
imrd
potenti
clinic
valu
crp
dog
imrd
warrant
investig
disclosur
disclosur
report
anna
om
phd
project
swedish
univers
agricultur
scienc
slu
partli
financ
gentian
compani
manufactur
crp
assay
use
studi
actual
report
bacteri
contamin
blood
unit
emerg
caus
morbid
mortal
human
transfus
medicin
rare
veterinari
literatur
underestim
extent
risk
bacteri
contamin
blood
unit
could
expect
studi
aim
detect
quantifi
bacteri
microorgan
canin
whole
blood
wb
unit
shelflif
estim
bacteri
contamin
rate
collect
process
storag
blood
unit
fortynin
wb
unit
includ
studi
blood
collect
healthi
anim
accord
guidelin
immedi
refriger
store
day
eight
steril
sampl
unit
test
bacteri
cultur
day
moreov
dna
extract
realtim
qpcr
assay
perform
accord
nakardini
et
al
procedur
obtain
sequenc
submit
blast
analysi
genbank
refer
databas
reveal
amplif
sourc
genera
bacteri
cultur
sampl
neg
time
point
one
sampl
posit
enterococcu
spp
ecoli
pcr
analysi
sampl
posit
least
one
time
point
sequenc
assign
propionobacterium
spp
corynebacterium
spp
caulobact
spp
hypomicorbium
spp
pseudomona
spp
enterococcu
spp
serratia
spp
leucobact
spp
uniqu
ecoli
growth
contamin
laboratori
techniqu
sinc
sampl
result
neg
pcr
assay
one
case
blood
cultur
pcr
assay
identifi
enterococcu
spp
speci
bacteria
assay
process
bacteri
cultur
slow
need
microorgan
grow
reach
appreci
number
cell
low
quantiti
bacteria
also
detect
bacteri
cultur
could
explain
differ
cultur
method
molecular
detect
organ
detect
qpcr
assay
tend
skinassoci
widespread
bacteria
soil
water
usual
implic
transfus
reaction
qpcr
assay
bacteri
load
vari
equival
genomemmc
state
bacteri
contamin
blood
unit
result
low
moreov
result
could
includ
detect
dead
degrad
bacteri
dna
disclosur
disclosur
report
cat
sever
respiratori
distress
may
unstabl
receiv
mani
clinic
manipul
aim
studi
noninvas
quantifi
tidal
breath
statu
cat
present
respiratori
distress
compar
differ
ventilatori
function
cat
respiratori
distress
healthi
cat
hypothes
ventilatori
paramet
respiratori
rate
volum
elev
cat
experienc
signific
labor
breath
respiratori
diseas
increas
ventilatori
demand
twelv
cat
present
ntuvh
persist
increas
respiratori
effort
due
variou
etiolog
lung
parenchym
diseas
pleural
space
diseas
upper
airway
obstruct
lower
airway
diseas
enrol
studi
inform
consent
obtain
owner
cat
place
transpar
plexigla
chamber
barometr
whole
bodi
plethysmographi
bwbp
system
without
restraint
record
tidal
breath
signal
breath
statu
cat
could
observ
easili
clinician
time
without
caus
disturb
stress
cat
compar
cat
without
respiratori
sign
histor
respiratori
diseas
cat
respiratori
distress
significantli
higher
minut
volum
bodi
weight
mvbw
versu
mlkg
p
tidal
volumebw
tvbw
versu
mlkg
p
peak
inspiratori
flowbw
pifbw
versu
mlskg
p
peak
expiratori
flowbw
pefbw
versu
mlskg
p
enhanc
paus
versu
p
significantli
lower
relax
time
versu
p
among
cat
respiratori
distress
cat
eventu
die
respiratori
failur
statist
higher
mvbw
cat
surviv
becam
stabl
least
month
versu
mlkg
p
interestingli
respiratori
rate
neither
significantli
differ
cat
respiratori
distress
control
cat
cat
die
cat
surviv
conclus
ventilatori
function
could
noninvas
nonharm
assess
cat
respiratori
distress
bwbp
method
elev
mvbw
natur
breath
impli
increas
ventilatori
demand
might
poor
prognost
indic
sever
index
cat
labor
breath
furthermor
respiratori
rate
might
reliabl
identifi
increas
respiratori
effort
diseas
sever
care
taken
assess
reli
respiratori
rate
alon
disclosur
disclosur
report
mani
caus
pleural
effus
pe
known
cat
littl
known
frequenc
potenti
indic
factor
time
diagnosi
studi
aim
identifi
aetiolog
lead
pe
cat
along
clinic
sign
treatment
outcom
associ
condit
hypothes
major
caus
pe
cat
would
congest
heart
failur
chf
neoplasia
also
cat
suffer
chf
would
lower
rectal
temperatur
rt
cat
noncardiogen
pe
medic
record
total
clientown
cat
pe
review
case
select
base
complet
demograph
data
physic
examin
presenc
pe
sever
procedur
perform
investig
underli
aetiolog
infecti
diseas
screen
clinic
patholog
analysi
diagnost
imag
examin
surgic
intervent
chf
neoplasia
common
caus
pe
cat
respect
caus
includ
pyothorax
idiopath
chylothorax
trauma
felin
infecti
periton
diaphragmat
hernia
cat
chf
younger
ae
year
old
neoplasia
ae
year
old
p
cat
lymphoma
ae
year
old
younger
carcinoma
ae
year
old
p
cat
chf
significantli
lower
rt
admiss
pe
due
caus
ae
versu
ae
respect
p
male
cat
significantli
overrepres
chf
group
quarter
global
popul
die
euthan
within
day
follow
diagnosi
conclus
chf
neoplasia
preval
caus
pe
cat
younger
age
male
cat
low
rt
admiss
indic
chf
cat
pe
poor
prognosi
addit
studi
necessari
determin
whether
rectal
temperatur
admiss
correl
neg
surviv
cat
pe
associ
chf
report
human
chf
cat
arteri
thromboembol
disclosur
disclosur
report
cat
suffer
multipl
autoimmun
diseas
diseas
fatal
cat
corticosteroid
effect
control
immun
respons
requir
altern
immunesuppress
therapi
mycophenol
mofetil
may
altern
immunosuppress
consid
use
cat
document
efficaci
control
autoimmun
diseas
human
dog
mycophenol
mofetil
prodrug
activ
compound
mycophenol
acid
mpa
select
noncompetit
inhibitor
dehydrogenas
express
mani
cell
mpa
induc
lymphocyt
cytotox
reduc
monocyt
recruit
suppress
dendrit
cell
matur
make
use
treat
immun
mediat
inflammatori
diseas
diarrhea
side
effect
mpa
human
dog
occur
patient
side
effect
observ
cat
propos
mpa
could
use
success
cat
minim
side
effect
multiday
intraven
dose
five
clinic
healthi
adult
cat
voluntarili
enrol
baselin
laboratori
test
perform
cat
prior
start
studi
rule
system
diseas
cat
administ
mgkg
mycophenol
mofetil
intraven
hour
bid
day
cat
bodi
weight
appetit
attitud
stool
monitor
pre
day
day
post
day
infus
particip
cat
maintain
bodi
weight
throughout
studi
attitud
remain
bright
alert
cat
show
gastrointestin
side
effect
normal
appetit
vomit
form
stool
total
lymphocyt
number
obtain
predos
hour
infus
initi
number
reduc
four
cat
ae
ae
hour
infus
hour
infus
number
slightli
reduc
ae
interestingli
one
cat
show
increas
number
lymphocyt
serum
chemistri
complet
blood
count
repeat
cat
day
final
mpa
administr
reveal
advers
effect
preliminari
result
suggest
mpa
rapidli
revers
reduc
lymphocyt
number
medic
administr
minim
side
effect
give
short
cours
intraven
mpa
therapi
healthi
cat
futur
studi
evalu
effect
mpa
felin
lymphocyt
short
term
long
term
oral
dose
effect
mpa
clinic
case
disclosur
disclosur
report
primari
immunemedi
hemolyt
anemia
pimha
type
ii
hypersensit
antibodydepend
cytotox
common
immunehematolog
disord
dog
lead
mostli
moder
sever
anemia
subsequ
hypoxemia
hypercoagul
often
fatal
outcom
retrospect
studi
examin
clinic
laboratori
find
present
visit
dog
pimha
two
veterinari
teach
hospit
pisa
itali
koret
israel
studi
includ
dog
pisa
n
koret
n
present
hematocrit
combin
follow
spherocytosi
posit
osmot
fragil
test
autoagglutin
posit
coomb
test
posit
flow
cytometri
rbcbound
igg
andor
igm
case
exclud
posit
tickborn
diseas
infect
base
serolog
pcr
assay
diagnos
system
neoplasia
data
retriev
medic
record
includ
signal
clinic
laboratori
find
data
regard
gender
breed
pisa
group
compar
control
popul
includ
dog
present
pisa
hospit
studi
period
n
find
pisa
koret
group
compar
dog
pimha
mainli
middleag
elderli
dog
present
season
pattern
pisa
group
neuter
femal
p
well
cockerspaniel
maltes
dog
p
p
respect
overrepres
compar
control
popul
frequent
clinic
sign
includ
pale
mucou
membran
lethargi
anorexia
tachycardia
tachypnea
pigmenturia
koret
dog
significantli
icter
tachycard
tachypn
compar
pisa
dog
p
p
p
respect
anemia
classifi
macrocytichypochrom
macrocyticnormochrom
macrocytichyperchrom
normocyticnormochrom
normocyt
hypochrom
normocytichyperchrom
koret
group
significantli
dog
anemia
classifi
hyperchrom
p
suggest
higher
frequenc
hemoglobinemia
due
intravascular
hemolysi
common
morpholog
cellular
blood
anomali
includ
polychromasia
anisocytosi
metarubricytosi
spherocytosi
leukocytosi
neutrophilia
howelljolli
bodi
leftshift
macrothrombocythemia
thrombocytopenia
monocytosi
autoagglutin
hypochromia
poikilocytosi
schistocytosi
studi
confirm
previou
find
regard
signal
clinic
laboratori
characterist
pimha
dog
microscop
evalu
blood
smear
valuabl
tool
diagnosi
pimha
koret
group
character
sever
present
diseas
like
hospit
admit
emerg
primari
care
case
disclosur
disclosur
report
plateletrich
plasma
prp
deriv
whole
blood
character
platelet
concentr
baselin
small
volum
plasma
lead
increas
concentr
plateletderiv
growth
factor
stimul
cell
prolifer
decreas
inflammatori
reaction
acceler
heal
process
aim
studi
report
clinic
efficaci
autolog
prp
obtain
doubl
centrifug
valid
method
treatment
canin
aural
hematoma
perian
fistula
dog
german
shepherd
year
old
femal
multipl
perian
fistula
treat
system
antibiot
local
disinfect
without
improv
two
month
dog
perin
fistula
three
confluent
erythema
serumhemat
exud
dyschezia
dog
rhodesian
ridgeback
year
old
femal
monolater
aural
hematoma
caus
accident
trauma
appear
day
treat
centesi
corticosteroid
therapi
initi
improv
subsequ
relaps
dog
unorgan
right
aural
hematoma
size
cm
cm
thick
dog
maltes
year
old
male
monolater
aural
hematoma
caus
intens
head
shake
bilater
bacteri
otiti
appear
day
treat
centesi
compress
bandag
without
improv
dog
partial
organ
right
aural
hematoma
size
cm
cm
thick
area
necrosi
purul
exud
edg
ear
pinna
erythema
pain
procedur
follow
medium
volum
ml
prp
obtain
blood
sampl
ml
follow
protocol
previous
describ
autolog
prp
inject
time
directli
fistula
ml
fistula
aural
hematoma
inject
complet
centesi
liquid
use
hole
drainag
inlet
dog
check
everi
day
two
week
two
time
month
month
evalu
improv
clinic
score
photograph
document
dog
complet
heal
lesion
one
month
treatment
prp
without
use
drug
antibiot
recurr
observ
one
month
follow
autolog
prp
obtain
inhous
doubl
centrifug
method
appear
effect
minim
invas
therapi
treatment
perian
fistula
aural
hematoma
dog
disclosur
disclosur
report
dog
breed
nova
scotia
duck
toll
retriev
nsdtr
affect
sever
immunemedi
diseas
particular
steroidrespons
meningitisarter
srma
immunemedi
rheumat
diseas
imrd
typic
acut
form
srma
often
character
cervic
rigid
pain
pyrexia
imrd
system
lupu
erythematosu
sle
relat
diseas
character
chronic
stiff
pain
sever
joint
initi
sign
imrd
usual
shown
year
age
acut
form
srma
often
seen
month
sever
studi
shown
dog
srma
often
display
elev
immunoglobulin
iga
concentr
serum
cerebrospin
fluid
anoth
studi
identifi
nsdtr
breed
gener
low
serum
iga
level
dog
iga
product
report
agedepend
assum
stabil
around
one
year
age
aim
studi
investig
serum
iga
level
nsdtr
affect
srma
imrd
healthi
control
serum
iga
measur
elisa
dog
elisa
set
nordic
biosit
sweden
dog
includ
studi
nsdtr
acut
srma
treatment
nsdtr
srma
treatment
clinic
sign
nsdtr
imrd
healthi
nsdtr
healthi
dog
repres
differ
breed
slight
elev
mean
iga
nsdtr
acut
srma
gl
sd
imrd
gl
sd
compar
nsdtr
treatment
gl
sd
healthi
nsdtr
gl
sd
mean
iga
healthi
dog
breed
gl
sd
chang
nsdtr
srma
minor
compar
studi
breed
srma
mayb
srma
nsdtr
influenc
etiolog
factor
genet
background
earlier
shown
may
genet
locu
share
srma
imrd
nsdtr
moreov
nsdtr
group
acut
srma
younger
dog
group
one
year
thu
low
age
may
present
studi
influenc
iga
valu
neg
conclus
studi
show
clear
elev
serum
iga
nsdtr
srma
shown
breed
diseas
healthi
nsdtr
display
lower
valu
serum
iga
compar
healthi
dog
breed
disclosur
disclosur
report
canin
idiopath
pulmonari
fibrosi
cipf
progress
interstiti
lung
diseas
mainli
affect
old
west
highland
white
terrier
whwt
cipf
share
sever
clinic
patholog
featur
human
ipf
imbal
thrombosi
fibrinolysi
demonstr
human
ipf
patient
favour
local
system
prothrombot
state
correl
diseas
sever
outcom
aim
present
studi
investig
coagul
fibrinolysi
system
cipf
purpos
coagul
profil
thromboelastographi
data
collect
compar
whwt
affect
cipf
unaffect
whwt
ctrl
coagul
time
pt
aptt
plasmat
concentr
fibrinogen
dimer
antithrombin
iii
protein
protein
c
activ
antifactor
xa
activ
fxa
activ
protein
c
ratio
apcr
retrospect
measur
use
sta
compact
autom
coagul
analyz
previous
store
plasma
sampl
obtain
ctrl
cipf
whwt
pointofcar
rotat
thromboelastomet
rotem
employ
prospect
measur
clottingtim
aangl
amplitud
min
maxim
clot
firm
lysi
min
maximum
lysi
wholecitr
blood
sampl
ctrl
cipf
whwt
satist
analys
perfom
commerci
avail
softwar
use
studentt
test
mannwithney
test
continu
variabl
fisher
exact
test
categor
variabl
statist
signific
set
p
compar
ctrl
whwt
affect
cipf
demonstr
longer
aptt
mean
ae
sd
ae
sec
versu
ae
p
wherea
result
obtain
group
within
refer
rang
trend
increas
fibrinogen
concentr
ae
gl
versu
ae
p
decreas
apcr
median
rang
versu
whwt
affect
cipf
observ
siginific
differ
group
factor
assess
fxa
found
upper
limit
refer
rang
whwt
affect
cipf
none
control
p
rotem
result
demonstr
signific
differ
group
paramet
studi
result
present
studi
provid
clear
evid
hypercoagul
state
whwt
affect
cipf
high
fibrinogen
concentr
found
cipf
whwt
tend
suggest
proinflammatori
state
may
risk
factor
thrombosi
find
confirm
investig
larger
cohort
dog
disclosur
disclosur
report
clinic
decis
often
base
comparison
patient
laboratori
result
refer
interv
ri
sever
breed
physiolog
peculiar
induc
variat
ri
compar
gener
canin
popul
howev
inform
avail
need
establish
breedspecif
ri
shetland
sheepdog
breed
report
potenti
affect
physiolog
hyperlipidemia
aim
studi
determin
whether
ri
refer
gener
canin
popul
may
appli
shetland
sheepdog
itali
determin
breedspecif
ri
gener
ri
valid
aim
clinic
healthi
fast
shetland
sheepdog
male
neuter
male
femal
spay
femal
age
year
median
repres
italian
popul
regist
nation
breed
associ
examin
dog
clinic
sign
diseas
receiv
medic
except
antiparasit
treatment
pregnant
femal
exclud
routin
haematolog
perform
use
laser
base
cell
counter
sysmex
sysmex
extend
panel
biochem
analyt
determin
serum
use
autom
spectrophotomet
coba
mira
roch
diagnost
transfer
method
use
compar
result
shetland
sheepdog
ri
gener
canin
popul
valu
outsid
claim
ri
new
ri
calcul
accord
asvcp
guidelin
use
excel
spreadsheet
refer
valu
advisor
set
macroinstruct
remov
far
outlier
base
data
distribut
nonparametr
method
robust
method
use
defin
ri
confid
interv
differ
haematolog
biochem
record
dog
differ
sex
age
aptitud
companion
versu
agil
dog
investig
linear
regress
u
mann
withney
test
transfer
method
valid
haematolog
biochem
refer
interv
paramet
differ
laboratori
ri
could
due
preanalyt
analyt
error
wherea
glucos
total
cholesterol
new
ri
requir
even
dog
present
cholesterol
level
mg
dl
consid
clinic
relev
valu
differ
associ
aptitud
sex
consist
breed
weak
probabl
biolog
signific
correl
found
cholesterolemia
age
p
studi
suggest
breedspecif
refer
interv
may
use
glucos
total
cholesterol
shetland
sheepdog
reduc
misinterpret
laboratori
result
disclosur
disclosur
report
bronchial
veget
foreign
bodi
common
problem
dog
europ
especi
summer
season
foxtail
usual
inhaledaspir
exercis
deepen
posit
bronchial
tree
torpedo
shape
awn
may
becom
irrevers
lodg
bronchi
even
migrat
pulmonari
parenchyma
region
ex
paravertebr
muscl
pleural
space
bronchoscopi
gold
standard
techniqu
local
often
remov
airway
foreign
bodi
afb
earli
diagnosi
treatment
import
avoid
respiratori
sometim
neurolog
complic
due
foreign
bodi
migrat
local
infect
aim
studi
describ
evalu
correl
laryng
lesion
presenc
foreign
bodi
insid
bronchial
tree
laryng
find
may
help
facilit
earli
diagnosi
sinc
presenc
could
relat
one
afb
review
bronchoscop
exam
dog
refer
perugia
veterinari
teach
hospit
respiratori
symptom
last
year
defin
puddl
presenc
purul
exud
ventral
part
larynx
vocal
cord
andor
first
tracheal
tract
among
dog
hunt
dog
nonhunt
dog
base
fci
breed
classif
case
dog
posit
afb
whenev
foreign
bodi
found
bal
bacteriolog
exam
perform
total
bal
result
higher
frequenc
afb
hunt
dog
right
lung
local
agreement
previou
studi
among
dog
present
afb
posit
puddl
sign
moreov
bal
posit
group
dog
present
puddl
sign
last
result
suggest
laryng
sign
evalu
specif
relat
presenc
afb
kind
bacteri
lower
respiratori
tract
infect
grass
awn
carri
mani
bacteri
agent
perpetu
continuo
highli
suppur
bronchial
infect
strong
expuls
effort
cough
tend
remov
purul
exud
remain
trap
ventral
part
larynx
probabl
due
conform
canin
upper
respiratori
tract
therefor
puddl
sign
could
help
direct
earli
diagnosi
treatment
afb
disclosur
disclosur
report
base
current
knowledg
electrochemotherapi
ect
use
dog
squamou
cell
carcinoma
scc
promot
substanti
tumor
remiss
aim
studi
evalu
effect
ect
tumor
volum
mitot
index
microscop
necrosi
canin
cutan
squamou
cell
carcinoma
scc
studi
includ
nine
dog
refer
veterinari
hospit
five
patient
one
lesion
three
two
lesion
one
four
lesion
fifteen
lesion
assess
tumor
sampl
taken
ect
day
later
ect
accomplish
use
electropor
lc
model
associ
intraven
bleomycin
plu
doxorubicin
protocol
tumor
volum
calcul
accord
formula
length
cm
width
cm
height
cm
mitot
index
determin
number
mitot
figur
ten
select
highpow
field
microscop
necrosi
classifi
absent
grade
less
grade
ii
previous
describ
test
normal
pair
ttest
mannwhitney
test
appli
make
comparison
common
site
tumor
abdomen
n
thorax
n
one
tumor
occur
prepuc
one
locat
pelvic
limb
treatment
thirteen
tumor
present
clinic
remiss
one
tumor
progress
one
remain
stabl
size
mean
tumor
volum
ae
higher
ae
p
mitot
index
decreas
twelv
lesion
increas
three
lesion
mean
mitot
index
ae
significantli
differ
ae
p
treatment
necrosi
classifi
grade
ten
lesion
grade
ii
four
lesion
necrosi
absent
one
tumor
ect
grade
necrosi
chang
tumor
n
one
lesion
decreas
necrosi
grade
ii
lesion
decreas
absent
one
tumor
present
absenc
necrosi
classifi
grade
signific
differ
necrosi
p
although
substanti
tumor
remiss
ect
significantli
decreas
mitot
index
scc
dog
moreov
ect
influenc
intens
microscop
necrosi
day
procedur
acknowledg
fundac
de
amparo
pesquisa
estado
de
paulo
fapesp
financi
support
disclosur
disclosur
report
adjunct
use
nutraceut
treat
human
cancer
shown
promis
littl
work
done
canin
neoplasia
specif
multimod
effect
polyphenol
carotenoid
establish
human
cell
line
rodent
model
limit
work
canin
cell
previous
identifi
two
natur
ingredi
turmer
extract
te
rosemari
extract
work
synergist
reduc
neoplast
cell
growth
cytotox
effect
normal
dermal
fibroblast
combin
addit
synergist
effect
use
chemotherapeut
agent
toceranib
doxorubicin
hydrochlorid
purpos
invitro
studi
examin
mechan
action
cocktail
three
canin
neoplast
cell
line
repres
varieti
tumor
use
mastocytoma
mammari
gland
carcinoma
osteosarcoma
apoptosi
determin
use
annexin
v
stain
commerci
avail
cleavag
assay
cell
cycl
chang
use
propidium
iodid
stain
gener
reactiv
oxygen
speci
use
modul
cellular
efflux
pump
cellular
accumul
curcumin
analyz
flow
cytometri
perturb
variou
cell
signal
pathway
assess
hour
incub
western
blot
cell
treat
extract
individu
combin
extract
vehicl
control
comparis
four
treatment
group
analyz
use
oneway
anova
follow
tukey
posthoc
analys
combin
treatment
induc
apoptosi
cell
line
beyond
effect
te
alon
hour
incub
extract
signific
antioxid
effect
p
cell
suscept
treatment
annexin
v
posit
increas
caspas
cleavag
presenc
significantli
increas
cellular
accumul
te
indic
increas
fluoresc
cell
line
show
greatest
accumul
western
blot
show
increas
amount
activ
cjun
ntermin
kinas
jnk
although
differ
vari
across
cell
line
te
interact
synergist
induc
apoptosi
invitro
mechan
may
includ
increas
cellular
accumul
te
activ
jnk
consid
dose
use
invitro
may
physiolog
achiev
invivo
studi
warrant
determin
pharmacokinet
efficaci
dual
treatment
disclosur
research
lead
result
support
royal
canin
sa
royal
canin
particip
write
protocol
analyz
data
contribut
compound
revis
manuscript
public
give
final
approv
version
publish
agre
account
aspect
work
jb
vb
employ
royal
canin
jw
receiv
honoraria
advisori
council
nestl
purina
mar
inc
golden
retriev
dog
breed
rel
high
risk
develop
cancer
compar
breed
suggest
germlin
genet
risk
factor
contribut
diseas
develop
breed
genom
wide
associ
studi
proven
effect
method
identifi
genet
risk
factor
even
complex
diseas
take
advantag
histor
genet
bottleneck
within
dog
breed
studi
done
smaller
number
case
control
compar
human
studi
conduct
genom
wide
associ
studi
investig
germlin
risk
factor
implic
develop
mast
cell
tumour
golden
retriev
collect
dna
healthi
geriatr
golden
retriev
golden
retriev
affect
mast
cell
tumour
europ
unit
state
individu
genotyp
use
illumina
k
genotyp
array
found
associ
two
differ
loci
american
european
popul
loci
contain
three
six
hyaluronidas
gene
suggest
hyaluronan
turnov
could
play
role
develop
mast
cell
tumour
target
sequenc
subsequ
fine
map
identifi
mutat
gene
introduc
altern
splice
form
present
mainli
european
golden
retriev
conduct
work
character
role
hyaluronidas
gene
diseas
develop
hope
find
shed
light
develop
cancer
golden
retriev
also
compar
valu
help
understand
human
cancer
disclosur
patent
applic
file
relat
work
patent
applic
number
malign
melanoma
common
oral
tumour
type
dog
high
metastat
potenti
latter
thought
associ
activ
phagocytosi
studi
aim
analys
phagocyt
behaviour
explant
canin
oral
melanoma
cell
line
address
issu
establish
cell
line
primari
metastat
canin
oral
melanoma
screen
cellular
melanoma
marker
whilst
lesion
test
melan
aposit
immunohistochemistri
flow
cytometr
analysi
score
neg
marker
although
cell
clearli
express
vimentin
phagocyt
activ
melanoma
cell
line
address
flow
cytometr
stain
macrophagespecif
surfac
antigen
melanomaassoci
antigen
well
incorpor
fluorochromelabel
latex
bead
establish
melanoma
cell
line
clearli
show
phagocyt
activ
cell
correl
strong
coexpress
express
macrophag
marker
although
latter
thought
involv
recognit
phagocytosi
apoptot
cell
tumour
type
initi
identifi
progress
marker
melanoma
recent
recogn
marker
epithelialtomesenchym
transit
transendotheli
migrat
addit
phagocyticlik
activ
tumour
cell
report
associ
invas
therefor
express
phagocyt
activ
canin
melanoma
cell
may
repres
valuabl
indic
malign
canin
oral
melanoma
ongo
metastat
process
disclosur
disclosur
report
hypercoagul
canin
multipl
myeloma
mm
describ
human
report
prognost
factor
relat
hemostasi
investig
aim
studi
describ
haemostat
profil
dog
mm
detect
possibl
hypercoagul
state
assess
whether
coagul
paramet
prognost
valu
haemostat
alter
initi
visit
dog
affect
mm
group
n
retriev
electron
databas
poa
systemplu
san
marco
veterinari
clinic
dog
mm
met
follow
criteria
bone
marrow
plasma
cell
osteolyt
lesion
serum
monobiclon
gammopathi
extens
coagul
profil
includ
platelet
count
aptt
pt
fibrinogen
thrombin
time
tt
fpd
ddimer
antithrombin
two
group
dog
individu
match
age
breed
sex
use
control
healthi
dog
group
n
sick
dog
without
mm
group
n
addit
hemostat
profil
clinic
bleed
bmm
n
eg
gum
bleedind
epistaxi
noclin
bleed
nbmm
n
dog
mm
evalu
kruskalw
wilcoxonmannwhitney
test
use
compar
group
risk
death
day
diagnosi
within
bmm
nbmm
dog
evalu
pearson
x
test
roc
curv
use
identifi
best
analyt
predict
death
prothrombin
time
aptt
increas
p
group
versu
group
tt
increas
p
group
versu
platelet
count
concentr
decreas
group
versu
group
p
fibrinogen
concentr
decreas
group
versu
p
differ
group
versu
group
fdp
ddimer
observ
platelet
count
concentr
decreas
bmm
versu
nbmm
p
p
pt
aptt
increas
bmm
versu
nbmm
p
p
differ
bmm
nbmm
observ
tt
fdp
ddimer
bmm
dog
show
lower
mortal
rate
respect
nbmm
patient
p
tt
result
best
haemostat
analyt
predict
death
dog
affect
mm
p
auc
ci
primari
secondari
haemostasi
compromis
dog
mm
tertiari
haemostasi
appear
unaffect
hypercoagul
state
opposit
human
unlik
dog
mm
surprisingli
dog
mm
clinic
bleed
appar
protect
effect
death
predict
mortal
canin
mm
relat
tt
disclosur
disclosur
report
bodi
condit
score
bc
method
commonli
use
diagnosi
nutrit
statu
small
anim
howev
clinic
veterinarian
recogn
bc
assess
error
extent
bc
assess
subject
method
base
ocular
inspect
palpat
therefor
built
bc
model
bc
assess
dog
examin
accuraci
report
variabl
bc
valu
less
bc
model
use
nutrit
assess
dog
studi
survey
conduct
make
clear
use
bc
model
clinic
veterinarian
dog
owner
bc
model
develop
resin
mold
artifici
rib
polychloropren
spong
sheet
natur
rubber
sheet
lamin
fit
palpat
feel
bc
survey
carri
clinic
veterinarian
n
dog
owner
n
main
question
follow
actual
use
bc
clinic
percept
use
bc
model
applic
bc
model
clinic
clinic
veterinarian
awar
bc
bc
assess
dog
dog
owner
clinic
veterinarian
use
bc
nutrit
assess
dog
mani
clinic
veterinarian
answer
follow
palpat
sensat
actual
dog
bc
model
consist
ii
descript
nutrit
statu
dog
dog
owner
becom
easier
hand
dog
owner
know
bc
mani
dog
owner
answer
nutrit
statu
dog
could
grasp
use
bc
model
result
suggest
recognit
nutrit
statu
dog
veterinarian
dog
owner
match
use
bc
model
result
bc
model
use
devic
introduc
weight
loss
program
obes
dog
disclosur
disclosur
report
approxim
cat
unit
state
consid
overweight
obes
mani
pet
owner
struggl
reduc
cat
bodi
weight
critic
compon
success
weight
loss
regimen
good
estim
bodi
composit
start
point
calcul
appropri
food
amount
weight
loss
newli
develop
method
call
bodi
fat
index
bfi
differenti
level
obes
establish
link
bfi
ideal
bodi
weight
dualenergi
xray
absorptiometri
dexa
provid
accur
way
measur
percent
bodi
fat
howev
readili
avail
gener
practition
current
studi
compar
percent
bodi
fat
determin
bfi
chart
dexa
scan
group
obes
cat
weight
loss
weight
mainten
fed
food
specif
formul
help
cat
achiev
healthi
weight
contain
g
protein
g
fat
g
insolubl
fiber
g
solubl
fiber
mg
lcarnitin
per
kilocalori
protocol
procedur
approv
institut
anim
care
use
committe
twelv
obes
cat
fed
weight
loss
achiev
ideal
bodi
weight
ibw
follow
weight
mainten
phase
cat
group
hous
room
natur
light
access
sunroom
three
anim
care
technician
independ
determin
bfi
cat
per
month
averag
bfi
calcul
bfi
chart
includ
imag
descriptor
use
determin
cat
percent
bodi
fat
cat
underw
monthli
dexa
scan
weight
loss
phase
everi
two
month
weight
mainten
phase
valu
percent
bodi
fat
determin
bfi
dexa
show
good
correl
r
across
rang
bodi
weight
bodi
fat
cat
undergo
weight
loss
bfi
slightli
underestim
percent
bodi
fat
initi
phase
studi
show
excel
agreement
dexa
result
weight
mainten
phase
purpos
studi
evalu
use
new
bfi
risk
chart
repeatedli
estim
percent
bodi
fat
overweight
cat
weight
loss
period
stabl
normal
bodi
weight
result
show
new
method
excel
tool
determin
bodi
fat
dexa
instrument
avail
would
practic
use
veterinari
clinic
disclosur
disclosur
report
present
coauthor
employe
hill
pet
nutrit
bodi
fat
index
chart
use
studi
develop
hill
pet
nutrit
home
blood
pressur
bp
monitor
great
potenti
improv
hypertens
control
human
dog
aim
prospect
studi
assess
level
agreement
highdefinit
oscillometr
method
vet
hdo
monitor
b
medvet
gmbh
wrist
blood
pressur
measur
devic
wbpdigicolor
microlif
corporationn
monitor
dog
studi
carri
januari
march
hospit
dog
weigh
kg
age
month
recruit
bp
measur
obtain
accord
acvim
american
colleg
veterinari
intern
